index	sentence	label
DDI-DrugBank.d572.s0.p0	@DRUG$: Concomitant @DRUG$ administration decreased the mean AUC of total ezetimibe approximately 55%.	DDI-false
DDI-DrugBank.d572.s0.p1	@DRUG$: Concomitant cholestyramine administration decreased the mean AUC of total @DRUG$ approximately 55%.	DDI-false
DDI-DrugBank.d572.s0.p2	Cholestyramine: Concomitant @DRUG$ administration decreased the mean AUC of total @DRUG$ approximately 55%.	DDI-mechanism
DDI-DrugBank.d572.s1.p0	The incremental LDL-C reduction due to adding @DRUG$ to @DRUG$ may be reduced by this interaction.	DDI-effect
DDI-DrugBank.d572.s10.p0	Patients who take both @DRUG$ and @DRUG$ should be carefully monitored.	DDI-advise
DDI-DrugBank.d572.s11.p0	Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with @DRUG$ was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$).	DDI-false
DDI-DrugBank.d572.s12.p0	A 104-week dietary carcinogenicity study with @DRUG$ was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$).	DDI-false
DDI-DrugBank.d572.s17.p0	In oral (gavage) fertility studies of @DRUG$ conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$).	DDI-false
DDI-DrugBank.d572.s2.p0	@DRUG$: The safety and effectiveness of @DRUG$ administered with fibrates have not been established.	DDI-false
DDI-DrugBank.d572.s2.p1	@DRUG$: The safety and effectiveness of ezetimibe administered with @DRUG$ have not been established.	DDI-false
DDI-DrugBank.d572.s2.p2	Fibrates: The safety and effectiveness of @DRUG$ administered with @DRUG$ have not been established.	DDI-false
DDI-DrugBank.d572.s22.p0	In rabbits treated with @DRUG$, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$).	DDI-false
DDI-DrugBank.d572.s24.p0	Multiple dose studies of @DRUG$ given in combination with @DRUG$ (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	DDI-false
DDI-DrugBank.d572.s24.p1	Multiple dose studies of @DRUG$ given in combination with HMG-CoA reductase inhibitors (@DRUG$) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	DDI-false
DDI-DrugBank.d572.s24.p2	Multiple dose studies of @DRUG$ given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures.	DDI-false
DDI-DrugBank.d572.s24.p3	Multiple dose studies of ezetimibe given in combination with @DRUG$ (@DRUG$) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	DDI-false
DDI-DrugBank.d572.s24.p4	Multiple dose studies of ezetimibe given in combination with @DRUG$ (statins) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures.	DDI-false
DDI-DrugBank.d572.s24.p5	Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (@DRUG$) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures.	DDI-false
DDI-DrugBank.d572.s27.p0	When @DRUG$ is administered with an @DRUG$ in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor.	DDI-false
DDI-DrugBank.d572.s27.p1	When @DRUG$ is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the @DRUG$.	DDI-false
DDI-DrugBank.d572.s27.p2	When ZETIA is administered with an @DRUG$ in a woman of childbearing potential, refer to the pregnancy category and package labeling for the @DRUG$.	DDI-false
DDI-DrugBank.d572.s5.p0	Co-administration of @DRUG$ with @DRUG$ is not recommended until use in patients is studied.	DDI-advise
DDI-DrugBank.d572.s6.p0	@DRUG$: In a pharmacokinetic study, concomitant @DRUG$ administration increased total ezetimibe concentrations approximately 1.5-fold.	DDI-false
DDI-DrugBank.d572.s6.p1	@DRUG$: In a pharmacokinetic study, concomitant fenofibrate administration increased total @DRUG$ concentrations approximately 1.5-fold.	DDI-false
DDI-DrugBank.d572.s6.p2	Fenofibrate: In a pharmacokinetic study, concomitant @DRUG$ administration increased total @DRUG$ concentrations approximately 1.5-fold.	DDI-mechanism
DDI-DrugBank.d572.s7.p0	@DRUG$: In a pharmacokinetic study, concomitant @DRUG$ administration increased total ezetimibe concentrations approximately 1.7-fold.	DDI-false
DDI-DrugBank.d572.s7.p1	@DRUG$: In a pharmacokinetic study, concomitant gemfibrozil administration increased total @DRUG$ concentrations approximately 1.7-fold.	DDI-false
DDI-DrugBank.d572.s7.p2	Gemfibrozil: In a pharmacokinetic study, concomitant @DRUG$ administration increased total @DRUG$ concentrations approximately 1.7-fold.	DDI-false
DDI-DrugBank.d572.s8.p0	@DRUG$: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p1	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p2	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p3	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p4	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p5	@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or @DRUG$.	DDI-false
DDI-DrugBank.d572.s8.p6	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p7	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p8	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p9	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p10	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or @DRUG$.	DDI-false
DDI-DrugBank.d572.s8.p11	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, @DRUG$, pravastatin, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p12	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, @DRUG$, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p13	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, @DRUG$, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p14	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or @DRUG$.	DDI-false
DDI-DrugBank.d572.s8.p15	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, @DRUG$, lovastatin, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p16	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, @DRUG$, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p17	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or @DRUG$.	DDI-false
DDI-DrugBank.d572.s8.p18	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, @DRUG$, or fluvastatin.	DDI-false
DDI-DrugBank.d572.s8.p19	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or @DRUG$.	DDI-false
DDI-DrugBank.d572.s8.p20	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d572.s9.p0	@DRUG$: The total @DRUG$ level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.	DDI-false
DDI-DrugBank.d572.s9.p1	@DRUG$: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including @DRUG$.	DDI-false
DDI-DrugBank.d572.s9.p2	Cyclosporine: The total @DRUG$ level increased 12-fold in one renal transplant patient receiving multiple medications, including @DRUG$.	DDI-mechanism
DDI-DrugBank.d573.s0.p0	Interaction with @DRUG$: Although @DRUG$ does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.	DDI-false
DDI-DrugBank.d573.s0.p1	Interaction with @DRUG$: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving @DRUG$ can result in profound orthostatic effects.	DDI-false
DDI-DrugBank.d573.s0.p2	Interaction with Guanethidine: Although @DRUG$ does not itself cause orthostatic hypotension, its administration to patients already receiving @DRUG$ can result in profound orthostatic effects.	DDI-effect
DDI-DrugBank.d573.s1.p0	If at all possible @DRUG$ should be discontinued well before @DRUG$ is begun.	DDI-advise
DDI-DrugBank.d575.s0.p0	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, @DRUG$ and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.	DDI-false
DDI-DrugBank.d575.s0.p1	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, sodium salicylate and @DRUG$ displaced protein-bound teniposide in fresh human serum to a small but significant extent.	DDI-false
DDI-DrugBank.d575.s0.p2	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, sodium salicylate and sulfamethizole displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent.	DDI-mechanism
DDI-DrugBank.d575.s0.p3	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, @DRUG$ and @DRUG$ displaced protein-bound teniposide in fresh human serum to a small but significant extent.	DDI-false
DDI-DrugBank.d575.s0.p4	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, @DRUG$ and sulfamethizole displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent.	DDI-mechanism
DDI-DrugBank.d575.s0.p5	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and @DRUG$ displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent.	DDI-mechanism
DDI-DrugBank.d575.s2.p0	Therefore, caution should be used in administering @DRUG$ (@DRUG$ injection) to patients receiving these other agents.	DDI-false
DDI-DrugBank.d575.s3.p0	There was no change in the plasma kinetics of @DRUG$ when coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d575.s5.p0	An increase in intracellular levels of @DRUG$ was observed in vitro in the presence of @DRUG$.	DDI-mechanism
DDI-DrugBank.d576.s1.p0	@DRUG$ AND OTHER @DRUG$ WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.	DDI-false
DDI-DrugBank.d576.s1.p1	@DRUG$ AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.	DDI-effect
DDI-DrugBank.d576.s1.p2	@DRUG$ AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS.	DDI-false
DDI-DrugBank.d576.s1.p3	ASPIRIN AND OTHER @DRUG$ WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.	DDI-effect
DDI-DrugBank.d576.s1.p4	ASPIRIN AND OTHER @DRUG$ WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS.	DDI-false
DDI-DrugBank.d576.s1.p5	ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS.	DDI-false
DDI-DrugBank.d576.s4.p0	@DRUG$ given concomitantly with @DRUG$ may predispose to systemic bleeding.	DDI-effect
DDI-DrugBank.d576.s5.p0	@DRUG$ may enhance the hypoglycemic effect of oral @DRUG$ of the sulfonylurea class.	DDI-effect
DDI-DrugBank.d576.s6.p0	@DRUG$ competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p1	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p2	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p3	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p4	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p5	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p6	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p7	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p8	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.	DDI-mechanism
DDI-DrugBank.d576.s6.p9	@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.	DDI-mechanism
DDI-DrugBank.d576.s6.p10	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p11	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p12	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p13	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p14	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p15	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p16	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p17	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p18	Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d576.s6.p19	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p20	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p21	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p22	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p23	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p24	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p25	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p26	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d576.s6.p27	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p28	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p29	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p30	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p31	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p32	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p33	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d576.s6.p34	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p35	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p36	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p37	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p38	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p39	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d576.s6.p40	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p41	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p42	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p43	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p44	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d576.s6.p45	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, @DRUG$, warfarin, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p46	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, @DRUG$, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p47	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, @DRUG$, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p48	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d576.s6.p49	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, @DRUG$, methotrexate, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p50	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, @DRUG$, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p51	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d576.s6.p52	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, @DRUG$, and possibly corticosteroids.	DDI-false
DDI-DrugBank.d576.s6.p53	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d576.s6.p54	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly @DRUG$.	DDI-false
DDI-DrugBank.d577.s0.p0	In elderly patients concurrently receiving certain @DRUG$, primarily @DRUG$, an increased incidence of thrombopenia with purpura has been reported.	DDI-false
DDI-DrugBank.d577.s1.p0	It has been reported that @DRUG$ may prolong the prothrombin time in patients who are receiving the @DRUG$ warfarin.	DDI-false
DDI-DrugBank.d577.s1.p1	It has been reported that @DRUG$ may prolong the prothrombin time in patients who are receiving the anticoagulant @DRUG$.	DDI-effect
DDI-DrugBank.d577.s1.p2	It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the @DRUG$ @DRUG$.	DDI-false
DDI-DrugBank.d577.s3.p0	@DRUG$ may inhibit the hepatic metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d577.s4.p0	At a 1.6-g dose, @DRUG$ produced a slight but significant increase in the half-life of @DRUG$ but did not produce a corresponding decrease in the metabolic clearance rate.	DDI-mechanism
DDI-DrugBank.d577.s6.p0	@DRUG$ can also displace @DRUG$ from plasma protein-binding sites, thus increasing free methotrexate concentrations.	DDI-mechanism
DDI-DrugBank.d577.s6.p1	@DRUG$ can also displace methotrexate from plasma protein-binding sites, thus increasing free @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d577.s6.p2	Sulfonamides can also displace @DRUG$ from plasma protein-binding sites, thus increasing free @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d578.s1.p0	Mutual inhibition of metabolism occurs with concurrent use of @DRUG$ and @DRUG$;	DDI-mechanism
DDI-DrugBank.d578.s10.p0	The effect of @DRUG$ on oral @DRUG$ is variable.	DDI-false
DDI-DrugBank.d578.s11.p0	There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$.	DDI-effect
DDI-DrugBank.d578.s3.p0	convulsions have been reported with concurrent use of @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d578.s4.p0	Drugs that induce hepatic enzymes such as @DRUG$, @DRUG$, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	DDI-false
DDI-DrugBank.d578.s4.p1	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	DDI-false
DDI-DrugBank.d578.s4.p2	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and rifampin may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d578.s4.p3	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response.	DDI-advise
DDI-DrugBank.d578.s4.p4	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	DDI-false
DDI-DrugBank.d578.s4.p5	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and rifampin may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d578.s4.p6	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and rifampin may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response.	DDI-advise
DDI-DrugBank.d578.s4.p7	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and @DRUG$ may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d578.s4.p8	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response.	DDI-advise
DDI-DrugBank.d578.s4.p9	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of @DRUG$ and may require increased in @DRUG$ dose to achieve the desired response.	DDI-false
DDI-DrugBank.d578.s5.p0	Drugs such as @DRUG$ and @DRUG$ may inhibit the metabolism of methylprednisolone and thus decrease its clearance.	DDI-false
DDI-DrugBank.d578.s5.p1	Drugs such as @DRUG$ and ketoconazole may inhibit the metabolism of @DRUG$ and thus decrease its clearance.	DDI-mechanism
DDI-DrugBank.d578.s5.p2	Drugs such as troleandomycin and @DRUG$ may inhibit the metabolism of @DRUG$ and thus decrease its clearance.	DDI-mechanism
DDI-DrugBank.d578.s7.p0	@DRUG$ may increase the clearance of chronic high dose @DRUG$.	DDI-mechanism
DDI-DrugBank.d578.s8.p0	This could lead to decreased @DRUG$ serum levels or increase the risk of @DRUG$ toxicity when methylprednisolone is withdrawn.	DDI-false
DDI-DrugBank.d578.s8.p1	This could lead to decreased @DRUG$ serum levels or increase the risk of salicylate toxicity when @DRUG$ is withdrawn.	DDI-false
DDI-DrugBank.d578.s8.p2	This could lead to decreased salicylate serum levels or increase the risk of @DRUG$ toxicity when @DRUG$ is withdrawn.	DDI-effect
DDI-DrugBank.d578.s9.p0	@DRUG$ should be used cautiously in conjunction with @DRUG$ in patients suffering from hypoprothrombinemia.	DDI-advise
DDI-DrugBank.d579.s0.p0	Patients receiving @DRUG$ and @DRUG$ generally should not be treated with ganglion blockers.	DDI-false
DDI-DrugBank.d579.s0.p1	Patients receiving @DRUG$ and sulfonamides generally should not be treated with @DRUG$.	DDI-advise
DDI-DrugBank.d579.s0.p2	Patients receiving antibiotics and @DRUG$ generally should not be treated with @DRUG$.	DDI-advise
DDI-DrugBank.d579.s1.p0	The action of @DRUG$ may be potentiated by anesthesia, other @DRUG$ and alcohol.	DDI-effect
DDI-DrugBank.d579.s1.p1	The action of @DRUG$ may be potentiated by anesthesia, other antihypertensive drugs and @DRUG$.	DDI-effect
DDI-DrugBank.d579.s1.p2	The action of Mecamylamine may be potentiated by anesthesia, other @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d580.s1.p0	However, @DRUG$, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of @DRUG$ during concomitant dosing.	DDI-mechanism
DDI-DrugBank.d581.s2.p0	patients receiving @DRUG$ and @DRUG$ should have more frequent monitoring of neutrophil counts.	DDI-advise
DDI-DrugBank.d584.s0.p0	@DRUG$ @DRUG$ may increase sensitivity to oral anticoagulants.	DDI-false
DDI-DrugBank.d584.s0.p1	@DRUG$ Anabolic steroids may increase sensitivity to oral @DRUG$.	DDI-false
DDI-DrugBank.d584.s0.p2	Anticoagulants @DRUG$ may increase sensitivity to oral @DRUG$.	DDI-effect
DDI-DrugBank.d584.s10.p0	@DRUG$ or @DRUG$ In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.	DDI-false
DDI-DrugBank.d584.s10.p1	@DRUG$ or ACTH In patients with edema, concomitant administration with @DRUG$ or ACTH may increase the edema.	DDI-false
DDI-DrugBank.d584.s10.p2	@DRUG$ or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or @DRUG$ may increase the edema.	DDI-false
DDI-DrugBank.d584.s10.p3	Adrenal steroids or @DRUG$ In patients with edema, concomitant administration with @DRUG$ or ACTH may increase the edema.	DDI-false
DDI-DrugBank.d584.s10.p4	Adrenal steroids or @DRUG$ In patients with edema, concomitant administration with adrenal cortical steroids or @DRUG$ may increase the edema.	DDI-false
DDI-DrugBank.d584.s10.p5	Adrenal steroids or ACTH In patients with edema, concomitant administration with @DRUG$ or @DRUG$ may increase the edema.	DDI-false
DDI-DrugBank.d584.s3.p0	@DRUG$: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s3.p1	@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s3.p2	@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s3.p3	@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s3.p4	Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	DDI-mechanism
DDI-DrugBank.d584.s3.p5	Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s3.p6	Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s3.p7	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s3.p8	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s3.p9	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected.	DDI-false
DDI-DrugBank.d584.s5.p0	A 5.5-fold decrease in the mean @DRUG$ dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of @DRUG$ dose), was necessary to maintain a target INR of 1.5.	DDI-false
DDI-DrugBank.d584.s6.p0	When @DRUG$ therapy is initiated in a patient already receiving treatment with @DRUG$, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.	DDI-advise
DDI-DrugBank.d584.s6.p1	When @DRUG$ therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of @DRUG$ adjusted as necessary until a stable target INR or PT has been achieved.	DDI-false
DDI-DrugBank.d584.s6.p2	When oxandrolone therapy is initiated in a patient already receiving treatment with @DRUG$, the INR or prothrombin time (PT) should be monitored closely and the dose of @DRUG$ adjusted as necessary until a stable target INR or PT has been achieved.	DDI-false
DDI-DrugBank.d584.s7.p0	Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the @DRUG$ dosage if indicated are recommended when the @DRUG$ dose is changed or discontinued.	DDI-advise
DDI-DrugBank.d584.s9.p0	Oral @DRUG$ @DRUG$ may inhibit the metabolism of oral hypoglycemic agents.	DDI-false
DDI-DrugBank.d584.s9.p1	Oral @DRUG$ Oxandrolone may inhibit the metabolism of oral @DRUG$.	DDI-false
DDI-DrugBank.d584.s9.p2	Oral hypoglycemic agents @DRUG$ may inhibit the metabolism of oral @DRUG$.	DDI-mechanism
DDI-DrugBank.d585.s0.p0	The following agents may increase certain actions or side effects of @DRUG$: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p1	The following agents may increase certain actions or side effects of @DRUG$: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p2	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p3	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p4	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p5	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p6	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p7	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p8	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p9	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p10	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p11	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p12	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p13	The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-effect
DDI-DrugBank.d585.s0.p14	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p15	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p16	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p17	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p18	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p19	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p20	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p21	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p22	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p23	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p24	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p25	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p26	The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p27	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p28	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p29	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p30	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p31	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p32	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p33	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p34	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p35	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p36	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p37	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p38	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p39	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p40	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p41	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p42	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p43	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p44	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p45	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p46	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p47	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p48	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p49	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p50	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p51	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p52	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p53	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p54	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p55	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p56	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p57	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p58	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p59	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p60	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p61	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p62	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p63	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p64	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p65	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p66	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p67	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p68	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p69	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p70	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p71	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p72	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p73	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p74	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p75	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p76	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p77	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p78	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p79	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p80	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p81	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p82	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p83	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p84	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p85	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p86	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p87	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p88	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p89	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p90	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p91	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p92	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p93	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p94	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p95	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p96	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p97	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p98	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p99	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p100	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p101	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p102	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p103	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s0.p104	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, @DRUG$, and other drugs having anticholinergic activity.	DDI-false
DDI-DrugBank.d585.s1.p0	@DRUG$ antagonize the effects of @DRUG$.	DDI-effect
DDI-DrugBank.d585.s2.p0	@DRUG$ in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as @DRUG$.	DDI-effect
DDI-DrugBank.d585.s3.p0	@DRUG$ may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of @DRUG$;	DDI-mechanism
DDI-DrugBank.d585.s5.p0	@DRUG$ may antagonize the effects of drugs that alter gastrointestinal motility, such as @DRUG$.	DDI-effect
DDI-DrugBank.d585.s6.p0	Because @DRUG$ may interfere with the absorption of @DRUG$, simultaneous use of these drugs should be avoided.	DDI-mechanism
DDI-DrugBank.d587.s0.p0	Since @DRUG$ (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	DDI-false
DDI-DrugBank.d587.s0.p1	Since @DRUG$ (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	DDI-advise
DDI-DrugBank.d587.s0.p2	Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital).	DDI-false
DDI-DrugBank.d587.s0.p3	Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital).	DDI-false
DDI-DrugBank.d587.s0.p4	Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$).	DDI-false
DDI-DrugBank.d587.s0.p5	Since Celontin (@DRUG$) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	DDI-advise
DDI-DrugBank.d587.s0.p6	Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital).	DDI-false
DDI-DrugBank.d587.s0.p7	Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital).	DDI-false
DDI-DrugBank.d587.s0.p8	Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$).	DDI-false
DDI-DrugBank.d587.s0.p9	Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital).	DDI-false
DDI-DrugBank.d587.s0.p10	Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital).	DDI-false
DDI-DrugBank.d587.s0.p11	Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$).	DDI-false
DDI-DrugBank.d587.s0.p12	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of @DRUG$ and phenobarbital).	DDI-mechanism
DDI-DrugBank.d587.s0.p13	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and @DRUG$).	DDI-mechanism
DDI-DrugBank.d587.s0.p14	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d588.s0.p0	@DRUG$: @DRUG$ and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	DDI-false
DDI-DrugBank.d588.s0.p1	@DRUG$: Furosemide and probably other @DRUG$ given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	DDI-false
DDI-DrugBank.d588.s0.p2	@DRUG$: Furosemide and probably other loop diuretics given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes.	DDI-false
DDI-DrugBank.d588.s0.p3	Diuretics: @DRUG$ and probably other @DRUG$ given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	DDI-false
DDI-DrugBank.d588.s0.p4	Diuretics: @DRUG$ and probably other loop diuretics given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes.	DDI-effect
DDI-DrugBank.d588.s0.p5	Diuretics: Furosemide and probably other @DRUG$ given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes.	DDI-effect
DDI-DrugBank.d588.s1.p0	Other @DRUG$: When @DRUG$ Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.	DDI-false
DDI-DrugBank.d588.s1.p1	Other @DRUG$: When MYKROX Tablets are used with other @DRUG$, care must be taken, especially during initial therapy.	DDI-false
DDI-DrugBank.d588.s1.p2	Other Antihypertensives: When @DRUG$ Tablets are used with other @DRUG$, care must be taken, especially during initial therapy.	DDI-advise
DDI-DrugBank.d588.s10.p0	@DRUG$ and Other @DRUG$: May decrease the antihypertensive effects of MYKROX Tablets.	DDI-false
DDI-DrugBank.d588.s10.p1	@DRUG$ and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of @DRUG$ Tablets.	DDI-effect
DDI-DrugBank.d588.s10.p2	Salicylates and Other @DRUG$: May decrease the antihypertensive effects of @DRUG$ Tablets.	DDI-effect
DDI-DrugBank.d588.s11.p0	@DRUG$: @DRUG$ may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	DDI-false
DDI-DrugBank.d588.s11.p1	@DRUG$: Metolazone may decrease arterial responsiveness to @DRUG$, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	DDI-false
DDI-DrugBank.d588.s11.p2	Sympathomimetics: @DRUG$ may decrease arterial responsiveness to @DRUG$, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	DDI-effect
DDI-DrugBank.d588.s12.p0	@DRUG$: Efficacy may be decreased due to urinary alkalizing effect of @DRUG$.	DDI-effect
DDI-DrugBank.d588.s13.p0	@DRUG$: @DRUG$, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;	DDI-false
DDI-DrugBank.d588.s13.p1	@DRUG$: Metolazone, as well as other @DRUG$, may affect the hypoprothrombinemic response to anticoagulants;	DDI-false
DDI-DrugBank.d588.s13.p2	@DRUG$: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to @DRUG$;	DDI-false
DDI-DrugBank.d588.s13.p3	Anticoagulants: @DRUG$, as well as other @DRUG$, may affect the hypoprothrombinemic response to anticoagulants;	DDI-false
DDI-DrugBank.d588.s13.p4	Anticoagulants: @DRUG$, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to @DRUG$;	DDI-effect
DDI-DrugBank.d588.s13.p5	Anticoagulants: Metolazone, as well as other @DRUG$, may affect the hypoprothrombinemic response to @DRUG$;	DDI-false
DDI-DrugBank.d588.s3.p0	@DRUG$, @DRUG$, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	DDI-false
DDI-DrugBank.d588.s3.p1	@DRUG$, Barbiturates, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	DDI-false
DDI-DrugBank.d588.s3.p2	@DRUG$, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy.	DDI-false
DDI-DrugBank.d588.s3.p3	Alcohol, @DRUG$, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	DDI-false
DDI-DrugBank.d588.s3.p4	Alcohol, @DRUG$, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy.	DDI-false
DDI-DrugBank.d588.s3.p5	Alcohol, Barbiturates, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy.	DDI-false
DDI-DrugBank.d588.s4.p0	@DRUG$: @DRUG$-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.	DDI-false
DDI-DrugBank.d588.s4.p1	@DRUG$: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to @DRUG$.	DDI-false
DDI-DrugBank.d588.s4.p2	Digitalis Glycosides: @DRUG$-induced hypokalemia can increase the sensitivity of the myocardium to @DRUG$.	DDI-effect
DDI-DrugBank.d588.s6.p0	@DRUG$ or @DRUG$: May increase the risk of hypokalemia and increase salt and water retention.	DDI-false
DDI-DrugBank.d588.s7.p0	@DRUG$: Serum @DRUG$ levels may increase.	DDI-false
DDI-DrugBank.d588.s8.p0	@DRUG$: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	DDI-false
DDI-DrugBank.d588.s8.p1	@DRUG$: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	DDI-false
DDI-DrugBank.d588.s8.p2	@DRUG$: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea.	DDI-false
DDI-DrugBank.d588.s8.p3	Curariform Drugs: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	DDI-effect
DDI-DrugBank.d588.s8.p4	Curariform Drugs: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea.	DDI-effect
DDI-DrugBank.d588.s8.p5	Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea.	DDI-false
DDI-DrugBank.d590.s0.p0	Coadministration of @DRUG$ with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	DDI-mechanism
DDI-DrugBank.d590.s0.p1	Coadministration of @DRUG$ with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	DDI-false
DDI-DrugBank.d590.s0.p2	Coadministration of @DRUG$ with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).	DDI-false
DDI-DrugBank.d590.s0.p3	Coadministration of TRITEC with @DRUG$ resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	DDI-false
DDI-DrugBank.d590.s0.p4	Coadministration of TRITEC with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).	DDI-false
DDI-DrugBank.d590.s0.p5	Coadministration of TRITEC with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).	DDI-false
DDI-DrugBank.d590.s1.p0	Coadministration with @DRUG$ results in a slight decrease in the rate of @DRUG$ absorption that is clinically unimportant.	DDI-false
DDI-DrugBank.d590.s2.p0	Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from TRITEC.	DDI-mechanism
DDI-DrugBank.d590.s2.p1	Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from @DRUG$.	DDI-mechanism
DDI-DrugBank.d590.s2.p2	Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from @DRUG$.	DDI-false
DDI-DrugBank.d590.s4.p0	For information on drug interactions associated with @DRUG$, refer to the @DRUG$     package insert.	DDI-false
DDI-DrugBank.d591.s0.p0	@DRUG$ should be used with caution in patients receiving other local @DRUG$ or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.	DDI-advise
DDI-DrugBank.d591.s0.p1	@DRUG$ should be used with caution in patients receiving other local anesthetics or agents structurally related to @DRUG$, since the toxic effects of these drugs are additive.	DDI-false
DDI-DrugBank.d591.s0.p2	Ropivacaine should be used with caution in patients receiving other local @DRUG$ or agents structurally related to @DRUG$, since the toxic effects of these drugs are additive.	DDI-false
DDI-DrugBank.d591.s2.p0	In vivo, the plasma clearance of @DRUG$ was reduced by 70% during coadministration of @DRUG$ (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.	DDI-mechanism
DDI-DrugBank.d591.s3.p0	Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of @DRUG$, can interact with Ropivacaine leading to increased ropivacaine plasma levels.	DDI-int
DDI-DrugBank.d591.s3.p1	Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of Ropivacaine, can interact with @DRUG$ leading to increased ropivacaine plasma levels.	DDI-false
DDI-DrugBank.d591.s3.p2	Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased @DRUG$ plasma levels.	DDI-false
DDI-DrugBank.d591.s3.p3	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of @DRUG$, can interact with @DRUG$ leading to increased ropivacaine plasma levels.	DDI-false
DDI-DrugBank.d591.s3.p4	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of @DRUG$, can interact with Ropivacaine leading to increased @DRUG$ plasma levels.	DDI-false
DDI-DrugBank.d591.s3.p5	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with @DRUG$ leading to increased @DRUG$ plasma levels.	DDI-false
DDI-DrugBank.d591.s5.p0	Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as @DRUG$ and @DRUG$ may also occur.	DDI-false
DDI-DrugBank.d591.s6.p0	Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	DDI-false
DDI-DrugBank.d591.s6.p1	Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	DDI-false
DDI-DrugBank.d591.s6.p2	Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d591.s6.p3	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	DDI-false
DDI-DrugBank.d591.s6.p4	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of @DRUG$.	DDI-false
DDI-DrugBank.d591.s6.p5	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of @DRUG$.	DDI-false
DDI-DrugBank.d595.s1.p0	@DRUG$ and @DRUG$ are incompatible with sodium bicarbonate solution.	DDI-false
DDI-DrugBank.d595.s1.p1	@DRUG$ and dobutamine are incompatible with @DRUG$ solution.	DDI-int
DDI-DrugBank.d595.s1.p2	norepinephrine and @DRUG$ are incompatible with @DRUG$ solution.	DDI-int
DDI-DrugBank.d595.s2.p0	The addition of @DRUG$ to parenteral solutions containing @DRUG$ should be avoided, except where compatibility has been previously established.	DDI-false
DDI-DrugBank.d596.s0.p0	Drug-Drug Interactions Effect of @DRUG$    (@DRUG$) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases.	DDI-false
DDI-DrugBank.d596.s0.p1	Drug-Drug Interactions Effect of @DRUG$    (rivastigmine tartrate) on the Metabolism of Other Drugs: @DRUG$ is primarily metabolized through hydrolysis by esterases.	DDI-false
DDI-DrugBank.d596.s0.p2	Drug-Drug Interactions Effect of Exelon    (@DRUG$) on the Metabolism of Other Drugs: @DRUG$ is primarily metabolized through hydrolysis by esterases.	DDI-false
DDI-DrugBank.d596.s3.p0	No pharmacokinetic interaction was observed between @DRUG$ and @DRUG$, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p1	No pharmacokinetic interaction was observed between @DRUG$ and digoxin, @DRUG$, diazepam, or fluoxetine in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p2	No pharmacokinetic interaction was observed between @DRUG$ and digoxin, warfarin, @DRUG$, or fluoxetine in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p3	No pharmacokinetic interaction was observed between @DRUG$ and digoxin, warfarin, diazepam, or @DRUG$ in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p4	No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, @DRUG$, diazepam, or fluoxetine in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p5	No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, warfarin, @DRUG$, or fluoxetine in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p6	No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, warfarin, diazepam, or @DRUG$ in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p7	No pharmacokinetic interaction was observed between rivastigmine and digoxin, @DRUG$, @DRUG$, or fluoxetine in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p8	No pharmacokinetic interaction was observed between rivastigmine and digoxin, @DRUG$, diazepam, or @DRUG$ in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s3.p9	No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, @DRUG$, or @DRUG$ in studies in healthy volunteers.	DDI-false
DDI-DrugBank.d596.s4.p0	The elevation of prothrombin time induced by @DRUG$ is not affected by administration of @DRUG$.	DDI-false
DDI-DrugBank.d596.s5.p0	Effect of Other Drugs on the Metabolism of @DRUG$: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of @DRUG$.	DDI-false
DDI-DrugBank.d596.s6.p0	Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of @DRUG$, warfarin, diazepam, or fluoxetine.	DDI-false
DDI-DrugBank.d596.s6.p1	Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, @DRUG$, diazepam, or fluoxetine.	DDI-false
DDI-DrugBank.d596.s6.p2	Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, warfarin, @DRUG$, or fluoxetine.	DDI-false
DDI-DrugBank.d596.s6.p3	Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or @DRUG$.	DDI-false
DDI-DrugBank.d596.s6.p4	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, @DRUG$, diazepam, or fluoxetine.	DDI-false
DDI-DrugBank.d596.s6.p5	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, warfarin, @DRUG$, or fluoxetine.	DDI-false
DDI-DrugBank.d596.s6.p6	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, warfarin, diazepam, or @DRUG$.	DDI-false
DDI-DrugBank.d596.s6.p7	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, @DRUG$, @DRUG$, or fluoxetine.	DDI-false
DDI-DrugBank.d596.s6.p8	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, @DRUG$, diazepam, or @DRUG$.	DDI-false
DDI-DrugBank.d596.s6.p9	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d596.s7.p0	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p1	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p2	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p3	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p4	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p5	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p6	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p7	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p8	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s7.p9	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p10	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p11	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p12	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p13	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p14	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p15	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p16	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s7.p17	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p18	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p19	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p20	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p21	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p22	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p23	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s7.p24	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p25	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p26	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p27	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p28	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p29	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s7.p30	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p31	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p32	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p33	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p34	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s7.p35	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p36	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p37	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p38	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s7.p39	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p40	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p41	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s7.p42	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), @DRUG$ (n=35), and antihistamines (n=15).	DDI-false
DDI-DrugBank.d596.s7.p43	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s7.p44	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and @DRUG$ (n=15).	DDI-false
DDI-DrugBank.d596.s8.p0	Use with @DRUG$: Because of their mechanism of action, @DRUG$ have the potential to interfere with the activity of anticholinergic medications.	DDI-false
DDI-DrugBank.d596.s8.p1	Use with @DRUG$: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of @DRUG$.	DDI-false
DDI-DrugBank.d596.s8.p2	Use with Anticholinergics: Because of their mechanism of action, @DRUG$ have the potential to interfere with the activity of @DRUG$.	DDI-int
DDI-DrugBank.d596.s9.p0	Use with @DRUG$ and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p1	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p2	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p3	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p4	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p5	Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$.	DDI-false
DDI-DrugBank.d596.s9.p6	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p7	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p8	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p9	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p10	Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$.	DDI-false
DDI-DrugBank.d596.s9.p11	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	DDI-effect
DDI-DrugBank.d596.s9.p12	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol.	DDI-effect
DDI-DrugBank.d596.s9.p13	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol.	DDI-effect
DDI-DrugBank.d596.s9.p14	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$.	DDI-effect
DDI-DrugBank.d596.s9.p15	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar @DRUG$ or cholinergic agonists such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p16	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or @DRUG$ such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p17	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$.	DDI-false
DDI-DrugBank.d596.s9.p18	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or @DRUG$ such as bethanechol.	DDI-false
DDI-DrugBank.d596.s9.p19	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as @DRUG$.	DDI-false
DDI-DrugBank.d596.s9.p20	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as @DRUG$.	DDI-false
DDI-DrugBank.d597.s0.p0	@DRUG$ Reports suggest that @DRUG$ may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.	DDI-false
DDI-DrugBank.d597.s0.p1	@DRUG$ Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
DDI-DrugBank.d597.s0.p2	ACE inhibitors Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
DDI-DrugBank.d597.s1.p0	This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
DDI-DrugBank.d597.s11.p0	@DRUG$: Concomitant administration of 200 mg @DRUG$ QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam.	DDI-false
DDI-DrugBank.d597.s11.p1	@DRUG$: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg @DRUG$.	DDI-false
DDI-DrugBank.d597.s11.p2	Cimetidine: Concomitant administration of 200 mg @DRUG$ QID did not alter the single-dose pharmacokinetics of 30 mg @DRUG$.	DDI-false
DDI-DrugBank.d597.s12.p0	@DRUG$: @DRUG$ 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.	DDI-false
DDI-DrugBank.d597.s12.p1	@DRUG$: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of @DRUG$ after b-acetyldigoxin administration for 7 days at clinical doses.	DDI-false
DDI-DrugBank.d597.s12.p2	Digoxin: @DRUG$ 15 mg once daily for 7 days did not alter the plasma concentration profile of @DRUG$ after b-acetyldigoxin administration for 7 days at clinical doses.	DDI-false
DDI-DrugBank.d597.s13.p0	In vitro testing found no protein binding drug interaction between @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d597.s14.p0	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.	DDI-false
DDI-DrugBank.d597.s14.p1	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazide diuretics in some patients.	DDI-false
DDI-DrugBank.d597.s14.p2	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-false
DDI-DrugBank.d597.s14.p3	Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazide diuretics in some patients.	DDI-effect
DDI-DrugBank.d597.s14.p4	Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
DDI-DrugBank.d597.s14.p5	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
DDI-DrugBank.d597.s16.p0	Studies with @DRUG$ agents and @DRUG$ have not demonstrated a reduction in natriuretic effect.	DDI-false
DDI-DrugBank.d597.s17.p0	@DRUG$: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of @DRUG$.	DDI-false
DDI-DrugBank.d597.s18.p0	Nevertheless, during concomitant therapy with @DRUG$ and @DRUG$, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.	DDI-advise
DDI-DrugBank.d597.s19.p0	@DRUG$: In clinical trials, @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	DDI-false
DDI-DrugBank.d597.s19.p1	@DRUG$: In clinical trials, NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-false
DDI-DrugBank.d597.s19.p2	@DRUG$: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
DDI-DrugBank.d597.s19.p3	Lithium: In clinical trials, @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-mechanism
DDI-DrugBank.d597.s19.p4	Lithium: In clinical trials, @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
DDI-DrugBank.d597.s19.p5	Lithium: In clinical trials, NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance.	DDI-false
DDI-DrugBank.d597.s2.p0	@DRUG$: Concomitant administration of @DRUG$ (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam.	DDI-false
DDI-DrugBank.d597.s2.p1	@DRUG$: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of @DRUG$.	DDI-false
DDI-DrugBank.d597.s2.p2	Aspirin: Concomitant administration of @DRUG$ (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of @DRUG$.	DDI-mechanism
DDI-DrugBank.d597.s20.p0	In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone.	DDI-false
DDI-DrugBank.d597.s20.p1	In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving lithium alone.	DDI-false
DDI-DrugBank.d597.s20.p2	In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving @DRUG$ alone.	DDI-false
DDI-DrugBank.d597.s20.p3	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving lithium alone.	DDI-mechanism
DDI-DrugBank.d597.s20.p4	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving @DRUG$ alone.	DDI-false
DDI-DrugBank.d597.s20.p5	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving @DRUG$ alone.	DDI-false
DDI-DrugBank.d597.s22.p0	Patients on @DRUG$ treatment should be closely monitored when @DRUG$ is introduced or withdrawn.	DDI-advise
DDI-DrugBank.d597.s23.p0	@DRUG$: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of @DRUG$ on the pharmacokinetics of methotrexate taken once weekly.	DDI-false
DDI-DrugBank.d597.s23.p1	@DRUG$: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of @DRUG$ taken once weekly.	DDI-false
DDI-DrugBank.d597.s23.p2	Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of @DRUG$ on the pharmacokinetics of @DRUG$ taken once weekly.	DDI-false
DDI-DrugBank.d597.s24.p0	@DRUG$ did not have a significant effect on the pharmacokinetics of single doses of @DRUG$.	DDI-false
DDI-DrugBank.d597.s25.p0	In vitro, @DRUG$ did not displace @DRUG$ from its human serum binding sites.	DDI-false
DDI-DrugBank.d597.s26.p0	@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.	DDI-false
DDI-DrugBank.d597.s26.p1	@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding.	DDI-false
DDI-DrugBank.d597.s26.p2	Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding.	DDI-advise
DDI-DrugBank.d597.s27.p0	The effect of @DRUG$ on the anticoagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8.	DDI-false
DDI-DrugBank.d597.s27.p1	The effect of @DRUG$ on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of @DRUG$ that produced an INR (International Normalized Ratio) between 1.2 and 1.8.	DDI-false
DDI-DrugBank.d597.s27.p2	The effect of meloxicam on the anticoagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of @DRUG$ that produced an INR (International Normalized Ratio) between 1.2 and 1.8.	DDI-false
DDI-DrugBank.d597.s28.p0	In these subjects, @DRUG$ did not alter @DRUG$ pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.	DDI-false
DDI-DrugBank.d597.s28.p1	In these subjects, @DRUG$ did not alter warfarin pharmacokinetics and the average anticoagulant effect of @DRUG$ as determined by prothrombin time.	DDI-false
DDI-DrugBank.d597.s28.p2	In these subjects, meloxicam did not alter @DRUG$ pharmacokinetics and the average anticoagulant effect of @DRUG$ as determined by prothrombin time.	DDI-false
DDI-DrugBank.d597.s30.p0	Caution should be used when administering @DRUG$ with @DRUG$ since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.	DDI-advise
DDI-DrugBank.d597.s30.p1	Caution should be used when administering @DRUG$ with warfarin since patients on @DRUG$ may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.	DDI-false
DDI-DrugBank.d597.s30.p2	Caution should be used when administering MOBIC with @DRUG$ since patients on @DRUG$ may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.	DDI-false
DDI-DrugBank.d597.s4.p0	however, as with other @DRUG$, concomitant administration of @DRUG$ and aspirin is not generally recommended because of the potential for increased adverse effects.	DDI-false
DDI-DrugBank.d597.s4.p1	however, as with other @DRUG$, concomitant administration of meloxicam and @DRUG$ is not generally recommended because of the potential for increased adverse effects.	DDI-advise
DDI-DrugBank.d597.s4.p2	however, as with other NSAIDs, concomitant administration of @DRUG$ and @DRUG$ is not generally recommended because of the potential for increased adverse effects.	DDI-advise
DDI-DrugBank.d597.s5.p0	Concomitant administration of low-dose @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.	DDI-effect
DDI-DrugBank.d597.s5.p1	Concomitant administration of low-dose @DRUG$ with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
DDI-DrugBank.d597.s5.p2	Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
DDI-DrugBank.d597.s6.p0	@DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.	DDI-false
DDI-DrugBank.d597.s7.p0	@DRUG$: Pretreatment for four days with @DRUG$ significantly increased the clearance of meloxicam by 50%.	DDI-false
DDI-DrugBank.d597.s7.p1	@DRUG$: Pretreatment for four days with cholestyramine significantly increased the clearance of @DRUG$ by 50%.	DDI-false
DDI-DrugBank.d597.s7.p2	Cholestyramine: Pretreatment for four days with @DRUG$ significantly increased the clearance of @DRUG$ by 50%.	DDI-mechanism
DDI-DrugBank.d598.s0.p0	@DRUG$ may inhibit the hepatic metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d598.s1.p0	@DRUG$, given at a common clinical dosage, increased the @DRUG$ half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.	DDI-mechanism
DDI-DrugBank.d598.s1.p1	@DRUG$, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the @DRUG$ metabolic clearance rate by 30%.	DDI-mechanism
DDI-DrugBank.d598.s1.p2	Trimethoprim, given at a common clinical dosage, increased the @DRUG$ half-life by 51% and decreased the @DRUG$ metabolic clearance rate by 30%.	DDI-false
DDI-DrugBank.d599.s4.p0	If @DRUG$ replacement is required, the @DRUG$ dose should be carefully adjusted.	DDI-false
DDI-DrugBank.d599.s6.p0	Limited published data indicate that @DRUG$ treatment increases cytochrome P450 (CP450) mediated @DRUG$ clearance in man.	DDI-mechanism
DDI-DrugBank.d599.s7.p0	These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, anticonvulsants, cyclosporin).	DDI-mechanism
DDI-DrugBank.d599.s7.p1	These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, anticonvulsants, cyclosporin).	DDI-mechanism
DDI-DrugBank.d599.s7.p2	These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, @DRUG$, cyclosporin).	DDI-mechanism
DDI-DrugBank.d599.s7.p3	These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, @DRUG$).	DDI-mechanism
DDI-DrugBank.d599.s7.p4	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, @DRUG$, anticonvulsants, cyclosporin).	DDI-false
DDI-DrugBank.d599.s7.p5	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, @DRUG$, cyclosporin).	DDI-false
DDI-DrugBank.d599.s7.p6	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, anticonvulsants, @DRUG$).	DDI-false
DDI-DrugBank.d599.s7.p7	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, @DRUG$, cyclosporin).	DDI-false
DDI-DrugBank.d599.s7.p8	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, anticonvulsants, @DRUG$).	DDI-false
DDI-DrugBank.d599.s7.p9	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, @DRUG$, @DRUG$).	DDI-false
DDI-DrugBank.d600.s1.p0	Concurrent use of @DRUG$ and other @DRUG$ may increase the CNS depressant effects of methyprylon or these other medications.	DDI-false
DDI-DrugBank.d600.s1.p1	Concurrent use of @DRUG$ and other CNS depression-producing drugs may increase the CNS depressant effects of @DRUG$ or these other medications.	DDI-effect
DDI-DrugBank.d600.s1.p2	Concurrent use of alcohol and other @DRUG$ may increase the CNS depressant effects of @DRUG$ or these other medications.	DDI-effect
DDI-DrugBank.d601.s0.p0	@DRUG$ may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-int
DDI-DrugBank.d601.s0.p1	@DRUG$ may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-int
DDI-DrugBank.d601.s0.p2	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-int
DDI-DrugBank.d601.s0.p3	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.	DDI-int
DDI-DrugBank.d601.s0.p4	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.	DDI-int
DDI-DrugBank.d601.s0.p5	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.	DDI-int
DDI-DrugBank.d601.s0.p6	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.	DDI-int
DDI-DrugBank.d601.s0.p7	Barbiturates may decrease the effectiveness of oral @DRUG$, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p8	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p9	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p10	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p11	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p12	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d601.s0.p13	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p14	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p15	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p16	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p17	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d601.s0.p18	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, @DRUG$, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p19	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, @DRUG$, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p20	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p21	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d601.s0.p22	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, @DRUG$, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p23	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p24	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d601.s0.p25	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d601.s0.p26	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d601.s0.p27	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d602.s0.p0	Caution is recommended when administering @DRUG$ with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. @DRUG$).	DDI-advise
DDI-DrugBank.d602.s1.p0	Concomitant treatment with @DRUG$ resulted in a 21% increase in the AUC of @DRUG$.	DDI-mechanism
DDI-DrugBank.d602.s2.p0	Caution is recommended when administering @DRUG$ with @DRUG$.	DDI-advise
DDI-DrugBank.d603.s0.p0	When administered concomitantly with @DRUG$   , @DRUG$ may enhance or precipitate bradycardia, A.V.	DDI-effect
DDI-DrugBank.d603.s2.p0	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p1	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p2	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p3	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p4	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-effect
DDI-DrugBank.d603.s2.p5	The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p6	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p7	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p8	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p9	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-effect
DDI-DrugBank.d603.s2.p10	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p11	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p12	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p13	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-effect
DDI-DrugBank.d603.s2.p14	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p15	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p16	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-effect
DDI-DrugBank.d603.s2.p17	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p18	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.	DDI-effect
DDI-DrugBank.d603.s2.p19	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s2.p20	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction.	DDI-false
DDI-DrugBank.d603.s3.p0	@DRUG$    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., @DRUG$), with or without salt supplementation.	DDI-false
DDI-DrugBank.d603.s5.p0	@DRUG$. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p1	@DRUG$. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p2	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p3	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p4	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p5	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p6	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p7	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p8	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p9	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p10	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p11	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p12	@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p13	ProAmatine. @DRUG$, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p14	ProAmatine. @DRUG$, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p15	ProAmatine. @DRUG$, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p16	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-effect
DDI-DrugBank.d603.s5.p17	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p18	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p19	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p20	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p21	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p22	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p23	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p24	ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p25	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p26	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p27	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-effect
DDI-DrugBank.d603.s5.p28	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p29	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p30	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p31	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p32	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p33	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p34	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p35	ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p36	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p37	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-effect
DDI-DrugBank.d603.s5.p38	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p39	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p40	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p41	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p42	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p43	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p44	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p45	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p46	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-effect
DDI-DrugBank.d603.s5.p47	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p48	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p49	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p50	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p51	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p52	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p53	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p54	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p55	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p56	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p57	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p58	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p59	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p60	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p61	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p62	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p63	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-mechanism
DDI-DrugBank.d603.s5.p64	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-mechanism
DDI-DrugBank.d603.s5.p65	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-mechanism
DDI-DrugBank.d603.s5.p66	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-mechanism
DDI-DrugBank.d603.s5.p67	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-mechanism
DDI-DrugBank.d603.s5.p68	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-mechanism
DDI-DrugBank.d603.s5.p69	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-mechanism
DDI-DrugBank.d603.s5.p70	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p71	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p72	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p73	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p74	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p75	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p76	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, @DRUG$, procainamide, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p77	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p78	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p79	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p80	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p81	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, @DRUG$, triamterene, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p82	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p83	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p84	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p85	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, @DRUG$, flecainide, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p86	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p87	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p88	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d603.s5.p89	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and @DRUG$.	DDI-false
DDI-DrugBank.d603.s5.p90	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d604.s0.p0	@DRUG$ has been reported to enhance the sedative activity of @DRUG$, alcohol, chlorpromazine, and reserpine.	DDI-effect
DDI-DrugBank.d604.s0.p1	@DRUG$ has been reported to enhance the sedative activity of barbiturates, @DRUG$, chlorpromazine, and reserpine.	DDI-false
DDI-DrugBank.d604.s0.p2	@DRUG$ has been reported to enhance the sedative activity of barbiturates, alcohol, @DRUG$, and reserpine.	DDI-false
DDI-DrugBank.d604.s0.p3	@DRUG$ has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and @DRUG$.	DDI-false
DDI-DrugBank.d604.s0.p4	Thalidomide has been reported to enhance the sedative activity of @DRUG$, @DRUG$, chlorpromazine, and reserpine.	DDI-false
DDI-DrugBank.d604.s0.p5	Thalidomide has been reported to enhance the sedative activity of @DRUG$, alcohol, @DRUG$, and reserpine.	DDI-false
DDI-DrugBank.d604.s0.p6	Thalidomide has been reported to enhance the sedative activity of @DRUG$, alcohol, chlorpromazine, and @DRUG$.	DDI-false
DDI-DrugBank.d604.s0.p7	Thalidomide has been reported to enhance the sedative activity of barbiturates, @DRUG$, @DRUG$, and reserpine.	DDI-false
DDI-DrugBank.d604.s0.p8	Thalidomide has been reported to enhance the sedative activity of barbiturates, @DRUG$, chlorpromazine, and @DRUG$.	DDI-false
DDI-DrugBank.d604.s0.p9	Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d604.s2.p0	Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	DDI-false
DDI-DrugBank.d604.s2.p1	Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	DDI-false
DDI-DrugBank.d604.s2.p2	Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied.	DDI-false
DDI-DrugBank.d604.s2.p3	Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied.	DDI-false
DDI-DrugBank.d604.s2.p4	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	DDI-false
DDI-DrugBank.d604.s2.p5	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied.	DDI-false
DDI-DrugBank.d604.s2.p6	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied.	DDI-false
DDI-DrugBank.d604.s2.p7	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied.	DDI-false
DDI-DrugBank.d604.s2.p8	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied.	DDI-false
DDI-DrugBank.d604.s2.p9	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of @DRUG$ were studied.	DDI-false
DDI-DrugBank.d604.s4.p0	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p1	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p2	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p3	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p4	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p5	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p6	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p7	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p8	Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p9	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p10	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p11	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p12	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p13	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p14	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p15	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p16	Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p17	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p18	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p19	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p20	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p21	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p22	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p23	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p24	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p25	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p26	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p27	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p28	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p29	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p30	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p31	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p32	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p33	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p34	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p35	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p36	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p37	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p38	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p39	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p40	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p41	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p42	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, @DRUG$, carbamazepine, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p43	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s4.p44	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, @DRUG$, or certain herbal supplements such as St.	DDI-false
DDI-DrugBank.d604.s5.p0	@DRUG$ with @DRUG$ may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.	DDI-effect
DDI-DrugBank.d605.s0.p0	@DRUG$ may enhance the effects of @DRUG$, barbiturates and other CNS depressants.	DDI-effect
DDI-DrugBank.d605.s0.p1	@DRUG$ may enhance the effects of alcohol, @DRUG$ and other CNS depressants.	DDI-effect
DDI-DrugBank.d605.s0.p2	@DRUG$ may enhance the effects of alcohol, barbiturates and other @DRUG$.	DDI-effect
DDI-DrugBank.d605.s0.p3	SKELAXIN may enhance the effects of @DRUG$, @DRUG$ and other CNS depressants.	DDI-false
DDI-DrugBank.d605.s0.p4	SKELAXIN may enhance the effects of @DRUG$, barbiturates and other @DRUG$.	DDI-false
DDI-DrugBank.d605.s0.p5	SKELAXIN may enhance the effects of alcohol, @DRUG$ and other @DRUG$.	DDI-false
DDI-DrugBank.d606.s0.p0	@DRUG$ and @DRUG$ increase the effects of pseudoephedrine.	DDI-false
DDI-DrugBank.d606.s0.p1	@DRUG$ and beta adrenergic blockers increase the effects of @DRUG$.	DDI-effect
DDI-DrugBank.d606.s0.p2	MAO inhibitors and @DRUG$ increase the effects of @DRUG$.	DDI-effect
DDI-DrugBank.d606.s1.p0	@DRUG$ may reduce the antihypertensive effects of @DRUG$, mecamylamine, reserpine and veratrum alkaloids.	DDI-effect
DDI-DrugBank.d606.s1.p1	@DRUG$ may reduce the antihypertensive effects of methyldopa, @DRUG$, reserpine and veratrum alkaloids.	DDI-effect
DDI-DrugBank.d606.s1.p2	@DRUG$ may reduce the antihypertensive effects of methyldopa, mecamylamine, @DRUG$ and veratrum alkaloids.	DDI-effect
DDI-DrugBank.d606.s1.p3	@DRUG$ may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and @DRUG$.	DDI-effect
DDI-DrugBank.d606.s1.p4	Sympathomimetics may reduce the antihypertensive effects of @DRUG$, @DRUG$, reserpine and veratrum alkaloids.	DDI-false
DDI-DrugBank.d606.s1.p5	Sympathomimetics may reduce the antihypertensive effects of @DRUG$, mecamylamine, @DRUG$ and veratrum alkaloids.	DDI-false
DDI-DrugBank.d606.s1.p6	Sympathomimetics may reduce the antihypertensive effects of @DRUG$, mecamylamine, reserpine and @DRUG$.	DDI-false
DDI-DrugBank.d606.s1.p7	Sympathomimetics may reduce the antihypertensive effects of methyldopa, @DRUG$, @DRUG$ and veratrum alkaloids.	DDI-false
DDI-DrugBank.d606.s1.p8	Sympathomimetics may reduce the antihypertensive effects of methyldopa, @DRUG$, reserpine and @DRUG$.	DDI-false
DDI-DrugBank.d606.s1.p9	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d607.s1.p0	Drugs which may potentiate the myeloproliferative effects of @DRUG$, such as @DRUG$ and corticosteroids, should be used with caution.	DDI-effect
DDI-DrugBank.d607.s1.p1	Drugs which may potentiate the myeloproliferative effects of @DRUG$, such as lithium and @DRUG$, should be used with caution.	DDI-effect
DDI-DrugBank.d607.s1.p2	Drugs which may potentiate the myeloproliferative effects of Leukine, such as @DRUG$ and @DRUG$, should be used with caution.	DDI-false
DDI-DrugBank.d608.s0.p0	The in vitro binding of @DRUG$ to human plasma proteins is unaffected by @DRUG$, and tolmetin does not alter the prothrombin time of normal volunteers.	DDI-false
DDI-DrugBank.d608.s0.p1	The in vitro binding of @DRUG$ to human plasma proteins is unaffected by tolmetin, and @DRUG$ does not alter the prothrombin time of normal volunteers.	DDI-false
DDI-DrugBank.d608.s0.p2	The in vitro binding of warfarin to human plasma proteins is unaffected by @DRUG$, and @DRUG$ does not alter the prothrombin time of normal volunteers.	DDI-false
DDI-DrugBank.d608.s1.p0	However, increased prothrombin time and bleeding have been reported in patients on concomitant @DRUG$ and @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d608.s2.p0	Therefore, caution should be exercised when administering @DRUG$ to patients on @DRUG$.	DDI-advise
DDI-DrugBank.d608.s3.p0	In adult diabetic patients under treatment with either @DRUG$ or @DRUG$ there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents.	DDI-false
DDI-DrugBank.d608.s3.p1	In adult diabetic patients under treatment with either @DRUG$ or insulin there is no change in the clinical effects of either @DRUG$ or the hypoglycemic agents.	DDI-false
DDI-DrugBank.d608.s3.p2	In adult diabetic patients under treatment with either @DRUG$ or insulin there is no change in the clinical effects of either TOLECTIN or the @DRUG$.	DDI-false
DDI-DrugBank.d608.s3.p3	In adult diabetic patients under treatment with either sulfonylureas or @DRUG$ there is no change in the clinical effects of either @DRUG$ or the hypoglycemic agents.	DDI-false
DDI-DrugBank.d608.s3.p4	In adult diabetic patients under treatment with either sulfonylureas or @DRUG$ there is no change in the clinical effects of either TOLECTIN or the @DRUG$.	DDI-false
DDI-DrugBank.d608.s3.p5	In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either @DRUG$ or the @DRUG$.	DDI-false
DDI-DrugBank.d608.s4.p0	Caution should be used if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
DDI-DrugBank.d608.s5.p0	@DRUG$ and other @DRUG$ have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.	DDI-false
DDI-DrugBank.d608.s5.p1	@DRUG$ and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of methotrexate.	DDI-mechanism
DDI-DrugBank.d608.s5.p2	@DRUG$ and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of @DRUG$.	DDI-false
DDI-DrugBank.d608.s5.p3	TOLECTIN and other @DRUG$ have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of methotrexate.	DDI-mechanism
DDI-DrugBank.d608.s5.p4	TOLECTIN and other @DRUG$ have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of @DRUG$.	DDI-false
DDI-DrugBank.d608.s5.p5	TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of @DRUG$.	DDI-false
DDI-DrugBank.d609.s0.p0	An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.	DDI-mechanism
DDI-DrugBank.d609.s0.p1	An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of rosiglitazone.	DDI-false
DDI-DrugBank.d609.s0.p2	An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of @DRUG$.	DDI-false
DDI-DrugBank.d609.s0.p3	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of rosiglitazone.	DDI-false
DDI-DrugBank.d609.s0.p4	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of @DRUG$.	DDI-false
DDI-DrugBank.d609.s0.p5	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of @DRUG$.	DDI-mechanism
DDI-DrugBank.d610.s0.p0	Pharmacokinetic properties of @DRUG$ were not altered by the addition of either @DRUG$ or zidovudine or the combination of lamivudine and zidovudine.	DDI-false
DDI-DrugBank.d610.s0.p1	Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or @DRUG$ or the combination of lamivudine and zidovudine.	DDI-false
DDI-DrugBank.d610.s0.p2	Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or zidovudine or the combination of @DRUG$ and zidovudine.	DDI-false
DDI-DrugBank.d610.s0.p3	Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and @DRUG$.	DDI-false
DDI-DrugBank.d610.s0.p4	Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or @DRUG$ or the combination of lamivudine and zidovudine.	DDI-false
DDI-DrugBank.d610.s0.p5	Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or zidovudine or the combination of @DRUG$ and zidovudine.	DDI-false
DDI-DrugBank.d610.s0.p6	Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or zidovudine or the combination of lamivudine and @DRUG$.	DDI-false
DDI-DrugBank.d610.s0.p7	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or @DRUG$ or the combination of @DRUG$ and zidovudine.	DDI-false
DDI-DrugBank.d610.s0.p8	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or @DRUG$ or the combination of lamivudine and @DRUG$.	DDI-false
DDI-DrugBank.d610.s0.p9	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d610.s1.p0	No clinically significant changes to @DRUG$ or @DRUG$ pharmacokinetics were observed following concomitant administration of abacavir.	DDI-false
DDI-DrugBank.d610.s1.p1	No clinically significant changes to @DRUG$ or zidovudine pharmacokinetics were observed following concomitant administration of @DRUG$.	DDI-false
DDI-DrugBank.d610.s1.p2	No clinically significant changes to lamivudine or @DRUG$ pharmacokinetics were observed following concomitant administration of @DRUG$.	DDI-false
DDI-DrugBank.d610.s2.p0	@DRUG$ has no effect on the pharmacokinetic properties of @DRUG$.	DDI-false
DDI-DrugBank.d610.s3.p0	@DRUG$ decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.	DDI-mechanism
DDI-DrugBank.d610.s3.p1	@DRUG$ decreases the elimination of abacavir causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of abacavir.	DDI-false
DDI-DrugBank.d610.s3.p2	@DRUG$ decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of @DRUG$.	DDI-false
DDI-DrugBank.d610.s3.p3	Ethanol decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of abacavir.	DDI-false
DDI-DrugBank.d610.s3.p4	Ethanol decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of @DRUG$.	DDI-false
DDI-DrugBank.d610.s3.p5	Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of @DRUG$.	DDI-false
DDI-DrugBank.d610.s4.p0	In a study of 11 HIV-infected patients receiving @DRUG$-maintenance therapy (40 mg and 90 mg daily) with 600 mg of @DRUG$ twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).	DDI-mechanism
DDI-DrugBank.d610.s4.p1	In a study of 11 HIV-infected patients receiving @DRUG$-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral @DRUG$ clearance increased 22% (90% CI 6% to 42%).	DDI-false
DDI-DrugBank.d610.s4.p2	In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of @DRUG$ twice daily (twice the currently recommended dose), oral @DRUG$ clearance increased 22% (90% CI 6% to 42%).	DDI-false
DDI-DrugBank.d611.s0.p0	Other @DRUG$ should not be used concomitantly with @DRUG$    (metaproterenol sulfate USP) because they may have additive effects.	DDI-advise
DDI-DrugBank.d611.s0.p1	Other @DRUG$ should not be used concomitantly with Alupent    (@DRUG$ USP) because they may have additive effects.	DDI-advise
DDI-DrugBank.d611.s0.p2	Other beta adrenergic aerosol bronchodilators should not be used concomitantly with @DRUG$    (@DRUG$ USP) because they may have additive effects.	DDI-false
DDI-DrugBank.d611.s1.p0	@DRUG$ should be administered with caution to patients being treated with @DRUG$ or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	DDI-advise
DDI-DrugBank.d611.s1.p1	@DRUG$ should be administered with caution to patients being treated with monoamine oxidase inhibitors or @DRUG$, since the action of beta adrenergic agonists on the vascular system may be potentiated.	DDI-advise
DDI-DrugBank.d611.s1.p2	@DRUG$ should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of @DRUG$ on the vascular system may be potentiated.	DDI-false
DDI-DrugBank.d611.s1.p3	Beta adrenergic agonists should be administered with caution to patients being treated with @DRUG$ or @DRUG$, since the action of beta adrenergic agonists on the vascular system may be potentiated.	DDI-false
DDI-DrugBank.d611.s1.p4	Beta adrenergic agonists should be administered with caution to patients being treated with @DRUG$ or tricyclic antidepressants, since the action of @DRUG$ on the vascular system may be potentiated.	DDI-false
DDI-DrugBank.d611.s1.p5	Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or @DRUG$, since the action of @DRUG$ on the vascular system may be potentiated.	DDI-false
DDI-DrugBank.d613.s0.p0	A study published in 2002 found that @DRUG$ causes a statistically significant increase in plasma clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d613.s1.p0	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering @DRUG$ with @DRUG$ lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.	DDI-mechanism
DDI-DrugBank.d613.s1.p1	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering @DRUG$ with phenytoin lowered the serum @DRUG$ concentration in patients with treatment-resistant epilepsy.	DDI-false
DDI-DrugBank.d613.s1.p2	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with @DRUG$ lowered the serum @DRUG$ concentration in patients with treatment-resistant epilepsy.	DDI-false
DDI-DrugBank.d615.s0.p0	@DRUG$ may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	DDI-effect
DDI-DrugBank.d615.s0.p1	@DRUG$ may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	DDI-effect
DDI-DrugBank.d615.s0.p2	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	DDI-effect
DDI-DrugBank.d615.s0.p3	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.	DDI-effect
DDI-DrugBank.d615.s0.p4	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.	DDI-effect
DDI-DrugBank.d615.s0.p5	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.	DDI-effect
DDI-DrugBank.d615.s0.p6	@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.	DDI-effect
DDI-DrugBank.d615.s0.p7	Triprolidine may enhance the sedative effects of @DRUG$ including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p8	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p9	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p10	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p11	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p12	Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.	DDI-false
DDI-DrugBank.d615.s0.p13	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p14	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p15	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p16	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p17	Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.	DDI-false
DDI-DrugBank.d615.s0.p18	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p19	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, @DRUG$, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p20	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p21	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and @DRUG$.	DDI-false
DDI-DrugBank.d615.s0.p22	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, @DRUG$, sedatives, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p23	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, @DRUG$, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p24	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and @DRUG$.	DDI-false
DDI-DrugBank.d615.s0.p25	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, @DRUG$, and tranquillisers.	DDI-false
DDI-DrugBank.d615.s0.p26	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and @DRUG$.	DDI-false
DDI-DrugBank.d615.s0.p27	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d615.s1.p0	The effects of @DRUG$, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.	DDI-false
DDI-DrugBank.d615.s1.p1	The effects of @DRUG$, such as atropine and @DRUG$ may be enhanced by the concomitant administration of triprolidine.	DDI-false
DDI-DrugBank.d615.s1.p2	The effects of @DRUG$, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$.	DDI-effect
DDI-DrugBank.d615.s1.p3	The effects of anticholinergic drugs, such as @DRUG$ and @DRUG$ may be enhanced by the concomitant administration of triprolidine.	DDI-false
DDI-DrugBank.d615.s1.p4	The effects of anticholinergic drugs, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$.	DDI-effect
DDI-DrugBank.d615.s1.p5	The effects of anticholinergic drugs, such as atropine and @DRUG$ may be enhanced by the concomitant administration of @DRUG$.	DDI-effect
DDI-DrugBank.d616.s1.p0	Caution should be exercised when administering @DRUG$ therapy in combination with other @DRUG$.	DDI-advise
DDI-DrugBank.d618.s1.p0	In addition to bleeding associated with @DRUG$ and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p1	In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p2	In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p3	In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p4	In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.	DDI-effect
DDI-DrugBank.d618.s1.p5	In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p6	In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p7	In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p8	In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.	DDI-effect
DDI-DrugBank.d618.s1.p9	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p10	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p11	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.	DDI-effect
DDI-DrugBank.d618.s1.p12	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	DDI-false
DDI-DrugBank.d618.s1.p13	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.	DDI-effect
DDI-DrugBank.d618.s1.p14	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy.	DDI-effect
DDI-DrugBank.d619.s0.p0	The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d619.s2.p0	This is typical of the interaction of @DRUG$ and @DRUG$.	DDI-int
DDI-DrugBank.d619.s4.p0	Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and @DRUG$ and selective serotonin reuptake inhibitors and ELDEPRYL.	DDI-effect
DDI-DrugBank.d619.s4.p1	Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and ELDEPRYL and @DRUG$ and ELDEPRYL.	DDI-false
DDI-DrugBank.d619.s4.p2	Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and ELDEPRYL and selective serotonin reuptake inhibitors and @DRUG$.	DDI-false
DDI-DrugBank.d619.s4.p3	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and @DRUG$ and @DRUG$ and ELDEPRYL.	DDI-false
DDI-DrugBank.d619.s4.p4	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and @DRUG$ and selective serotonin reuptake inhibitors and @DRUG$.	DDI-false
DDI-DrugBank.d619.s4.p5	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d619.s5.p0	One case of hypertensive crisis has been reported in a patient taking the recommended doses of @DRUG$ and a @DRUG$ (ephedrine).	DDI-effect
DDI-DrugBank.d619.s5.p1	One case of hypertensive crisis has been reported in a patient taking the recommended doses of @DRUG$ and a sympathomimetic medication (@DRUG$).	DDI-effect
DDI-DrugBank.d619.s5.p2	One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d622.s0.p0	When @DRUG$ and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.	DDI-effect
DDI-DrugBank.d622.s0.p1	When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when @DRUG$ is used alone.	DDI-false
DDI-DrugBank.d622.s0.p2	When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when @DRUG$ is used alone.	DDI-false
DDI-DrugBank.d622.s1.p0	This is especially true if the total dose of @DRUG$ has been large and the administration of @DRUG$ has been delayed.	DDI-false
DDI-DrugBank.d622.s2.p0	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of @DRUG$: since @DRUG$ are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;	DDI-false
DDI-DrugBank.d622.s2.p1	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of @DRUG$: since barbiturates are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions;	DDI-false
DDI-DrugBank.d622.s2.p2	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since @DRUG$ are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions;	DDI-effect
DDI-DrugBank.d622.s3.p0	@DRUG$, @DRUG$, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p1	@DRUG$, theophylline, @DRUG$, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p2	@DRUG$, theophylline, aminophylline, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p3	@DRUG$, theophylline, aminophylline, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p4	@DRUG$, theophylline, aminophylline, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p5	morphine, @DRUG$, @DRUG$, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p6	morphine, @DRUG$, aminophylline, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p7	morphine, @DRUG$, aminophylline, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p8	morphine, @DRUG$, aminophylline, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p9	morphine, theophylline, @DRUG$, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p10	morphine, theophylline, @DRUG$, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p11	morphine, theophylline, @DRUG$, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p12	morphine, theophylline, aminophylline, @DRUG$, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p13	morphine, theophylline, aminophylline, @DRUG$, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d622.s3.p14	morphine, theophylline, aminophylline, succinylcholine, @DRUG$, and @DRUG$ should be avoided in patients with organophosphate poisoning.	DDI-false
DDI-DrugBank.d623.s1.p0	@DRUG$ administered concomitantly with @DRUG$ may significantly decrease the serum concentrations of MPA.	DDI-mechanism
DDI-DrugBank.d623.s1.p1	@DRUG$ administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d623.s1.p2	Aminoglutethimide administered concomitantly with @DRUG$ may significantly decrease the serum concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d624.s0.p0	In clinical studies of @DRUG$, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p1	In clinical studies of @DRUG$, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p2	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p3	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p4	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p5	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p6	In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p7	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-effect
DDI-DrugBank.d624.s0.p8	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-effect
DDI-DrugBank.d624.s0.p9	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-effect
DDI-DrugBank.d624.s0.p10	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-effect
DDI-DrugBank.d624.s0.p11	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-effect
DDI-DrugBank.d624.s0.p12	In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.	DDI-effect
DDI-DrugBank.d624.s0.p13	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p14	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p15	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p16	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p17	In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p18	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p19	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p20	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p21	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p22	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p23	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p24	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p25	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p26	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s0.p27	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole.	DDI-false
DDI-DrugBank.d624.s2.p0	Some @DRUG$ can enhance @DRUG$ toxicity by altering antibiotic concentrations in serum and tissue.	DDI-effect
DDI-DrugBank.d624.s2.p1	Some @DRUG$ can enhance aminoglycoside toxicity by altering @DRUG$ concentrations in serum and tissue.	DDI-false
DDI-DrugBank.d624.s2.p2	Some diuretics can enhance @DRUG$ toxicity by altering @DRUG$ concentrations in serum and tissue.	DDI-false
DDI-DrugBank.d624.s3.p0	@DRUG$ should not be administered concomitantly with @DRUG$, furosemide, urea, or mannitol.	DDI-advise
DDI-DrugBank.d624.s3.p1	@DRUG$ should not be administered concomitantly with ethacrynic acid, @DRUG$, urea, or mannitol.	DDI-advise
DDI-DrugBank.d624.s3.p2	@DRUG$ should not be administered concomitantly with ethacrynic acid, furosemide, @DRUG$, or mannitol.	DDI-advise
DDI-DrugBank.d624.s3.p3	@DRUG$ should not be administered concomitantly with ethacrynic acid, furosemide, urea, or @DRUG$.	DDI-advise
DDI-DrugBank.d624.s3.p4	TOBI should not be administered concomitantly with @DRUG$, @DRUG$, urea, or mannitol.	DDI-false
DDI-DrugBank.d624.s3.p5	TOBI should not be administered concomitantly with @DRUG$, furosemide, @DRUG$, or mannitol.	DDI-false
DDI-DrugBank.d624.s3.p6	TOBI should not be administered concomitantly with @DRUG$, furosemide, urea, or @DRUG$.	DDI-false
DDI-DrugBank.d624.s3.p7	TOBI should not be administered concomitantly with ethacrynic acid, @DRUG$, @DRUG$, or mannitol.	DDI-false
DDI-DrugBank.d624.s3.p8	TOBI should not be administered concomitantly with ethacrynic acid, @DRUG$, urea, or @DRUG$.	DDI-false
DDI-DrugBank.d624.s3.p9	TOBI should not be administered concomitantly with ethacrynic acid, furosemide, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d625.s0.p0	DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	DDI-false
DDI-DrugBank.d625.s0.p1	DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	DDI-false
DDI-DrugBank.d625.s0.p2	DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis.	DDI-false
DDI-DrugBank.d625.s0.p3	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	DDI-false
DDI-DrugBank.d625.s0.p4	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis.	DDI-false
DDI-DrugBank.d625.s0.p5	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis.	DDI-effect
DDI-DrugBank.d625.s1.p0	Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous @DRUG$ and who subsequently received @DRUG$ to prevent graft-versus-host disease	DDI-effect
DDI-DrugBank.d627.s0.p0	@DRUG$ should be administered with caution to patients taking @DRUG$ because of the possibility of conduction disturbances.	DDI-advise
DDI-DrugBank.d627.s3.p0	These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., @DRUG$, inhaled @DRUG$).	DDI-false
DDI-DrugBank.d627.s4.p0	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p1	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p2	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p3	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p4	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p5	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p6	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p7	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p8	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p9	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p10	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p11	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p12	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p13	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p14	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p15	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p16	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p17	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p18	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p19	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p20	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p21	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p22	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p23	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p24	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p25	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p26	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p27	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p28	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p29	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p30	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p31	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p32	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p33	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p34	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p35	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p36	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p37	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p38	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p39	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p40	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p41	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p42	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p43	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p44	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p45	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p46	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p47	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p48	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p49	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p50	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p51	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p52	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p53	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p54	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p55	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p56	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p57	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p58	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p59	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p60	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p61	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p62	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p63	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p64	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p65	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p66	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p67	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p68	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, @DRUG$, omeprazole, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p69	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p70	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p71	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p72	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, @DRUG$, paracetamol, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p73	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p74	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p75	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, @DRUG$, and prednisone.	DDI-false
DDI-DrugBank.d627.s4.p76	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and @DRUG$.	DDI-false
DDI-DrugBank.d627.s4.p77	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d628.s0.p0	The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, meperidine, and fentanyl, etc.)	DDI-effect
DDI-DrugBank.d628.s0.p1	The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, meperidine, and fentanyl, etc.)	DDI-effect
DDI-DrugBank.d628.s0.p2	The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, @DRUG$, and fentanyl, etc.)	DDI-effect
DDI-DrugBank.d628.s0.p3	The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and @DRUG$, etc.)	DDI-effect
DDI-DrugBank.d628.s0.p4	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, @DRUG$, meperidine, and fentanyl, etc.)	DDI-false
DDI-DrugBank.d628.s0.p5	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, @DRUG$, and fentanyl, etc.)	DDI-false
DDI-DrugBank.d628.s0.p6	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, meperidine, and @DRUG$, etc.)	DDI-false
DDI-DrugBank.d628.s0.p7	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, @DRUG$, and fentanyl, etc.)	DDI-false
DDI-DrugBank.d628.s0.p8	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, meperidine, and @DRUG$, etc.)	DDI-false
DDI-DrugBank.d628.s0.p9	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, @DRUG$, and @DRUG$, etc.)	DDI-false
DDI-DrugBank.d628.s1.p0	and combinations of @DRUG$ and @DRUG$ (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p1	and combinations of @DRUG$ and sedatives (eg, @DRUG$, barbiturates, chloral hydrate, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p2	and combinations of @DRUG$ and sedatives (eg, benzodiazepines, @DRUG$, chloral hydrate, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p3	and combinations of @DRUG$ and sedatives (eg, benzodiazepines, barbiturates, @DRUG$, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p4	and combinations of @DRUG$ and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, @DRUG$, etc.).	DDI-false
DDI-DrugBank.d628.s1.p5	and combinations of opioids and @DRUG$ (eg, @DRUG$, barbiturates, chloral hydrate, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p6	and combinations of opioids and @DRUG$ (eg, benzodiazepines, @DRUG$, chloral hydrate, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p7	and combinations of opioids and @DRUG$ (eg, benzodiazepines, barbiturates, @DRUG$, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p8	and combinations of opioids and @DRUG$ (eg, benzodiazepines, barbiturates, chloral hydrate, @DRUG$, etc.).	DDI-false
DDI-DrugBank.d628.s1.p9	and combinations of opioids and sedatives (eg, @DRUG$, @DRUG$, chloral hydrate, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p10	and combinations of opioids and sedatives (eg, @DRUG$, barbiturates, @DRUG$, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p11	and combinations of opioids and sedatives (eg, @DRUG$, barbiturates, chloral hydrate, @DRUG$, etc.).	DDI-false
DDI-DrugBank.d628.s1.p12	and combinations of opioids and sedatives (eg, benzodiazepines, @DRUG$, @DRUG$, droperidol, etc.).	DDI-false
DDI-DrugBank.d628.s1.p13	and combinations of opioids and sedatives (eg, benzodiazepines, @DRUG$, chloral hydrate, @DRUG$, etc.).	DDI-false
DDI-DrugBank.d628.s1.p14	and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, @DRUG$, @DRUG$, etc.).	DDI-false
DDI-DrugBank.d628.s3.p0	During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, nitrous oxide or opioids).	DDI-advise
DDI-DrugBank.d628.s3.p1	During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, @DRUG$ or opioids).	DDI-advise
DDI-DrugBank.d628.s3.p2	During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or @DRUG$).	DDI-advise
DDI-DrugBank.d628.s3.p3	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, @DRUG$ or opioids).	DDI-false
DDI-DrugBank.d628.s3.p4	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, nitrous oxide or @DRUG$).	DDI-false
DDI-DrugBank.d628.s3.p5	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, @DRUG$ or @DRUG$).	DDI-false
DDI-DrugBank.d628.s4.p0	The concurrent administration of potent inhalational agents (eg, @DRUG$, @DRUG$, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.	DDI-false
DDI-DrugBank.d628.s4.p1	The concurrent administration of potent inhalational agents (eg, @DRUG$, enflurane, and @DRUG$) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.	DDI-false
DDI-DrugBank.d628.s4.p2	The concurrent administration of potent inhalational agents (eg, @DRUG$, enflurane, and halothane) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated.	DDI-false
DDI-DrugBank.d628.s4.p3	The concurrent administration of potent inhalational agents (eg, isoflurane, @DRUG$, and @DRUG$) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.	DDI-false
DDI-DrugBank.d628.s4.p4	The concurrent administration of potent inhalational agents (eg, isoflurane, @DRUG$, and halothane) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated.	DDI-false
DDI-DrugBank.d628.s4.p5	The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and @DRUG$) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated.	DDI-false
DDI-DrugBank.d628.s6.p0	@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, succinylcholine and nondepolarizing muscle relaxants).	DDI-false
DDI-DrugBank.d628.s6.p1	@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, @DRUG$ and nondepolarizing muscle relaxants).	DDI-false
DDI-DrugBank.d628.s6.p2	@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and @DRUG$).	DDI-false
DDI-DrugBank.d628.s6.p3	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, @DRUG$ and nondepolarizing muscle relaxants).	DDI-false
DDI-DrugBank.d628.s6.p4	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, succinylcholine and @DRUG$).	DDI-false
DDI-DrugBank.d628.s6.p5	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d628.s7.p0	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of @DRUG$, inhalational agents, @DRUG$, and local anesthetic agents) have been observed.	DDI-false
DDI-DrugBank.d628.s7.p1	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of @DRUG$, inhalational agents, analgesic agents, and local @DRUG$) have been observed.	DDI-false
DDI-DrugBank.d628.s7.p2	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, @DRUG$, and local @DRUG$) have been observed.	DDI-false
DDI-DrugBank.d629.s0.p0	Oral @DRUG$ has been reported to potentiate the anticoagulant effect of @DRUG$ and warfarin, resulting in a prolongation of prothrombin time.	DDI-effect
DDI-DrugBank.d629.s0.p1	Oral @DRUG$ has been reported to potentiate the anticoagulant effect of coumarin and @DRUG$, resulting in a prolongation of prothrombin time.	DDI-effect
DDI-DrugBank.d629.s0.p2	Oral metronidazole has been reported to potentiate the anticoagulant effect of @DRUG$ and @DRUG$, resulting in a prolongation of prothrombin time.	DDI-false
DDI-DrugBank.d629.s1.p0	Drug interactions should be kept in mind when @DRUG$ (@DRUG$ gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.	DDI-false
DDI-DrugBank.d629.s1.p1	Drug interactions should be kept in mind when @DRUG$ (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical @DRUG$ administration because of low absorption.	DDI-false
DDI-DrugBank.d629.s1.p2	Drug interactions should be kept in mind when METROGEL (@DRUG$ gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical @DRUG$ administration because of low absorption.	DDI-false
DDI-DrugBank.d630.s1.p0	Caution is advised for patients receiving high-dose @DRUG$ and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	DDI-advise
DDI-DrugBank.d630.s1.p1	Caution is advised for patients receiving high-dose @DRUG$ and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and carbonic anhydrase inhibitors.	DDI-false
DDI-DrugBank.d630.s1.p2	Caution is advised for patients receiving high-dose @DRUG$ and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and @DRUG$.	DDI-false
DDI-DrugBank.d630.s1.p3	Caution is advised for patients receiving high-dose aspirin and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and carbonic anhydrase inhibitors.	DDI-false
DDI-DrugBank.d630.s1.p4	Caution is advised for patients receiving high-dose aspirin and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and @DRUG$.	DDI-false
DDI-DrugBank.d630.s1.p5	Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d631.s0.p0	@DRUG$ may be used with @DRUG$, quinine and other antimalarials, and with other antibiotics.	DDI-false
DDI-DrugBank.d631.s0.p1	@DRUG$ may be used with sulfonamides, @DRUG$ and other antimalarials, and with other antibiotics.	DDI-false
DDI-DrugBank.d631.s0.p2	@DRUG$ may be used with sulfonamides, quinine and other @DRUG$, and with other antibiotics.	DDI-false
DDI-DrugBank.d631.s0.p3	@DRUG$ may be used with sulfonamides, quinine and other antimalarials, and with other @DRUG$.	DDI-false
DDI-DrugBank.d631.s0.p4	Pyrimethamine may be used with @DRUG$, @DRUG$ and other antimalarials, and with other antibiotics.	DDI-false
DDI-DrugBank.d631.s0.p5	Pyrimethamine may be used with @DRUG$, quinine and other @DRUG$, and with other antibiotics.	DDI-false
DDI-DrugBank.d631.s0.p6	Pyrimethamine may be used with @DRUG$, quinine and other antimalarials, and with other @DRUG$.	DDI-false
DDI-DrugBank.d631.s0.p7	Pyrimethamine may be used with sulfonamides, @DRUG$ and other @DRUG$, and with other antibiotics.	DDI-false
DDI-DrugBank.d631.s0.p8	Pyrimethamine may be used with sulfonamides, @DRUG$ and other antimalarials, and with other @DRUG$.	DDI-false
DDI-DrugBank.d631.s0.p9	Pyrimethamine may be used with sulfonamides, quinine and other @DRUG$, and with other @DRUG$.	DDI-false
DDI-DrugBank.d631.s2.p0	@DRUG$ (@DRUG$) should be administered until normal hematopoiesis is restored.	DDI-false
DDI-DrugBank.d631.s3.p0	Mild hepatotoxicity has been reported in some patients when @DRUG$ and @DRUG$ were administered concomitantly.	DDI-effect
DDI-DrugBank.d632.s0.p0	Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	DDI-advise
DDI-DrugBank.d632.s0.p1	Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	DDI-advise
DDI-DrugBank.d632.s0.p2	Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$).	DDI-advise
DDI-DrugBank.d632.s0.p3	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	DDI-false
DDI-DrugBank.d632.s0.p4	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$).	DDI-false
DDI-DrugBank.d632.s0.p5	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$).	DDI-false
DDI-DrugBank.d632.s3.p0	When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as @DRUG$), the agent should be administered at least 1 hour prior to or 2 hours after @DRUG$ injection.	DDI-advise
DDI-DrugBank.d632.s4.p0	In clinical trials, the concomitant use of @DRUG$ or @DRUG$ did not alter the adverse event profile of SYMLIN.	DDI-false
DDI-DrugBank.d632.s4.p1	In clinical trials, the concomitant use of @DRUG$ or biguanides did not alter the adverse event profile of @DRUG$.	DDI-false
DDI-DrugBank.d632.s4.p2	In clinical trials, the concomitant use of sulfonylureas or @DRUG$ did not alter the adverse event profile of @DRUG$.	DDI-false
DDI-DrugBank.d632.s5.p0	No formal interaction studies have been performed to assess the effect of @DRUG$ on the kinetics of oral @DRUG$.	DDI-false
DDI-DrugBank.d632.s6.p0	Mixing @DRUG$ and @DRUG$ The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	DDI-false
DDI-DrugBank.d632.s6.p1	Mixing @DRUG$ and Insulin The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	DDI-false
DDI-DrugBank.d632.s6.p2	Mixing @DRUG$ and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection.	DDI-false
DDI-DrugBank.d632.s6.p3	Mixing SYMLIN and @DRUG$ The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	DDI-false
DDI-DrugBank.d632.s6.p4	Mixing SYMLIN and @DRUG$ The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection.	DDI-false
DDI-DrugBank.d632.s6.p5	Mixing SYMLIN and Insulin The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection.	DDI-mechanism
DDI-DrugBank.d632.s7.p0	Thus, @DRUG$ and @DRUG$ should not be mixed and must be administered separately.	DDI-false
DDI-DrugBank.d633.s0.p0	Since @DRUG$ is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d633.s1.p0	In a formal, single-dose interaction study (n = 6 males) the clearance of @DRUG$ was decreased by 38% following the coadministration of @DRUG$, an inhibitor of CYP1A2.	DDI-mechanism
DDI-DrugBank.d633.s11.p0	In a formal study, @DRUG$ were shown not to affect @DRUG$    plasma concentrations.	DDI-false
DDI-DrugBank.d633.s12.p0	ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and @DRUG$, diuretics, or propranolol.	DDI-false
DDI-DrugBank.d633.s12.p1	ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and digoxin, @DRUG$, or propranolol.	DDI-false
DDI-DrugBank.d633.s12.p2	ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and digoxin, diuretics, or @DRUG$.	DDI-false
DDI-DrugBank.d633.s12.p3	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and @DRUG$, @DRUG$, or propranolol.	DDI-false
DDI-DrugBank.d633.s12.p4	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and @DRUG$, diuretics, or @DRUG$.	DDI-false
DDI-DrugBank.d633.s12.p5	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d633.s13.p0	Concurrent administration of @DRUG$ and @DRUG$    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels;	DDI-mechanism
DDI-DrugBank.d633.s13.p1	Concurrent administration of @DRUG$ and Mexitil    has been reported to increase, decrease, or leave unchanged @DRUG$    plasma levels;	DDI-false
DDI-DrugBank.d633.s13.p2	Concurrent administration of cimetidine and @DRUG$    has been reported to increase, decrease, or leave unchanged @DRUG$    plasma levels;	DDI-false
DDI-DrugBank.d633.s15.p0	@DRUG$    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.	DDI-false
DDI-DrugBank.d633.s15.p1	@DRUG$    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.	DDI-false
DDI-DrugBank.d633.s15.p2	@DRUG$    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels.	DDI-false
DDI-DrugBank.d633.s15.p3	@DRUG$    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels.	DDI-false
DDI-DrugBank.d633.s15.p4	Mexitil    does not alter serum @DRUG$ levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.	DDI-false
DDI-DrugBank.d633.s15.p5	Mexitil    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels.	DDI-false
DDI-DrugBank.d633.s15.p6	Mexitil    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels.	DDI-false
DDI-DrugBank.d633.s15.p7	Mexitil    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels.	DDI-false
DDI-DrugBank.d633.s15.p8	Mexitil    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels.	DDI-mechanism
DDI-DrugBank.d633.s15.p9	Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum @DRUG$ levels.	DDI-false
DDI-DrugBank.d633.s16.p0	Concurrent use of @DRUG$    and @DRUG$ may lead to increased plasma theophylline levels.	DDI-mechanism
DDI-DrugBank.d633.s16.p1	Concurrent use of @DRUG$    and theophylline may lead to increased plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d633.s16.p2	Concurrent use of Mexitil    and @DRUG$ may lead to increased plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d633.s18.p0	This increase was observed at the first test point which was the second day after starting @DRUG$   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p1	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p2	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p3	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p4	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p5	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p6	This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p7	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p8	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-mechanism
DDI-DrugBank.d633.s18.p9	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p10	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p11	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p12	This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p13	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p14	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p15	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p16	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p17	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p18	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p19	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p20	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p21	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p22	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-advise
DDI-DrugBank.d633.s18.p23	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p24	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p25	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p26	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed.	DDI-false
DDI-DrugBank.d633.s18.p27	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the @DRUG$    dose is changed.	DDI-false
DDI-DrugBank.d633.s2.p0	In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of @DRUG$ did not alter the kinetics of @DRUG$ in the poor CYP2D6 metabolizer group.	DDI-false
DDI-DrugBank.d633.s20.p0	Additionally, in one controlled study in five normal subjects and seven patients, the clearance of @DRUG$ was decreased 50% following the administration of @DRUG$   .	DDI-mechanism
DDI-DrugBank.d633.s4.p0	In this crossover steady state study, the pharmacokinetics of @DRUG$ were unaffected in either phenotype by the coadministration of @DRUG$.	DDI-false
DDI-DrugBank.d633.s5.p0	Addition of @DRUG$ to @DRUG$ did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.	DDI-false
DDI-DrugBank.d633.s5.p1	Addition of @DRUG$ to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than @DRUG$ alone.	DDI-false
DDI-DrugBank.d633.s5.p2	Addition of mexiletine to @DRUG$ did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than @DRUG$ alone.	DDI-false
DDI-DrugBank.d633.s6.p0	When concomitant administration of either of these two drugs with @DRUG$ is initiated, the dose of @DRUG$ should be slowly titrated to desired effect.	DDI-false
DDI-DrugBank.d633.s7.p0	In a large compassionate use program @DRUG$    has been used concurrently with commonly employed antianginal, @DRUG$, and anticoagulant drugs without observed interactions.	DDI-false
DDI-DrugBank.d633.s7.p1	In a large compassionate use program @DRUG$    has been used concurrently with commonly employed antianginal, antihypertensive, and @DRUG$ without observed interactions.	DDI-false
DDI-DrugBank.d633.s7.p2	In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, @DRUG$, and @DRUG$ without observed interactions.	DDI-false
DDI-DrugBank.d633.s8.p0	A variety of @DRUG$ such as @DRUG$ or propranolol were also added, sometimes with improved control of ventricular ectopy.	DDI-false
DDI-DrugBank.d633.s8.p1	A variety of @DRUG$ such as quinidine or @DRUG$ were also added, sometimes with improved control of ventricular ectopy.	DDI-false
DDI-DrugBank.d633.s8.p2	A variety of antiarrhythmics such as @DRUG$ or @DRUG$ were also added, sometimes with improved control of ventricular ectopy.	DDI-false
DDI-DrugBank.d633.s9.p0	When @DRUG$ or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.	DDI-false
DDI-DrugBank.d633.s9.p1	When @DRUG$ or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.	DDI-false
DDI-DrugBank.d633.s9.p2	When @DRUG$ or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported.	DDI-mechanism
DDI-DrugBank.d633.s9.p3	When @DRUG$ or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported.	DDI-false
DDI-DrugBank.d633.s9.p4	When phenytoin or other hepatic enzyme inducers such as @DRUG$ and @DRUG$ have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.	DDI-false
DDI-DrugBank.d633.s9.p5	When phenytoin or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported.	DDI-mechanism
DDI-DrugBank.d633.s9.p6	When phenytoin or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported.	DDI-false
DDI-DrugBank.d633.s9.p7	When phenytoin or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported.	DDI-mechanism
DDI-DrugBank.d633.s9.p8	When phenytoin or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported.	DDI-false
DDI-DrugBank.d633.s9.p9	When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with @DRUG$   , lowered @DRUG$    plasma levels have been reported.	DDI-false
DDI-DrugBank.d634.s0.p0	@DRUG$ (oral): The activity of oral @DRUG$ may be potentiated by anti-vitamin-K activity attributed to methimazole.	DDI-false
DDI-DrugBank.d634.s0.p1	@DRUG$ (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to @DRUG$.	DDI-false
DDI-DrugBank.d634.s0.p2	Anticoagulants (oral): The activity of oral @DRUG$ may be potentiated by anti-vitamin-K activity attributed to @DRUG$.	DDI-effect
DDI-DrugBank.d634.s3.p0	@DRUG$: Serum digitalis levels may be increased when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid;	DDI-false
DDI-DrugBank.d634.s5.p0	@DRUG$: @DRUG$ clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid;	DDI-false
DDI-DrugBank.d634.s5.p1	@DRUG$: Theophylline clearance may decrease when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid;	DDI-false
DDI-DrugBank.d634.s5.p2	Theophylline: @DRUG$ clearance may decrease when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid;	DDI-false
DDI-DrugBank.d635.s0.p0	Other @DRUG$ should not be used concomitantly with @DRUG$ because they may have additive effects.	DDI-advise
DDI-DrugBank.d636.s0.p0	Some @DRUG$ may interact with @DRUG$.	DDI-int
DDI-DrugBank.d636.s2.p0	Those @DRUG$ include @DRUG$, valproic acid, and phenobarbital.	DDI-false
DDI-DrugBank.d636.s2.p1	Those @DRUG$ include divalproex sodium, @DRUG$, and phenobarbital.	DDI-false
DDI-DrugBank.d636.s2.p2	Those @DRUG$ include divalproex sodium, valproic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d636.s2.p3	Those anticonvulsants include @DRUG$, @DRUG$, and phenobarbital.	DDI-false
DDI-DrugBank.d636.s2.p4	Those anticonvulsants include @DRUG$, valproic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d636.s2.p5	Those anticonvulsants include divalproex sodium, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d636.s3.p0	@DRUG$ may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-effect
DDI-DrugBank.d636.s3.p1	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-effect
DDI-DrugBank.d636.s3.p2	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-effect
DDI-DrugBank.d636.s3.p3	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-effect
DDI-DrugBank.d636.s3.p4	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-effect
DDI-DrugBank.d636.s3.p5	@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p6	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p7	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p8	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p9	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p10	Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p11	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p12	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p13	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p14	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p15	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p16	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p17	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p18	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p19	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d636.s3.p20	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that @DRUG$ may interact with other drugs that are not listed here.	DDI-false
DDI-DrugBank.d637.s0.p0	Use with Other @DRUG$: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p1	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p2	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p3	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p4	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p5	Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or @DRUG$.	DDI-false
DDI-DrugBank.d637.s0.p6	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	DDI-effect
DDI-DrugBank.d637.s0.p7	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs.	DDI-effect
DDI-DrugBank.d637.s0.p8	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs.	DDI-effect
DDI-DrugBank.d637.s0.p9	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or psychotropic drugs.	DDI-effect
DDI-DrugBank.d637.s0.p10	Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or @DRUG$.	DDI-effect
DDI-DrugBank.d637.s0.p11	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p12	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p13	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, @DRUG$, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p14	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or @DRUG$.	DDI-false
DDI-DrugBank.d637.s0.p15	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, @DRUG$, antihistaminics, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p16	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, @DRUG$, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p17	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or @DRUG$.	DDI-false
DDI-DrugBank.d637.s0.p18	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, @DRUG$, or psychotropic drugs.	DDI-false
DDI-DrugBank.d637.s0.p19	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or @DRUG$.	DDI-false
DDI-DrugBank.d637.s0.p20	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d637.s1.p0	Use of @DRUG$ in conjunction with oral @DRUG$ may increase the risk of respiratory depression, hypotension and profound sedation or coma.	DDI-effect
DDI-DrugBank.d637.s2.p0	Interaction with @DRUG$: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p1	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p2	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p3	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p4	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p5	Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.	DDI-false
DDI-DrugBank.d637.s2.p6	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p7	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p8	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p9	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p10	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.	DDI-advise
DDI-DrugBank.d637.s2.p11	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p12	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p13	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p14	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.	DDI-advise
DDI-DrugBank.d637.s2.p15	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p16	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p17	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.	DDI-advise
DDI-DrugBank.d637.s2.p18	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	DDI-false
DDI-DrugBank.d637.s2.p19	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.	DDI-advise
DDI-DrugBank.d637.s2.p20	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$.	DDI-advise
DDI-DrugBank.d638.s0.p0	@DRUG$ may decrease the hypotensive effect of @DRUG$.	DDI-effect
DDI-DrugBank.d638.s2.p0	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p1	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p2	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p3	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p4	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p5	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p6	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p7	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p8	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).	DDI-mechanism
DDI-DrugBank.d638.s2.p9	Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).	DDI-mechanism
DDI-DrugBank.d638.s2.p10	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p11	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p12	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p13	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p14	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p15	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p16	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p17	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p18	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).	DDI-false
DDI-DrugBank.d638.s2.p19	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p20	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p21	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p22	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p23	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p24	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p25	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p26	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).	DDI-false
DDI-DrugBank.d638.s2.p27	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p28	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p29	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p30	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p31	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p32	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p33	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).	DDI-false
DDI-DrugBank.d638.s2.p34	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p35	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p36	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p37	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p38	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p39	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).	DDI-false
DDI-DrugBank.d638.s2.p40	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p41	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p42	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p43	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p44	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$).	DDI-false
DDI-DrugBank.d638.s2.p45	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and @DRUG$ (imipramine, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p46	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (@DRUG$, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p47	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, @DRUG$, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p48	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, @DRUG$).	DDI-false
DDI-DrugBank.d638.s2.p49	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (@DRUG$, clomipramine, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p50	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, @DRUG$, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p51	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, @DRUG$).	DDI-false
DDI-DrugBank.d638.s2.p52	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, @DRUG$, desipramine).	DDI-false
DDI-DrugBank.d638.s2.p53	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, @DRUG$).	DDI-false
DDI-DrugBank.d638.s2.p54	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, @DRUG$).	DDI-false
DDI-DrugBank.d638.s5.p0	The safety of using @DRUG$ in combination with @DRUG$ or other centrally acting alpha-2 agonists has not been systemically evaluated.	DDI-false
DDI-DrugBank.d638.s5.p1	The safety of using @DRUG$ in combination with clonidine or other centrally acting @DRUG$ has not been systemically evaluated.	DDI-false
DDI-DrugBank.d638.s5.p2	The safety of using methylphenidate in combination with @DRUG$ or other centrally acting @DRUG$ has not been systemically evaluated.	DDI-false
DDI-DrugBank.d639.s0.p0	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p1	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p2	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p3	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p4	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p5	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p6	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p7	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p8	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p9	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p10	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s0.p11	Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p12	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p13	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p14	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p15	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p16	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p17	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p18	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p19	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p20	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p21	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p22	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p23	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p24	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p25	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p26	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p27	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p28	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p29	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p30	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p31	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p32	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p33	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p34	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p35	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p36	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p37	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p38	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p39	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p40	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p41	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p42	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p43	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p44	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p45	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p46	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p47	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p48	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p49	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p50	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p51	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p52	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p53	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p54	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p55	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p56	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p57	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p58	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p59	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p60	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p61	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p62	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p63	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p64	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p65	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p66	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p67	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p68	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p69	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p70	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p71	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p72	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, @DRUG$, voriconizole) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p73	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p74	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p75	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, @DRUG$) may increases sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s0.p76	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s0.p77	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s2.p0	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s2.p1	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s2.p2	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s2.p3	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s2.p4	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s2.p5	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s2.p6	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.	DDI-mechanism
DDI-DrugBank.d639.s2.p7	Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s2.p8	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p9	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p10	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p11	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p12	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p13	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p14	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s2.p15	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p16	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p17	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p18	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p19	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p20	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s2.p21	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p22	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p23	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p24	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p25	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s2.p26	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p27	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p28	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p29	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s2.p30	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p31	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p32	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s2.p33	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations.	DDI-false
DDI-DrugBank.d639.s2.p34	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d639.s2.p35	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d640.s0.p0	@DRUG$: Excessive reductions in blood pressure may occur in patients on diuretic therapy when @DRUG$ are started.	DDI-false
DDI-DrugBank.d640.s1.p0	The possibility of hypotensive effects with @DRUG$    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with @DRUG$   . If this is not possible, the starting dose of moexpril should be reduced..	DDI-false
DDI-DrugBank.d640.s1.p1	The possibility of hypotensive effects with @DRUG$    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of @DRUG$ should be reduced..	DDI-false
DDI-DrugBank.d640.s1.p2	The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with @DRUG$   . If this is not possible, the starting dose of @DRUG$ should be reduced..	DDI-false
DDI-DrugBank.d640.s10.p0	@DRUG$    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p1	@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p2	@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p3	@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p4	@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p5	UNIVASC    has been used in clinical trials concomitantly with @DRUG$, @DRUG$, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p6	UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p7	UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p8	UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p9	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p10	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p11	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p12	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p13	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, digoxin, oral @DRUG$, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s10.p14	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, @DRUG$, oral @DRUG$, and cholesterol-lowering agents.	DDI-false
DDI-DrugBank.d640.s2.p0	@DRUG$ Supplements and @DRUG$: UNIVASC    can increase serum potassium because it decreases aldosterone secretion.	DDI-false
DDI-DrugBank.d640.s2.p1	@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$    can increase serum potassium because it decreases aldosterone secretion.	DDI-false
DDI-DrugBank.d640.s2.p2	Potassium Supplements and @DRUG$: @DRUG$    can increase serum potassium because it decreases aldosterone secretion.	DDI-false
DDI-DrugBank.d640.s3.p0	Use of @DRUG$ (@DRUG$, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p1	Use of @DRUG$ (spironolactone, @DRUG$, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p2	Use of @DRUG$ (spironolactone, triamterene, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p3	Use of @DRUG$ (spironolactone, triamterene, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p4	Use of @DRUG$ (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.	DDI-effect
DDI-DrugBank.d640.s3.p5	Use of potassium-sparing diuretics (@DRUG$, @DRUG$, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p6	Use of potassium-sparing diuretics (@DRUG$, triamterene, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p7	Use of potassium-sparing diuretics (@DRUG$, triamterene, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p8	Use of potassium-sparing diuretics (@DRUG$, triamterene, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.	DDI-effect
DDI-DrugBank.d640.s3.p9	Use of potassium-sparing diuretics (spironolactone, @DRUG$, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p10	Use of potassium-sparing diuretics (spironolactone, @DRUG$, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p11	Use of potassium-sparing diuretics (spironolactone, @DRUG$, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.	DDI-effect
DDI-DrugBank.d640.s3.p12	Use of potassium-sparing diuretics (spironolactone, triamterene, @DRUG$) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d640.s3.p13	Use of potassium-sparing diuretics (spironolactone, triamterene, @DRUG$) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.	DDI-effect
DDI-DrugBank.d640.s3.p14	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or @DRUG$ supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia.	DDI-effect
DDI-DrugBank.d640.s5.p0	Oral @DRUG$: Interaction studies with @DRUG$ failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.	DDI-false
DDI-DrugBank.d640.s5.p1	Oral @DRUG$: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the @DRUG$ or on its anticoagulant effect.	DDI-false
DDI-DrugBank.d640.s5.p2	Oral Anticoagulants: Interaction studies with @DRUG$ failed to identify any clinically important effect on the serum concentrations of the @DRUG$ or on its anticoagulant effect.	DDI-false
DDI-DrugBank.d640.s6.p0	@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.	DDI-false
DDI-DrugBank.d640.s6.p1	@DRUG$: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.	DDI-false
DDI-DrugBank.d640.s6.p2	@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.	DDI-false
DDI-DrugBank.d640.s6.p3	@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.	DDI-false
DDI-DrugBank.d640.s6.p4	Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.	DDI-false
DDI-DrugBank.d640.s6.p5	Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.	DDI-false
DDI-DrugBank.d640.s6.p6	Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.	DDI-false
DDI-DrugBank.d640.s6.p7	Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.	DDI-false
DDI-DrugBank.d640.s6.p8	Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.	DDI-false
DDI-DrugBank.d640.s6.p9	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with @DRUG$.	DDI-effect
DDI-DrugBank.d640.s8.p0	If a @DRUG$ is also used, the risk of @DRUG$ toxicity may be increased.	DDI-effect
DDI-DrugBank.d640.s9.p0	Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with @DRUG$, digoxin, or cimetidine.	DDI-false
DDI-DrugBank.d640.s9.p1	Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with hydrochlorothiazide, @DRUG$, or cimetidine.	DDI-false
DDI-DrugBank.d640.s9.p2	Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with hydrochlorothiazide, digoxin, or @DRUG$.	DDI-false
DDI-DrugBank.d640.s9.p3	Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with @DRUG$, @DRUG$, or cimetidine.	DDI-false
DDI-DrugBank.d640.s9.p4	Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with @DRUG$, digoxin, or @DRUG$.	DDI-false
DDI-DrugBank.d640.s9.p5	Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d641.s2.p0	Concomitant administration of substances that are also tubularly secreted (e.g., @DRUG$) could potentially result in delayed clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d641.s3.p0	Although @DRUG$ (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	DDI-false
DDI-DrugBank.d641.s3.p1	Although @DRUG$ (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	DDI-false
DDI-DrugBank.d641.s3.p2	Although @DRUG$ (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	DDI-false
DDI-DrugBank.d641.s3.p3	Although ibuprofen (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	DDI-false
DDI-DrugBank.d641.s3.p4	Although ibuprofen (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	DDI-false
DDI-DrugBank.d641.s3.p5	Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	DDI-advise
DDI-DrugBank.d641.s4.p0	Patients with mild to moderate renal insufficiency should avoid taking @DRUG$ with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of @DRUG$.	DDI-advise
DDI-DrugBank.d641.s5.p0	In the absence of data regarding potential interaction between @DRUG$ and @DRUG$ with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.	DDI-false
DDI-DrugBank.d641.s5.p1	In the absence of data regarding potential interaction between @DRUG$ and NSAIDs with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.	DDI-false
DDI-DrugBank.d641.s5.p2	In the absence of data regarding potential interaction between @DRUG$ and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration.	DDI-false
DDI-DrugBank.d641.s5.p3	In the absence of data regarding potential interaction between ALIMTA and @DRUG$ with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.	DDI-false
DDI-DrugBank.d641.s5.p4	In the absence of data regarding potential interaction between ALIMTA and @DRUG$ with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration.	DDI-false
DDI-DrugBank.d641.s5.p5	In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration.	DDI-advise
DDI-DrugBank.d642.s0.p0	Prothrombin time or other suitable anticoagulation test should be monitored if @DRUG$ is administered with @DRUG$.	DDI-advise
DDI-DrugBank.d642.s1.p0	Concurrent use of @DRUG$ with oral @DRUG$ may render oral contraceptives less effective.	DDI-effect
DDI-DrugBank.d642.s1.p1	Concurrent use of @DRUG$ with oral contraceptives may render oral @DRUG$ less effective.	DDI-false
DDI-DrugBank.d642.s1.p2	Concurrent use of antibacterial drugs with oral @DRUG$ may render oral @DRUG$ less effective.	DDI-false
DDI-DrugBank.d643.s0.p0	@DRUG$ may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-int
DDI-DrugBank.d643.s0.p1	@DRUG$ may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-int
DDI-DrugBank.d643.s0.p2	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p3	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-int
DDI-DrugBank.d643.s0.p4	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p5	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-int
DDI-DrugBank.d643.s0.p6	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p7	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-int
DDI-DrugBank.d643.s0.p8	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-int
DDI-DrugBank.d643.s0.p9	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p10	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p11	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-int
DDI-DrugBank.d643.s0.p12	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-int
DDI-DrugBank.d643.s0.p13	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p14	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p15	@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p16	Melatonin may interact with the following drugs: @DRUG$ and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p17	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p18	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p19	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p20	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p21	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p22	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p23	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p24	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p25	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p26	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p27	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p28	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p29	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p30	Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p31	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p32	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p33	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p34	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p35	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p36	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p37	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p38	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p39	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p40	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p41	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p42	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p43	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p44	Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p45	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p46	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p47	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p48	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p49	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p50	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p51	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p52	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p53	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p54	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p55	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p56	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p57	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p58	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p59	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p60	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p61	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p62	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p63	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p64	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p65	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p66	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p67	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p68	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p69	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p70	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p71	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p72	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p73	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p74	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p75	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p76	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p77	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p78	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p79	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p80	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p81	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p82	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p83	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p84	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p85	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p86	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p87	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p88	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p89	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p90	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p91	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p92	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p93	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p94	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p95	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p96	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p97	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p98	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p99	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p100	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p101	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p102	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p103	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p104	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p105	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p106	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p107	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p108	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p109	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p110	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p111	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p112	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p113	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p114	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p115	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-effect
DDI-DrugBank.d643.s0.p116	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p117	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p118	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p119	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p120	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p121	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p122	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p123	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p124	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p125	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p126	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p127	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p128	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p129	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p130	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p131	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-false
DDI-DrugBank.d643.s0.p132	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p133	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and @DRUG$ may interfere with the efficacy of the corticosteroids).	DDI-effect
DDI-DrugBank.d643.s0.p134	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d643.s0.p135	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the @DRUG$).	DDI-false
DDI-DrugBank.d645.s0.p0	In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of @DRUG$, ethinylestradiol, ethoxycoumarin, and cyclosporine.	DDI-false
DDI-DrugBank.d645.s0.p1	In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, @DRUG$, ethoxycoumarin, and cyclosporine.	DDI-false
DDI-DrugBank.d645.s0.p2	In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, ethinylestradiol, @DRUG$, and cyclosporine.	DDI-false
DDI-DrugBank.d645.s0.p3	In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s0.p4	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, @DRUG$, ethoxycoumarin, and cyclosporine.	DDI-false
DDI-DrugBank.d645.s0.p5	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, ethinylestradiol, @DRUG$, and cyclosporine.	DDI-false
DDI-DrugBank.d645.s0.p6	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, ethinylestradiol, ethoxycoumarin, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s0.p7	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, @DRUG$, @DRUG$, and cyclosporine.	DDI-false
DDI-DrugBank.d645.s0.p8	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, @DRUG$, ethoxycoumarin, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s0.p9	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s2.p0	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, @DRUG$ (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.	DDI-false
DDI-DrugBank.d645.s2.p1	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, selective serotonin reuptake inhibitors (@DRUG$), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.	DDI-false
DDI-DrugBank.d645.s2.p2	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and @DRUG$, if they have a narrow therapeutic window.	DDI-false
DDI-DrugBank.d645.s2.p3	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, @DRUG$ (@DRUG$), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.	DDI-false
DDI-DrugBank.d645.s2.p4	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, @DRUG$ (SSRIs), and @DRUG$, if they have a narrow therapeutic window.	DDI-false
DDI-DrugBank.d645.s2.p5	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (@DRUG$), and @DRUG$, if they have a narrow therapeutic window.	DDI-false
DDI-DrugBank.d645.s3.p0	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that @DRUG$ does not affect the clearance of @DRUG$ or digoxin.	DDI-false
DDI-DrugBank.d645.s3.p1	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that @DRUG$ does not affect the clearance of antipyrine or @DRUG$.	DDI-false
DDI-DrugBank.d645.s3.p2	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d645.s4.p0	@DRUG$ decreases the clearance of @DRUG$ by 19%.	DDI-mechanism
DDI-DrugBank.d645.s5.p0	@DRUG$ increases the clearance of @DRUG$ by 15%.	DDI-mechanism
DDI-DrugBank.d645.s6.p0	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral @DRUG$ and @DRUG$, however, a causal relationship between LAMISIL    Tablets and these changes has not been established.	DDI-effect
DDI-DrugBank.d645.s6.p1	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral @DRUG$ and warfarin, however, a causal relationship between @DRUG$    Tablets and these changes has not been established.	DDI-false
DDI-DrugBank.d645.s6.p2	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and @DRUG$, however, a causal relationship between @DRUG$    Tablets and these changes has not been established.	DDI-false
DDI-DrugBank.d645.s7.p0	@DRUG$ clearance is increased 100% by @DRUG$, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.	DDI-mechanism
DDI-DrugBank.d645.s7.p1	@DRUG$ clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by @DRUG$, a CyP450 enzyme inhibitor.	DDI-mechanism
DDI-DrugBank.d645.s7.p2	Terbinafine clearance is increased 100% by @DRUG$, a CyP450 enzyme inducer, and decreased 33% by @DRUG$, a CyP450 enzyme inhibitor.	DDI-false
DDI-DrugBank.d645.s8.p0	@DRUG$ clearance is unaffected by @DRUG$.	DDI-false
DDI-DrugBank.d645.s9.p0	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p1	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p2	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p3	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p4	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p5	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s9.p6	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p7	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p8	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, @DRUG$, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p9	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p10	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, beta blockers, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s9.p11	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p12	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, @DRUG$, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p13	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p14	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s9.p15	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, @DRUG$, beta blockers, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p16	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, @DRUG$, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p17	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s9.p18	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, @DRUG$, and calcium channel blockers.	DDI-false
DDI-DrugBank.d645.s9.p19	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, beta blockers, and @DRUG$.	DDI-false
DDI-DrugBank.d645.s9.p20	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d647.s1.p0	@DRUG$ has been reported to prolong the elimination half-life of @DRUG$ and may lead to severe bone marrow suppression;	DDI-mechanism
DDI-DrugBank.d647.s2.p0	a reduction of the @DRUG$ dosage should be considered in patients receiving @DRUG$ concurrently.	DDI-advise
DDI-DrugBank.d647.s3.p0	The concurrent use of @DRUG$ and @DRUG$ has been reported in one case to result in reduced streptozocin cytotoxicity.	DDI-effect
DDI-DrugBank.d647.s3.p1	The concurrent use of @DRUG$ and phenytoin has been reported in one case to result in reduced @DRUG$ cytotoxicity.	DDI-false
DDI-DrugBank.d647.s3.p2	The concurrent use of streptozocin and @DRUG$ has been reported in one case to result in reduced @DRUG$ cytotoxicity.	DDI-false
DDI-DrugBank.d648.s0.p0	@DRUG$: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.	DDI-false
DDI-DrugBank.d648.s0.p1	@DRUG$: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with EVISTA.	DDI-false
DDI-DrugBank.d648.s0.p2	@DRUG$: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d648.s0.p3	Cholestyramine: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with EVISTA.	DDI-mechanism
DDI-DrugBank.d648.s0.p4	Cholestyramine: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with @DRUG$.	DDI-advise
DDI-DrugBank.d648.s0.p5	Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d648.s1.p0	@DRUG$: The coadministration of @DRUG$ and warfarin has not been assessed under chronic conditions.	DDI-false
DDI-DrugBank.d648.s1.p1	@DRUG$: The coadministration of EVISTA and @DRUG$ has not been assessed under chronic conditions.	DDI-false
DDI-DrugBank.d648.s1.p2	Warfarin: The coadministration of @DRUG$ and @DRUG$ has not been assessed under chronic conditions.	DDI-false
DDI-DrugBank.d648.s3.p0	If @DRUG$ is given concurrently with @DRUG$, prothrombin time should be monitored.	DDI-advise
DDI-DrugBank.d648.s5.p0	In vitro, @DRUG$ did not affect the binding of @DRUG$, phenytoin, or tamoxifen.	DDI-false
DDI-DrugBank.d648.s5.p1	In vitro, @DRUG$ did not affect the binding of warfarin, @DRUG$, or tamoxifen.	DDI-false
DDI-DrugBank.d648.s5.p2	In vitro, @DRUG$ did not affect the binding of warfarin, phenytoin, or @DRUG$.	DDI-false
DDI-DrugBank.d648.s5.p3	In vitro, raloxifene did not affect the binding of @DRUG$, @DRUG$, or tamoxifen.	DDI-false
DDI-DrugBank.d648.s5.p4	In vitro, raloxifene did not affect the binding of @DRUG$, phenytoin, or @DRUG$.	DDI-false
DDI-DrugBank.d648.s5.p5	In vitro, raloxifene did not affect the binding of warfarin, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d648.s6.p0	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	DDI-advise
DDI-DrugBank.d648.s6.p1	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, diazepam, and diazoxide.	DDI-advise
DDI-DrugBank.d648.s6.p2	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, diazepam, and diazoxide.	DDI-advise
DDI-DrugBank.d648.s6.p3	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, diazepam, and diazoxide.	DDI-advise
DDI-DrugBank.d648.s6.p4	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, @DRUG$, and diazoxide.	DDI-advise
DDI-DrugBank.d648.s6.p5	Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and @DRUG$.	DDI-advise
DDI-DrugBank.d648.s6.p6	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, @DRUG$, naproxen, ibuprofen, diazepam, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p7	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, @DRUG$, ibuprofen, diazepam, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p8	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, @DRUG$, diazepam, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p9	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, @DRUG$, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p10	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, diazepam, and @DRUG$.	DDI-false
DDI-DrugBank.d648.s6.p11	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, @DRUG$, ibuprofen, diazepam, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p12	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, @DRUG$, diazepam, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p13	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, @DRUG$, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p14	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, diazepam, and @DRUG$.	DDI-false
DDI-DrugBank.d648.s6.p15	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, @DRUG$, diazepam, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p16	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, @DRUG$, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p17	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, diazepam, and @DRUG$.	DDI-false
DDI-DrugBank.d648.s6.p18	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, @DRUG$, and diazoxide.	DDI-false
DDI-DrugBank.d648.s6.p19	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, diazepam, and @DRUG$.	DDI-false
DDI-DrugBank.d648.s6.p20	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d649.s0.p0	@DRUG$ may increase the effects of @DRUG$, tolbutamide, and uricosurics.	DDI-effect
DDI-DrugBank.d649.s0.p1	@DRUG$ may increase the effects of barbiturates, @DRUG$, and uricosurics.	DDI-effect
DDI-DrugBank.d649.s0.p2	@DRUG$ may increase the effects of barbiturates, tolbutamide, and @DRUG$.	DDI-effect
DDI-DrugBank.d649.s0.p3	Sulfamethizole may increase the effects of @DRUG$, @DRUG$, and uricosurics.	DDI-false
DDI-DrugBank.d649.s0.p4	Sulfamethizole may increase the effects of @DRUG$, tolbutamide, and @DRUG$.	DDI-false
DDI-DrugBank.d649.s0.p5	Sulfamethizole may increase the effects of barbiturates, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d649.s1.p0	It may also interact with @DRUG$ (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p1	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p2	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p3	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p4	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p5	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p6	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d649.s1.p7	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p8	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p9	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p10	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p11	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p12	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d649.s1.p13	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p14	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p15	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p16	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p17	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d649.s1.p18	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p19	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p20	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p21	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d649.s1.p22	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p23	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p24	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d649.s1.p25	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d649.s1.p26	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d649.s1.p27	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d650.s0.p0	@DRUG$, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p1	@DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p2	@DRUG$, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p3	@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p4	@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p5	@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);	DDI-advise
DDI-DrugBank.d650.s0.p6	@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);	DDI-false
DDI-DrugBank.d650.s0.p7	Dopamine antagonists, such as the @DRUG$ (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p8	Dopamine antagonists, such as the @DRUG$ (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p9	Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p10	Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p11	Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);	DDI-advise
DDI-DrugBank.d650.s0.p12	Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);	DDI-false
DDI-DrugBank.d650.s0.p13	Dopamine antagonists, such as the neuroleptics (@DRUG$, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p14	Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p15	Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p16	Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);	DDI-advise
DDI-DrugBank.d650.s0.p17	Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);	DDI-false
DDI-DrugBank.d650.s0.p18	Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p19	Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p20	Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);	DDI-advise
DDI-DrugBank.d650.s0.p21	Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);	DDI-false
DDI-DrugBank.d650.s0.p22	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	DDI-false
DDI-DrugBank.d650.s0.p23	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);	DDI-advise
DDI-DrugBank.d650.s0.p24	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$);	DDI-false
DDI-DrugBank.d650.s0.p25	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist);	DDI-advise
DDI-DrugBank.d650.s0.p26	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a @DRUG$);	DDI-false
DDI-DrugBank.d650.s0.p27	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a @DRUG$);	DDI-false
DDI-DrugBank.d650.s2.p0	Because @DRUG$ is approximately 90% bound to plasma proteins, caution should be exercised if @DRUG$ is coadministered with other drugs known to affect protein binding.	DDI-false
DDI-DrugBank.d651.s0.p0	Drug Interactions: Women on oral @DRUG$ have shown a significant increase in plasma @DRUG$ levels.	DDI-mechanism
DDI-DrugBank.d652.s0.p0	The effects of @DRUG$ on gastrointestinal motility are antagonized by @DRUG$ and narcotic analgesics.	DDI-effect
DDI-DrugBank.d652.s0.p1	The effects of @DRUG$ on gastrointestinal motility are antagonized by anticholinergic drugs and @DRUG$.	DDI-effect
DDI-DrugBank.d652.s0.p2	The effects of metoclopramide on gastrointestinal motility are antagonized by @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d652.s1.p0	Additive sedative effects can occur when @DRUG$ is given with @DRUG$, sedatives, hypnotics, narcotics, or tranquilizers.	DDI-effect
DDI-DrugBank.d652.s1.p1	Additive sedative effects can occur when @DRUG$ is given with alcohol, @DRUG$, hypnotics, narcotics, or tranquilizers.	DDI-effect
DDI-DrugBank.d652.s1.p2	Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, @DRUG$, narcotics, or tranquilizers.	DDI-effect
DDI-DrugBank.d652.s1.p3	Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, hypnotics, @DRUG$, or tranquilizers.	DDI-effect
DDI-DrugBank.d652.s1.p4	Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, hypnotics, narcotics, or @DRUG$.	DDI-effect
DDI-DrugBank.d652.s1.p5	Additive sedative effects can occur when metoclopramide is given with @DRUG$, @DRUG$, hypnotics, narcotics, or tranquilizers.	DDI-false
DDI-DrugBank.d652.s1.p6	Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, @DRUG$, narcotics, or tranquilizers.	DDI-false
DDI-DrugBank.d652.s1.p7	Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, hypnotics, @DRUG$, or tranquilizers.	DDI-false
DDI-DrugBank.d652.s1.p8	Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, hypnotics, narcotics, or @DRUG$.	DDI-false
DDI-DrugBank.d652.s1.p9	Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, @DRUG$, narcotics, or tranquilizers.	DDI-false
DDI-DrugBank.d652.s1.p10	Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, hypnotics, @DRUG$, or tranquilizers.	DDI-false
DDI-DrugBank.d652.s1.p11	Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, hypnotics, narcotics, or @DRUG$.	DDI-false
DDI-DrugBank.d652.s1.p12	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, @DRUG$, @DRUG$, or tranquilizers.	DDI-false
DDI-DrugBank.d652.s1.p13	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, @DRUG$, narcotics, or @DRUG$.	DDI-false
DDI-DrugBank.d652.s1.p14	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d652.s2.p0	The finding that @DRUG$ releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving @DRUG$.	DDI-advise
DDI-DrugBank.d652.s3.p0	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	DDI-mechanism
DDI-DrugBank.d652.s3.p1	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p2	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p3	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p4	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p5	Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, @DRUG$).	DDI-false
DDI-DrugBank.d652.s3.p6	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, cyclosporine).	DDI-mechanism
DDI-DrugBank.d652.s3.p7	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p8	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p9	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p10	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, @DRUG$).	DDI-false
DDI-DrugBank.d652.s3.p11	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, @DRUG$, levodopa, ethanol, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p12	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, @DRUG$, ethanol, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p13	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, @DRUG$, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p14	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, @DRUG$).	DDI-false
DDI-DrugBank.d652.s3.p15	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, @DRUG$, ethanol, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p16	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, @DRUG$, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p17	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, @DRUG$).	DDI-false
DDI-DrugBank.d652.s3.p18	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, @DRUG$, cyclosporine).	DDI-false
DDI-DrugBank.d652.s3.p19	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, @DRUG$).	DDI-false
DDI-DrugBank.d652.s3.p20	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, @DRUG$).	DDI-false
DDI-DrugBank.d652.s6.p0	Because the action of @DRUG$ will influence the delivery of food to the intestines and thus the rate of absorption, @DRUG$ dosage or timing of dosage may require adjustment.	DDI-advise
DDI-DrugBank.d653.s1.p0	Drugs that induce hepatic enzymes such as @DRUG$, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	DDI-false
DDI-DrugBank.d653.s1.p1	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	DDI-false
DDI-DrugBank.d653.s1.p2	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d653.s1.p3	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d653.s1.p4	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	DDI-false
DDI-DrugBank.d653.s1.p5	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d653.s1.p6	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d653.s1.p7	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d653.s1.p8	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d653.s1.p9	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in @DRUG$ dose to achieve the desired response.	DDI-false
DDI-DrugBank.d653.s2.p0	Drugs such as @DRUG$ and @DRUG$ may inhibit the metabolism of corticosteroids and thus decrease their clearance.	DDI-false
DDI-DrugBank.d653.s2.p1	Drugs such as @DRUG$ and ketoconazole may inhibit the metabolism of @DRUG$ and thus decrease their clearance.	DDI-mechanism
DDI-DrugBank.d653.s2.p2	Drugs such as troleandomycin and @DRUG$ may inhibit the metabolism of @DRUG$ and thus decrease their clearance.	DDI-mechanism
DDI-DrugBank.d653.s4.p0	@DRUG$ may increase the clearance of chronic high dose @DRUG$.	DDI-mechanism
DDI-DrugBank.d653.s5.p0	This could lead to decreased @DRUG$ serum levels or increase the risk of @DRUG$ toxicity when corticosteroid is withdrawn.	DDI-false
DDI-DrugBank.d653.s5.p1	This could lead to decreased @DRUG$ serum levels or increase the risk of salicylate toxicity when @DRUG$ is withdrawn.	DDI-false
DDI-DrugBank.d653.s5.p2	This could lead to decreased salicylate serum levels or increase the risk of @DRUG$ toxicity when @DRUG$ is withdrawn.	DDI-effect
DDI-DrugBank.d653.s6.p0	@DRUG$ should be used cautiously in conjunction with @DRUG$ in patients suffering from hypoprothrombinemia.	DDI-advise
DDI-DrugBank.d653.s7.p0	The effect of @DRUG$ on oral @DRUG$ is variable.	DDI-effect
DDI-DrugBank.d653.s8.p0	There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$.	DDI-effect
DDI-DrugBank.d654.s0.p0	Co-administration of oral @DRUG$ 200 mg twice daily increased @DRUG$ geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.	DDI-false
DDI-DrugBank.d654.s0.p1	Co-administration of oral @DRUG$ 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of @DRUG$ ointment, 1% on the abraded skin of healthy adult males.	DDI-mechanism
DDI-DrugBank.d654.s0.p2	Co-administration of oral ketoconazole 200 mg twice daily increased @DRUG$ geometric mean AUC(0-24) and Cmax by 81% after topical application of @DRUG$ ointment, 1% on the abraded skin of healthy adult males.	DDI-false
DDI-DrugBank.d654.s1.p0	Due to low systemic exposure to @DRUG$ following topical application in patients, dosage adjustments for @DRUG$ are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole.	DDI-false
DDI-DrugBank.d654.s1.p1	Due to low systemic exposure to @DRUG$ following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as @DRUG$.	DDI-false
DDI-DrugBank.d654.s1.p2	Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for @DRUG$ are unnecessary when co-administered with CYP3A4 inhibitors, such as @DRUG$.	DDI-false
DDI-DrugBank.d654.s2.p0	Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of @DRUG$, @DRUG$ is unlikely to affect the metabolism of other P450 substrates.	DDI-false
DDI-DrugBank.d655.s0.p0	@DRUG$ may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p1	@DRUG$ may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p2	@DRUG$ may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p3	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p4	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p5	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p6	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p7	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p8	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p9	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p10	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p11	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p12	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p13	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p14	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p15	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p16	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p17	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p18	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p19	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p20	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-int
DDI-DrugBank.d655.s0.p21	@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-int
DDI-DrugBank.d655.s0.p22	Methscopolamine may interact with @DRUG$ (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p23	Methscopolamine may interact with @DRUG$ (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p24	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p25	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p26	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p27	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p28	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p29	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p30	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p31	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p32	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p33	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p34	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p35	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p36	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p37	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p38	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p39	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p40	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p41	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p42	Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p43	Methscopolamine may interact with antidepressants (@DRUG$ type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p44	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p45	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p46	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p47	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p48	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p49	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p50	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p51	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p52	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p53	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p54	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p55	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p56	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p57	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p58	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p59	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p60	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p61	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p62	Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p63	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p64	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p65	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p66	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p67	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p68	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p69	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p70	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p71	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p72	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p73	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p74	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p75	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p76	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p77	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p78	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p79	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p80	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p81	Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p82	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p83	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p84	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p85	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p86	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p87	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p88	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p89	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p90	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p91	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p92	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p93	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p94	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p95	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p96	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p97	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p98	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p99	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p100	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p101	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p102	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p103	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p104	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p105	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p106	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p107	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p108	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p109	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p110	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p111	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p112	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p113	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p114	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p115	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p116	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p117	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p118	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p119	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p120	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p121	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p122	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p123	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p124	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p125	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p126	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p127	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p128	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p129	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p130	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p131	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p132	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p133	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p134	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p135	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p136	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p137	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p138	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p139	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p140	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p141	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p142	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p143	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p144	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p145	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p146	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p147	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p148	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p149	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p150	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p151	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p152	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p153	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p154	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p155	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p156	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p157	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p158	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p159	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p160	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p161	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p162	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p163	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p164	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p165	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p166	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p167	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p168	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p169	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p170	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p171	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p172	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p173	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p174	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p175	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p176	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p177	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p178	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p179	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p180	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p181	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p182	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p183	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p184	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p185	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p186	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p187	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p188	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p189	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p190	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p191	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p192	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p193	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p194	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p195	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p196	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p197	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p198	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p199	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p200	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p201	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p202	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p203	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p204	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p205	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p206	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p207	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p208	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p209	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p210	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p211	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p212	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p213	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p214	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p215	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p216	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p217	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p218	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p219	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p220	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p221	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p222	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p223	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p224	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p225	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p226	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p227	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p228	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p229	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p230	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p231	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p232	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p233	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p234	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p235	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p236	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p237	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p238	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p239	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p240	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p241	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p242	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p243	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p244	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p245	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p246	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p247	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), @DRUG$ (e.g., chlorpromazine, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p248	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p249	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p250	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., @DRUG$, promethazine).	DDI-false
DDI-DrugBank.d655.s0.p251	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, @DRUG$).	DDI-false
DDI-DrugBank.d655.s0.p252	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, @DRUG$).	DDI-false
DDI-DrugBank.d656.s1.p0	Although this has not occurred in in vitro studies with @DRUG$, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	DDI-false
DDI-DrugBank.d656.s1.p1	Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	DDI-false
DDI-DrugBank.d656.s1.p2	Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	DDI-false
DDI-DrugBank.d656.s1.p3	Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs.	DDI-false
DDI-DrugBank.d656.s1.p4	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	DDI-int
DDI-DrugBank.d656.s1.p5	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	DDI-false
DDI-DrugBank.d656.s1.p6	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs.	DDI-false
DDI-DrugBank.d656.s1.p7	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	DDI-false
DDI-DrugBank.d656.s1.p8	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs.	DDI-false
DDI-DrugBank.d656.s1.p9	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on @DRUG$ and other highly protein-bound drugs.	DDI-advise
DDI-DrugBank.d656.s2.p0	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p1	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p2	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p3	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p4	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p5	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p6	Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d656.s2.p7	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-mechanism
DDI-DrugBank.d656.s2.p8	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p9	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p10	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p11	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p12	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d656.s2.p13	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p14	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p15	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p16	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p17	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d656.s2.p18	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p19	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p20	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p21	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d656.s2.p22	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p23	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p24	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d656.s2.p25	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including @DRUG$, have been reported to increase steady state plasma lithium levels.	DDI-false
DDI-DrugBank.d656.s2.p26	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels.	DDI-mechanism
DDI-DrugBank.d656.s2.p27	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma @DRUG$ levels.	DDI-mechanism
DDI-DrugBank.d656.s3.p0	It is recommended that plasma @DRUG$ levels be monitored when initiating, adjusting and discontinuing @DRUG$.	DDI-advise
DDI-DrugBank.d658.s0.p0	When administered concurrently, @DRUG$ may increase the effects of oral @DRUG$;	DDI-effect
DDI-DrugBank.d659.s0.p0	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with @DRUG$ with and without @DRUG$ or platelet aggregation inhibitors.	DDI-effect
DDI-DrugBank.d659.s0.p1	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with @DRUG$ with and without anticoagulants or @DRUG$.	DDI-effect
DDI-DrugBank.d659.s0.p2	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d659.s2.p0	Concomitant administration of @DRUG$ and @DRUG$-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.	DDI-mechanism
DDI-DrugBank.d659.s2.p1	Concomitant administration of @DRUG$ and theophylline-containing drugs leads to increased @DRUG$ levels and theophylline toxicity in some individuals.	DDI-false
DDI-DrugBank.d659.s2.p2	Concomitant administration of @DRUG$ and theophylline-containing drugs leads to increased theophylline levels and @DRUG$ toxicity in some individuals.	DDI-false
DDI-DrugBank.d659.s2.p3	Concomitant administration of TRENTAL and @DRUG$-containing drugs leads to increased @DRUG$ levels and theophylline toxicity in some individuals.	DDI-false
DDI-DrugBank.d659.s2.p4	Concomitant administration of TRENTAL and @DRUG$-containing drugs leads to increased theophylline levels and @DRUG$ toxicity in some individuals.	DDI-false
DDI-DrugBank.d659.s2.p5	Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased @DRUG$ levels and @DRUG$ toxicity in some individuals.	DDI-false
DDI-DrugBank.d659.s4.p0	@DRUG$ has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p1	@DRUG$ has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p2	@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p3	@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p4	@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p5	@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p6	TRENTAL has been used concurrently with @DRUG$, @DRUG$, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p7	TRENTAL has been used concurrently with @DRUG$, beta blockers, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p8	TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p9	TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p10	TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p11	TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p12	TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p13	TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p14	TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p15	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p16	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, @DRUG$, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p17	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, antidiabetic agents, and @DRUG$, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p18	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, @DRUG$, and antiarrhythmics, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p19	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, antidiabetic agents, and @DRUG$, without observed problems.	DDI-false
DDI-DrugBank.d659.s4.p20	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, @DRUG$, and @DRUG$, without observed problems.	DDI-false
DDI-DrugBank.d661.s0.p0	Drug Interactions: The use of @DRUG$    (@DRUG$) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	DDI-false
DDI-DrugBank.d661.s0.p1	Drug Interactions: The use of @DRUG$    (rocuronium bromide) Injection before @DRUG$, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	DDI-false
DDI-DrugBank.d661.s0.p2	Drug Interactions: The use of @DRUG$    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied.	DDI-false
DDI-DrugBank.d661.s0.p3	Drug Interactions: The use of ZEMURON    (@DRUG$) Injection before @DRUG$, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	DDI-false
DDI-DrugBank.d661.s0.p4	Drug Interactions: The use of ZEMURON    (@DRUG$) Injection before succinylcholine, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied.	DDI-false
DDI-DrugBank.d661.s0.p5	Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before @DRUG$, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied.	DDI-false
DDI-DrugBank.d661.s1.p0	If @DRUG$    is administered following administration of @DRUG$, it should not be given until recovery from succinylcholine has been observed.	DDI-advise
DDI-DrugBank.d661.s1.p1	If @DRUG$    is administered following administration of succinylcholine, it should not be given until recovery from @DRUG$ has been observed.	DDI-false
DDI-DrugBank.d661.s1.p2	If ZEMURON    is administered following administration of @DRUG$, it should not be given until recovery from @DRUG$ has been observed.	DDI-false
DDI-DrugBank.d661.s2.p0	The median duration of action of @DRUG$    0.6 mg/kg administered after a 1 mg/kg dose of @DRUG$ when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs.	DDI-false
DDI-DrugBank.d661.s4.p0	There are no controlled studies documenting the use of @DRUG$    before or after other @DRUG$.	DDI-false
DDI-DrugBank.d665.s0.p0	Concurrent administration of @DRUG$ (e.g., @DRUG$, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	DDI-false
DDI-DrugBank.d665.s0.p1	Concurrent administration of @DRUG$ (e.g., erythromycin, @DRUG$) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	DDI-false
DDI-DrugBank.d665.s0.p2	Concurrent administration of @DRUG$ (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth.	DDI-effect
DDI-DrugBank.d665.s0.p3	Concurrent administration of bacteriostatic antibiotics (e.g., @DRUG$, @DRUG$) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	DDI-false
DDI-DrugBank.d665.s0.p4	Concurrent administration of bacteriostatic antibiotics (e.g., @DRUG$, tetracycline) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth.	DDI-effect
DDI-DrugBank.d665.s0.p5	Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, @DRUG$) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth.	DDI-effect
DDI-DrugBank.d665.s6.p0	@DRUG$ blood levels may be prolonged by concurrent administration of @DRUG$ which blocks the renal tubular secretion of penicillins.	DDI-mechanism
DDI-DrugBank.d665.s6.p1	@DRUG$ blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of @DRUG$.	DDI-false
DDI-DrugBank.d665.s6.p2	Penicillin blood levels may be prolonged by concurrent administration of @DRUG$ which blocks the renal tubular secretion of @DRUG$.	DDI-false
DDI-DrugBank.d665.s7.p0	Displacement of @DRUG$ from plasma protein binding sites will elevate the level of free @DRUG$ in the serum.	DDI-false
DDI-DrugBank.d666.s0.p0	Catecholamine-depleting drugs (e.g., @DRUG$) may have an additive effect when given with @DRUG$.	DDI-effect
DDI-DrugBank.d666.s2.p0	@DRUG$ has been used with a variety of @DRUG$, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p1	@DRUG$ has been used with a variety of antihypertensive agents, including @DRUG$, hydralazine, and guanethidine without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p2	@DRUG$ has been used with a variety of antihypertensive agents, including hydrochlorothiazide, @DRUG$, and guanethidine without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p3	@DRUG$ has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and @DRUG$ without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p4	Pindolol has been used with a variety of @DRUG$, including @DRUG$, hydralazine, and guanethidine without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p5	Pindolol has been used with a variety of @DRUG$, including hydrochlorothiazide, @DRUG$, and guanethidine without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p6	Pindolol has been used with a variety of @DRUG$, including hydrochlorothiazide, hydralazine, and @DRUG$ without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p7	Pindolol has been used with a variety of antihypertensive agents, including @DRUG$, @DRUG$, and guanethidine without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p8	Pindolol has been used with a variety of antihypertensive agents, including @DRUG$, hydralazine, and @DRUG$ without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s2.p9	Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, @DRUG$, and @DRUG$ without unexpected adverse interactions.	DDI-false
DDI-DrugBank.d666.s3.p0	@DRUG$ has been shown to increase serum @DRUG$ levels when both drugs are co-administered.	DDI-mechanism
DDI-DrugBank.d668.s0.p0	Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s0.p1	Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s0.p2	Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s0.p3	Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$).	DDI-false
DDI-DrugBank.d668.s0.p4	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s0.p5	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s0.p6	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$).	DDI-mechanism
DDI-DrugBank.d668.s0.p7	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s0.p8	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$).	DDI-mechanism
DDI-DrugBank.d668.s0.p9	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$).	DDI-mechanism
DDI-DrugBank.d668.s1.p0	Furthermore, @DRUG$, @DRUG$, St.	DDI-false
DDI-DrugBank.d668.s2.p0	John   s Wort, and certain @DRUG$ (@DRUG$, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s2.p1	John   s Wort, and certain @DRUG$ (phenytoin, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s2.p2	John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s2.p3	John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone).	DDI-mechanism
DDI-DrugBank.d668.s2.p4	John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$).	DDI-false
DDI-DrugBank.d668.s2.p5	John   s Wort, and certain anticonvulsants (@DRUG$, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s2.p6	John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s2.p7	John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone).	DDI-mechanism
DDI-DrugBank.d668.s2.p8	John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$).	DDI-false
DDI-DrugBank.d668.s2.p9	John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone).	DDI-false
DDI-DrugBank.d668.s2.p10	John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone).	DDI-mechanism
DDI-DrugBank.d668.s2.p11	John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$).	DDI-false
DDI-DrugBank.d668.s2.p12	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, @DRUG$) may induce @DRUG$ metabolism (lowering serum levels of mifepristone).	DDI-mechanism
DDI-DrugBank.d668.s2.p13	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of @DRUG$).	DDI-false
DDI-DrugBank.d668.s2.p14	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of @DRUG$).	DDI-false
DDI-DrugBank.d669.s0.p0	Concomitant administration of @DRUG$ and @DRUG$ has been associated with erythema and histamine-like flushing and anaphylactoid reactions.	DDI-effect
DDI-DrugBank.d669.s1.p0	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p1	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p2	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p3	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p4	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p5	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p6	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p7	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p8	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p9	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p10	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p11	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p12	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p13	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p14	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p15	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p16	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p17	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p18	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, @DRUG$, or cisplatin, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p19	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or @DRUG$, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d669.s1.p20	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or @DRUG$, when indicated, requires careful monitoring.	DDI-false
DDI-DrugBank.d670.s0.p0	Potential for @DRUG$    to Affect Other Drugs @DRUG$ is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.	DDI-false
DDI-DrugBank.d670.s6.p0	Given the primary CNS effects of @DRUG$, @DRUG$    should be used with caution in combination with other centrally acting drugs and alcohol.	DDI-false
DDI-DrugBank.d670.s6.p1	Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other @DRUG$ and alcohol.	DDI-advise
DDI-DrugBank.d670.s6.p2	Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other centrally acting drugs and @DRUG$.	DDI-advise
DDI-DrugBank.d670.s6.p3	Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other @DRUG$ and alcohol.	DDI-advise
DDI-DrugBank.d670.s6.p4	Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other centrally acting drugs and @DRUG$.	DDI-advise
DDI-DrugBank.d670.s6.p5	Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d670.s7.p0	@DRUG$ may antagonize the effect of @DRUG$ and other dopamine agonists.	DDI-effect
DDI-DrugBank.d670.s7.p1	@DRUG$ may antagonize the effect of levodopa and other @DRUG$.	DDI-effect
DDI-DrugBank.d670.s7.p2	Paliperidone may antagonize the effect of @DRUG$ and other @DRUG$.	DDI-false
DDI-DrugBank.d670.s9.p0	Potential for Other Drugs to Affect @DRUG$    @DRUG$ is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.	DDI-false
DDI-DrugBank.d671.s0.p0	The interaction of @DRUG$ (@DRUG$) with other drugs has not been studied in humans.	DDI-false
DDI-DrugBank.d671.s2.p0	Decreased seizure threshold has been reported in patients receiving @DRUG$ concomitantly with @DRUG$.	DDI-effect
DDI-DrugBank.d675.s0.p0	CYP 3A4 Inhibitors (e.g. @DRUG$ and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p1	CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p2	CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p3	CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p4	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p5	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p6	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p7	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p8	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s0.p9	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	DDI-false
DDI-DrugBank.d675.s2.p0	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p1	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p2	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p3	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p4	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p5	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p6	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p7	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p8	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p9	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p10	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p11	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p12	Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p13	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p14	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p15	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p16	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p17	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p18	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p19	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p20	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p21	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p22	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p23	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p24	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p25	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p26	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p27	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p28	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p29	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p30	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p31	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p32	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p33	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p34	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p35	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p36	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p37	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p38	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p39	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p40	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p41	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p42	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p43	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p44	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p45	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p46	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG-DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p47	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p48	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p49	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p50	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p51	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p52	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p53	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p54	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p55	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p56	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p57	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p58	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p59	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p60	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p61	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p62	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p63	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p64	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p65	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p66	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p67	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p68	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p69	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p70	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p71	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p72	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p73	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p74	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p75	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p76	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p77	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p78	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p79	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p80	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p81	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p82	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p83	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p84	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p85	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., @DRUG$, itraconazole, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p86	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p87	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p88	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, @DRUG$, voriconazole).	DDI-false
DDI-DrugBank.d675.s2.p89	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, @DRUG$).	DDI-false
DDI-DrugBank.d675.s2.p90	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, @DRUG$).	DDI-false
DDI-DrugBank.d675.s4.p0	Less potent inhibitors include @DRUG$, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p1	Less potent inhibitors include @DRUG$, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p2	Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p3	Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p4	Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p5	Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$.	DDI-false
DDI-DrugBank.d675.s4.p6	Less potent inhibitors include saquinavir, @DRUG$, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p7	Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p8	Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p9	Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p10	Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$.	DDI-false
DDI-DrugBank.d675.s4.p11	Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p12	Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p13	Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p14	Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$.	DDI-false
DDI-DrugBank.d675.s4.p15	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, @DRUG$, zileuton, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p16	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, @DRUG$, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p17	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and @DRUG$.	DDI-false
DDI-DrugBank.d675.s4.p18	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, @DRUG$, and clotrimazole.	DDI-false
DDI-DrugBank.d675.s4.p19	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and @DRUG$.	DDI-false
DDI-DrugBank.d675.s4.p20	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d675.s7.p0	Caution should be exercised when @DRUG$    (@DRUG$) is used concurrently with other vasoconstrictors or ergot alkaloids.	DDI-false
DDI-DrugBank.d675.s7.p1	Caution should be exercised when @DRUG$    (methylergonovine maleate) is used concurrently with other @DRUG$ or ergot alkaloids.	DDI-advise
DDI-DrugBank.d675.s7.p2	Caution should be exercised when @DRUG$    (methylergonovine maleate) is used concurrently with other vasoconstrictors or @DRUG$.	DDI-advise
DDI-DrugBank.d675.s7.p3	Caution should be exercised when Methergine    (@DRUG$) is used concurrently with other @DRUG$ or ergot alkaloids.	DDI-advise
DDI-DrugBank.d675.s7.p4	Caution should be exercised when Methergine    (@DRUG$) is used concurrently with other vasoconstrictors or @DRUG$.	DDI-false
DDI-DrugBank.d675.s7.p5	Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d676.s0.p0	To minimize CNS depression and possible potentiation, @DRUG$, @DRUG$, narcotics, hypotensive agents or phenothiazines should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p1	To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, @DRUG$, hypotensive agents or phenothiazines should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p2	To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, narcotics, @DRUG$ or phenothiazines should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p3	To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, narcotics, hypotensive agents or @DRUG$ should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p4	To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, @DRUG$, hypotensive agents or phenothiazines should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p5	To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, narcotics, @DRUG$ or phenothiazines should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p6	To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, narcotics, hypotensive agents or @DRUG$ should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p7	To minimize CNS depression and possible potentiation, barbiturates, antihistamines, @DRUG$, @DRUG$ or phenothiazines should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p8	To minimize CNS depression and possible potentiation, barbiturates, antihistamines, @DRUG$, hypotensive agents or @DRUG$ should be used with caution.	DDI-false
DDI-DrugBank.d676.s0.p9	To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, @DRUG$ or @DRUG$ should be used with caution.	DDI-false
DDI-DrugBank.d676.s2.p0	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-advise
DDI-DrugBank.d676.s2.p1	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-advise
DDI-DrugBank.d676.s2.p2	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-advise
DDI-DrugBank.d676.s2.p3	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-advise
DDI-DrugBank.d676.s2.p4	Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-advise
DDI-DrugBank.d676.s2.p5	Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p6	Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p7	Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p8	Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p9	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p10	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p11	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p12	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p13	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s2.p14	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	DDI-false
DDI-DrugBank.d676.s4.p0	No cross-resistance with other @DRUG$, radiotherapy or @DRUG$ has been demonstrated.	DDI-false
DDI-DrugBank.d677.s0.p0	@DRUG$ are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	DDI-effect
DDI-DrugBank.d677.s0.p1	@DRUG$ are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, opiates, alcohol, etc.)	DDI-effect
DDI-DrugBank.d677.s0.p2	@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, opiates, alcohol, etc.)	DDI-effect
DDI-DrugBank.d677.s0.p3	@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, @DRUG$, alcohol, etc.)	DDI-effect
DDI-DrugBank.d677.s0.p4	@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, @DRUG$, etc.)	DDI-effect
DDI-DrugBank.d677.s0.p5	Phenothiazines are capable of potentiating @DRUG$ (e.g., @DRUG$, anesthetics, opiates, alcohol, etc.)	DDI-false
DDI-DrugBank.d677.s0.p6	Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, @DRUG$, opiates, alcohol, etc.)	DDI-false
DDI-DrugBank.d677.s0.p7	Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, @DRUG$, alcohol, etc.)	DDI-false
DDI-DrugBank.d677.s0.p8	Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, opiates, @DRUG$, etc.)	DDI-false
DDI-DrugBank.d677.s0.p9	Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, @DRUG$, opiates, alcohol, etc.)	DDI-false
DDI-DrugBank.d677.s0.p10	Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, @DRUG$, alcohol, etc.)	DDI-false
DDI-DrugBank.d677.s0.p11	Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, opiates, @DRUG$, etc.)	DDI-false
DDI-DrugBank.d677.s0.p12	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, @DRUG$, alcohol, etc.)	DDI-false
DDI-DrugBank.d677.s0.p13	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, opiates, @DRUG$, etc.)	DDI-false
DDI-DrugBank.d677.s0.p14	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, @DRUG$, @DRUG$, etc.)	DDI-false
DDI-DrugBank.d677.s1.p0	as well as @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d678.s1.p0	The metabolism of @DRUG$ is accelerated by @DRUG$;	DDI-mechanism
DDI-DrugBank.d678.s4.p0	@DRUG$ inhibits the glucuronidation of @DRUG$ and could possibly potentiate acetaminophen toxicity.	DDI-mechanism
DDI-DrugBank.d678.s4.p1	@DRUG$ inhibits the glucuronidation of acetaminophen and could possibly potentiate @DRUG$ toxicity.	DDI-effect
DDI-DrugBank.d678.s4.p2	Metopirone inhibits the glucuronidation of @DRUG$ and could possibly potentiate @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d679.s0.p0	Preliminary evidence suggests that @DRUG$ inhibits @DRUG$ metabolism and may result in an increase in plasma concentrations of mebendazole.	DDI-mechanism
DDI-DrugBank.d679.s0.p1	Preliminary evidence suggests that @DRUG$ inhibits mebendazole metabolism and may result in an increase in plasma concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d679.s0.p2	Preliminary evidence suggests that cimetidine inhibits @DRUG$ metabolism and may result in an increase in plasma concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p0	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p1	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p2	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p3	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p4	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p5	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p6	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p7	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p8	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p9	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p10	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p11	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p12	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p13	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p14	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p15	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p16	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p17	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p18	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p19	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p20	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p21	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p22	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p23	Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p24	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p25	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p26	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p27	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p28	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p29	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p30	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p31	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p32	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p33	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p34	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p35	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p36	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p37	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p38	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p39	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p40	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p41	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p42	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p43	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p44	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p45	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p46	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p47	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p48	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p49	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p50	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p51	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p52	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p53	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p54	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p55	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p56	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p57	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p58	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p59	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p60	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p61	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p62	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p63	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p64	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p65	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p66	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p67	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p68	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p69	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p70	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p71	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p72	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p73	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p74	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p75	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p76	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p77	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p78	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p79	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p80	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p81	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p82	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p83	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p84	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p85	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p86	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p87	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p88	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p89	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p90	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p91	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p92	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p93	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p94	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p95	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p96	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p97	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p98	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p99	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p100	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p101	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p102	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p103	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p104	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p105	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p106	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p107	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p108	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p109	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p110	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p111	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p112	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p113	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p114	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p115	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p116	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p117	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p118	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p119	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p120	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p121	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p122	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p123	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p124	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p125	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p126	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p127	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p128	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p129	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p130	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p131	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p132	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p133	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p134	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p135	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p136	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p137	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p138	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p139	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p140	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p141	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p142	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p143	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p144	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p145	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p146	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p147	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p148	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p149	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p150	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p151	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p152	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p153	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p154	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p155	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p156	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p157	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p158	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p159	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p160	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p161	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p162	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p163	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p164	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p165	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p166	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p167	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p168	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p169	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p170	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p171	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p172	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p173	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p174	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p175	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p176	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p177	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p178	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p179	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p180	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p181	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p182	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p183	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p184	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p185	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p186	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p187	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p188	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p189	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p190	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p191	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p192	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p193	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p194	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p195	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p196	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p197	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p198	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p199	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p200	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p201	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p202	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p203	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p204	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p205	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p206	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p207	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p208	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p209	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p210	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p211	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p212	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p213	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p214	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p215	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p216	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p217	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p218	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p219	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p220	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p221	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p222	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p223	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p224	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p225	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p226	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p227	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p228	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p229	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p230	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p231	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p232	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p233	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p234	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p235	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p236	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p237	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p238	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p239	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p240	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p241	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p242	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p243	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p244	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p245	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p246	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p247	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p248	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p249	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p250	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p251	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p252	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p253	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p254	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p255	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p256	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p257	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p258	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p259	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p260	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p261	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p262	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p263	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p264	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p265	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p266	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p267	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p268	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p269	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p270	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p271	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p272	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p273	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p274	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p275	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p276	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p277	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p278	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p279	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p280	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p281	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p282	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p283	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p284	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p285	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p286	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p287	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p288	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p289	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p290	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, @DRUG$, clarithromycin, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p291	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p292	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p293	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p294	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, @DRUG$, metronidazole, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p295	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p296	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p297	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, @DRUG$, or amoxicillin.	DDI-false
DDI-DrugBank.d680.s1.p298	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s1.p299	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d680.s3.p0	Therefore, when coadministered with @DRUG$, adjustment of the dosage of @DRUG$ or of such drugs may not be necessary.	DDI-false
DDI-DrugBank.d680.s5.p0	There have been postmarketing reports of increased INR and prothrombin time in patients receiving @DRUG$, including @DRUG$, and warfarin concomitantly.	DDI-false
DDI-DrugBank.d680.s5.p1	There have been postmarketing reports of increased INR and prothrombin time in patients receiving @DRUG$, including pantoprazole, and @DRUG$ concomitantly.	DDI-effect
DDI-DrugBank.d680.s5.p2	There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including @DRUG$, and @DRUG$ concomitantly.	DDI-effect
DDI-DrugBank.d680.s7.p0	Patients treated with @DRUG$ and @DRUG$ concomitantly should be monitored for increases in INR and prothrombin time.	DDI-advise
DDI-DrugBank.d680.s8.p0	Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, ampicillin esters, and iron salts).	DDI-mechanism
DDI-DrugBank.d680.s8.p1	Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, @DRUG$ esters, and iron salts).	DDI-mechanism
DDI-DrugBank.d680.s8.p2	Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and @DRUG$ salts).	DDI-mechanism
DDI-DrugBank.d680.s8.p3	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, @DRUG$ esters, and iron salts).	DDI-false
DDI-DrugBank.d680.s8.p4	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, ampicillin esters, and @DRUG$ salts).	DDI-false
DDI-DrugBank.d680.s8.p5	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, @DRUG$ esters, and @DRUG$ salts).	DDI-false
DDI-DrugBank.d680.s9.p0	Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (@DRUG$) in patients receiving most proton pump inhibitors, including pantoprazole.	DDI-false
DDI-DrugBank.d680.s9.p1	Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (THC) in patients receiving most @DRUG$, including pantoprazole.	DDI-false
DDI-DrugBank.d680.s9.p2	Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (THC) in patients receiving most proton pump inhibitors, including @DRUG$.	DDI-false
DDI-DrugBank.d680.s9.p3	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (@DRUG$) in patients receiving most @DRUG$, including pantoprazole.	DDI-false
DDI-DrugBank.d680.s9.p4	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (@DRUG$) in patients receiving most proton pump inhibitors, including @DRUG$.	DDI-false
DDI-DrugBank.d680.s9.p5	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most @DRUG$, including @DRUG$.	DDI-false
DDI-DrugBank.d682.s0.p0	@DRUG$ may increase the effects of @DRUG$, tolbutamide, and uricosurics.	DDI-effect
DDI-DrugBank.d682.s0.p1	@DRUG$ may increase the effects of barbiturates, @DRUG$, and uricosurics.	DDI-effect
DDI-DrugBank.d682.s0.p2	@DRUG$ may increase the effects of barbiturates, tolbutamide, and @DRUG$.	DDI-effect
DDI-DrugBank.d682.s0.p3	Sulfoxone may increase the effects of @DRUG$, @DRUG$, and uricosurics.	DDI-false
DDI-DrugBank.d682.s0.p4	Sulfoxone may increase the effects of @DRUG$, tolbutamide, and @DRUG$.	DDI-false
DDI-DrugBank.d682.s0.p5	Sulfoxone may increase the effects of barbiturates, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d682.s1.p0	It may also interact with @DRUG$ (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p1	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p2	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p3	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p4	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p5	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p6	It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d682.s1.p7	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p8	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p9	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p10	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p11	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p12	It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d682.s1.p13	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p14	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p15	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p16	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p17	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d682.s1.p18	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p19	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p20	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p21	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d682.s1.p22	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p23	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p24	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d682.s1.p25	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), @DRUG$ (decreased hepatic clearance of phenytoin).	DDI-false
DDI-DrugBank.d682.s1.p26	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d682.s1.p27	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of @DRUG$).	DDI-false
DDI-DrugBank.d686.s0.p0	@DRUG$ may compete with other drugs, such as @DRUG$, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.	DDI-mechanism
DDI-DrugBank.d686.s1.p0	Therefore, when concomitant use of @DRUG$ and @DRUG$ is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.	DDI-advise
DDI-DrugBank.d687.s0.p0	Administration of @DRUG$ decreases oral clearance of @DRUG$ by about 5%.	DDI-mechanism
DDI-DrugBank.d688.s0.p0	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of @DRUG$ or @DRUG$ to warrant dosage adjustment when megestrol acetate is administered with these drugs.	DDI-false
DDI-DrugBank.d688.s0.p1	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of @DRUG$ or rifabutin to warrant dosage adjustment when @DRUG$ is administered with these drugs.	DDI-false
DDI-DrugBank.d688.s0.p2	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or @DRUG$ to warrant dosage adjustment when @DRUG$ is administered with these drugs.	DDI-false
DDI-DrugBank.d688.s1.p0	A pharmacokinetic study demonstrated that coadministration of @DRUG$ and @DRUG$ results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.	DDI-mechanism
DDI-DrugBank.d688.s1.p1	A pharmacokinetic study demonstrated that coadministration of @DRUG$ and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of @DRUG$.	DDI-false
DDI-DrugBank.d688.s1.p2	A pharmacokinetic study demonstrated that coadministration of megestrol acetate and @DRUG$ results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of @DRUG$.	DDI-false
DDI-DrugBank.d688.s2.p0	Administration of a higher dose of @DRUG$ should be considered when coadministering with @DRUG$.	DDI-advise
DDI-DrugBank.d688.s3.p0	The effects of @DRUG$, @DRUG$ or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	DDI-false
DDI-DrugBank.d688.s3.p1	The effects of @DRUG$, zidovudine or @DRUG$ on the pharmacokinetics of megestrol acetate were not studied.	DDI-false
DDI-DrugBank.d688.s3.p2	The effects of @DRUG$, zidovudine or rifabutin on the pharmacokinetics of @DRUG$ were not studied.	DDI-false
DDI-DrugBank.d688.s3.p3	The effects of indinavir, @DRUG$ or @DRUG$ on the pharmacokinetics of megestrol acetate were not studied.	DDI-false
DDI-DrugBank.d688.s3.p4	The effects of indinavir, @DRUG$ or rifabutin on the pharmacokinetics of @DRUG$ were not studied.	DDI-false
DDI-DrugBank.d688.s3.p5	The effects of indinavir, zidovudine or @DRUG$ on the pharmacokinetics of @DRUG$ were not studied.	DDI-false
DDI-DrugBank.d689.s0.p0	@DRUG$, particularly @DRUG$, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	DDI-false
DDI-DrugBank.d689.s0.p1	@DRUG$, particularly metaraminol, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all.	DDI-effect
DDI-DrugBank.d689.s0.p2	Vasopressors, particularly @DRUG$, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all.	DDI-effect
DDI-DrugBank.d689.s1.p0	@DRUG$ - The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).	DDI-false
DDI-DrugBank.d689.s1.p1	@DRUG$ - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (MAOI).	DDI-false
DDI-DrugBank.d689.s1.p2	@DRUG$ - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$).	DDI-false
DDI-DrugBank.d689.s1.p3	MAO Inhibitors - The pressor effect of @DRUG$ is markedly potentiated in patients receiving @DRUG$ (MAOI).	DDI-effect
DDI-DrugBank.d689.s1.p4	MAO Inhibitors - The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$).	DDI-effect
DDI-DrugBank.d689.s1.p5	MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d689.s3.p0	The pressor response of @DRUG$ may also be potentiated by @DRUG$.	DDI-effect
DDI-DrugBank.d690.s0.p0	The CNS-depressant effect of @DRUG$ is additive with that of other @DRUG$, including alcohol.	DDI-effect
DDI-DrugBank.d690.s0.p1	The CNS-depressant effect of @DRUG$ is additive with that of other CNS depressants, including @DRUG$.	DDI-effect
DDI-DrugBank.d690.s0.p2	The CNS-depressant effect of propoxyphene is additive with that of other @DRUG$, including @DRUG$.	DDI-false
DDI-DrugBank.d690.s3.p0	Such occurrences have been reported when @DRUG$ was administered to patients on @DRUG$, anticonvulsants, or warfarin-like drugs.	DDI-false
DDI-DrugBank.d690.s3.p1	Such occurrences have been reported when @DRUG$ was administered to patients on antidepressants, @DRUG$, or warfarin-like drugs.	DDI-false
DDI-DrugBank.d690.s3.p2	Such occurrences have been reported when @DRUG$ was administered to patients on antidepressants, anticonvulsants, or @DRUG$-like drugs.	DDI-false
DDI-DrugBank.d690.s3.p3	Such occurrences have been reported when propoxyphene was administered to patients on @DRUG$, @DRUG$, or warfarin-like drugs.	DDI-false
DDI-DrugBank.d690.s3.p4	Such occurrences have been reported when propoxyphene was administered to patients on @DRUG$, anticonvulsants, or @DRUG$-like drugs.	DDI-false
DDI-DrugBank.d690.s3.p5	Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, @DRUG$, or @DRUG$-like drugs.	DDI-false
DDI-DrugBank.d693.s0.p0	Reduced absorption of @DRUG$ and @DRUG$ have been reported when those agents were administered concomitantly with sulfasalazine.	DDI-false
DDI-DrugBank.d693.s0.p1	Reduced absorption of @DRUG$ and digoxin have been reported when those agents were administered concomitantly with @DRUG$.	DDI-mechanism
DDI-DrugBank.d693.s0.p2	Reduced absorption of folic acid and @DRUG$ have been reported when those agents were administered concomitantly with @DRUG$.	DDI-mechanism
DDI-DrugBank.d693.s1.p0	When daily doses of @DRUG$ 2 g and weekly doses of @DRUG$ 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.	DDI-false
DDI-DrugBank.d693.s2.p0	Daily doses of @DRUG$ 2 g (maximum 3 g) and weekly doses of @DRUG$ 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies.	DDI-false
DDI-DrugBank.d694.s0.p0	@DRUG$: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of @DRUG$ with the co-administration of 100 mg sitagliptin for 10 days.	DDI-false
DDI-DrugBank.d694.s0.p1	@DRUG$: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg @DRUG$ for 10 days.	DDI-false
DDI-DrugBank.d694.s0.p2	Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of @DRUG$ with the co-administration of 100 mg @DRUG$ for 10 days.	DDI-mechanism
DDI-DrugBank.d694.s2.p0	No dosage adjustment of @DRUG$ or @DRUG$ is recommended.	DDI-false
DDI-DrugBank.d695.s0.p0	While co-administration of @DRUG$    appeared to increase the clearance of @DRUG$ by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.	DDI-mechanism
DDI-DrugBank.d695.s0.p1	While co-administration of @DRUG$    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of @DRUG$.	DDI-false
DDI-DrugBank.d695.s0.p2	While co-administration of ZAVESCA    appeared to increase the clearance of @DRUG$ by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of @DRUG$.	DDI-false
DDI-DrugBank.d695.s1.p0	Combination therapy with @DRUG$    (@DRUG$) and ZAVESCA    is not indicated.	DDI-false
DDI-DrugBank.d695.s1.p1	Combination therapy with @DRUG$    (imiglucerase) and @DRUG$    is not indicated.	DDI-advise
DDI-DrugBank.d695.s1.p2	Combination therapy with Cerezyme    (@DRUG$) and @DRUG$    is not indicated.	DDI-advise
DDI-DrugBank.d696.s0.p0	@DRUG$ may reverse the analgesic activity of @DRUG$.	DDI-effect
DDI-DrugBank.d696.s1.p0	Concurrent use with @DRUG$ including @DRUG$, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	DDI-false
DDI-DrugBank.d696.s1.p1	Concurrent use with @DRUG$ including ergot alkaloids, @DRUG$, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	DDI-false
DDI-DrugBank.d696.s1.p2	Concurrent use with @DRUG$ including ergot alkaloids, sumatriptan, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction.	DDI-false
DDI-DrugBank.d696.s1.p3	Concurrent use with vasoconstrictor agents including @DRUG$, @DRUG$, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	DDI-false
DDI-DrugBank.d696.s1.p4	Concurrent use with vasoconstrictor agents including @DRUG$, sumatriptan, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction.	DDI-false
DDI-DrugBank.d696.s1.p5	Concurrent use with vasoconstrictor agents including ergot alkaloids, @DRUG$, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction.	DDI-false
DDI-DrugBank.d697.s0.p0	Interactions for @DRUG$ (@DRUG$):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	DDI-false
DDI-DrugBank.d697.s0.p1	Interactions for @DRUG$ (Thiamine):  @DRUG$, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	DDI-int
DDI-DrugBank.d697.s0.p2	Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral @DRUG$, Stavudine, Tricyclic Antidepressants	DDI-int
DDI-DrugBank.d697.s0.p3	Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants	DDI-int
DDI-DrugBank.d697.s0.p4	Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, @DRUG$	DDI-int
DDI-DrugBank.d697.s0.p5	Interactions for Vitamin B1 (@DRUG$):  @DRUG$, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	DDI-int
DDI-DrugBank.d697.s0.p6	Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral @DRUG$, Stavudine, Tricyclic Antidepressants	DDI-int
DDI-DrugBank.d697.s0.p7	Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants	DDI-int
DDI-DrugBank.d697.s0.p8	Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral Contraceptives, Stavudine, @DRUG$	DDI-int
DDI-DrugBank.d697.s0.p9	Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral @DRUG$, Stavudine, Tricyclic Antidepressants	DDI-false
DDI-DrugBank.d697.s0.p10	Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants	DDI-false
DDI-DrugBank.d697.s0.p11	Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral Contraceptives, Stavudine, @DRUG$	DDI-false
DDI-DrugBank.d697.s0.p12	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral @DRUG$, @DRUG$, Tricyclic Antidepressants	DDI-false
DDI-DrugBank.d697.s0.p13	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral @DRUG$, Stavudine, @DRUG$	DDI-false
DDI-DrugBank.d697.s0.p14	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, @DRUG$, @DRUG$	DDI-false
DDI-DrugBank.d698.s0.p0	Interactions for @DRUG$ (@DRUG$):  Alcohol - impairs the intestinal absorption of riboflavin	DDI-false
DDI-DrugBank.d698.s0.p1	Interactions for @DRUG$ (Riboflavin):  @DRUG$ - impairs the intestinal absorption of riboflavin	DDI-false
DDI-DrugBank.d698.s0.p2	Interactions for @DRUG$ (Riboflavin):  Alcohol - impairs the intestinal absorption of @DRUG$	DDI-false
DDI-DrugBank.d698.s0.p3	Interactions for Vitamin B2 (@DRUG$):  @DRUG$ - impairs the intestinal absorption of riboflavin	DDI-false
DDI-DrugBank.d698.s0.p4	Interactions for Vitamin B2 (@DRUG$):  Alcohol - impairs the intestinal absorption of @DRUG$	DDI-false
DDI-DrugBank.d698.s0.p5	Interactions for Vitamin B2 (Riboflavin):  @DRUG$ - impairs the intestinal absorption of @DRUG$	DDI-mechanism
DDI-DrugBank.d698.s1.p0	@DRUG$ - concurrent use decreases gastrointestinal absorption of @DRUG$;	DDI-mechanism
DDI-DrugBank.d698.s2.p0	requirements for @DRUG$ may be increased in patients receiving @DRUG$.	DDI-effect
DDI-DrugBank.d699.s0.p0	@DRUG$ can interact with @DRUG$, antichlolinergic, TCA, MAOIs, and alcohol.	DDI-int
DDI-DrugBank.d699.s0.p1	@DRUG$ can interact with CNS depressant, @DRUG$, TCA, MAOIs, and alcohol.	DDI-int
DDI-DrugBank.d699.s0.p2	@DRUG$ can interact with CNS depressant, antichlolinergic, @DRUG$, MAOIs, and alcohol.	DDI-int
DDI-DrugBank.d699.s0.p3	@DRUG$ can interact with CNS depressant, antichlolinergic, TCA, @DRUG$, and alcohol.	DDI-int
DDI-DrugBank.d699.s0.p4	@DRUG$ can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and @DRUG$.	DDI-int
DDI-DrugBank.d699.s0.p5	Mequitazine can interact with @DRUG$, @DRUG$, TCA, MAOIs, and alcohol.	DDI-false
DDI-DrugBank.d699.s0.p6	Mequitazine can interact with @DRUG$, antichlolinergic, @DRUG$, MAOIs, and alcohol.	DDI-false
DDI-DrugBank.d699.s0.p7	Mequitazine can interact with @DRUG$, antichlolinergic, TCA, @DRUG$, and alcohol.	DDI-false
DDI-DrugBank.d699.s0.p8	Mequitazine can interact with @DRUG$, antichlolinergic, TCA, MAOIs, and @DRUG$.	DDI-false
DDI-DrugBank.d699.s0.p9	Mequitazine can interact with CNS depressant, @DRUG$, @DRUG$, MAOIs, and alcohol.	DDI-false
DDI-DrugBank.d699.s0.p10	Mequitazine can interact with CNS depressant, @DRUG$, TCA, @DRUG$, and alcohol.	DDI-false
DDI-DrugBank.d699.s0.p11	Mequitazine can interact with CNS depressant, @DRUG$, TCA, MAOIs, and @DRUG$.	DDI-false
DDI-DrugBank.d699.s0.p12	Mequitazine can interact with CNS depressant, antichlolinergic, @DRUG$, @DRUG$, and alcohol.	DDI-false
DDI-DrugBank.d699.s0.p13	Mequitazine can interact with CNS depressant, antichlolinergic, @DRUG$, MAOIs, and @DRUG$.	DDI-false
DDI-DrugBank.d699.s0.p14	Mequitazine can interact with CNS depressant, antichlolinergic, TCA, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d700.s0.p0	@DRUG$: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p1	@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p2	@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p3	@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p4	@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p5	Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-mechanism
DDI-DrugBank.d700.s0.p6	Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-mechanism
DDI-DrugBank.d700.s0.p7	Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p8	Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p9	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p10	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p11	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p12	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p13	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s0.p14	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions.	DDI-false
DDI-DrugBank.d700.s1.p0	It is recommended that @DRUG$ and @DRUG$ not be administered simultaneously.	DDI-advise
DDI-DrugBank.d700.s10.p0	However, in a drug-drug interaction study, mean @DRUG$ AUC was decreased by 15% when coadministered with @DRUG$.	DDI-mechanism
DDI-DrugBank.d700.s11.p0	Therefore, it is recommended that oral @DRUG$ are co- administered with @DRUG$ with caution and additional birth control methods be considered.	DDI-advise
DDI-DrugBank.d700.s12.p0	@DRUG$: During treatment with @DRUG$, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.	DDI-false
DDI-DrugBank.d700.s12.p1	@DRUG$: During treatment with Myfortic, the use of @DRUG$ should be avoided and patients should be advised that vaccinations may be less effective.	DDI-false
DDI-DrugBank.d700.s12.p2	Live Vaccines: During treatment with @DRUG$, the use of @DRUG$ should be avoided and patients should be advised that vaccinations may be less effective.	DDI-advise
DDI-DrugBank.d700.s16.p0	Interference of @DRUG$ hydrolysis may lead to less @DRUG$ available for absorption.	DDI-false
DDI-DrugBank.d700.s2.p0	@DRUG$: When studied in stable renal transplant patients, @DRUG$, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic.	DDI-false
DDI-DrugBank.d700.s2.p1	@DRUG$: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of @DRUG$.	DDI-false
DDI-DrugBank.d700.s2.p2	Cyclosporine: When studied in stable renal transplant patients, @DRUG$, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of @DRUG$.	DDI-false
DDI-DrugBank.d700.s3.p0	@DRUG$/@DRUG$: may be taken with Myfortic;	DDI-false
DDI-DrugBank.d700.s3.p1	@DRUG$/Ganciclovir: may be taken with @DRUG$;	DDI-false
DDI-DrugBank.d700.s3.p2	Acyclovir/@DRUG$: may be taken with @DRUG$;	DDI-false
DDI-DrugBank.d700.s5.p0	Both @DRUG$/@DRUG$ and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	DDI-false
DDI-DrugBank.d700.s5.p1	Both @DRUG$/ganciclovir and @DRUG$ concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	DDI-false
DDI-DrugBank.d700.s5.p2	Both acyclovir/@DRUG$ and @DRUG$ concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	DDI-false
DDI-DrugBank.d700.s6.p0	@DRUG$/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p1	@DRUG$/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p2	@DRUG$/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p3	@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p4	@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p5	@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$.	DDI-false
DDI-DrugBank.d700.s6.p6	Azathioprine/@DRUG$: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p7	Azathioprine/@DRUG$: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p8	Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p9	Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p10	Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$.	DDI-false
DDI-DrugBank.d700.s6.p11	Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p12	Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p13	Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p14	Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$.	DDI-false
DDI-DrugBank.d700.s6.p15	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p16	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s6.p17	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$.	DDI-false
DDI-DrugBank.d700.s6.p18	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with @DRUG$ or mycophenolate mofetil.	DDI-advise
DDI-DrugBank.d700.s6.p19	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or @DRUG$.	DDI-advise
DDI-DrugBank.d700.s6.p20	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d700.s7.p0	@DRUG$ and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce @DRUG$ exposure when coadministered with mycophenolate mofetil.	DDI-false
DDI-DrugBank.d700.s7.p1	@DRUG$ and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d700.s7.p2	Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce @DRUG$ exposure when coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d700.s8.p0	Therefore, do not administer @DRUG$ with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.	DDI-advise
DDI-DrugBank.d700.s8.p1	Therefore, do not administer @DRUG$ with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of Myfortic.	DDI-advise
DDI-DrugBank.d700.s8.p2	Therefore, do not administer @DRUG$ with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of @DRUG$.	DDI-false
DDI-DrugBank.d700.s8.p3	Therefore, do not administer Myfortic with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of Myfortic.	DDI-false
DDI-DrugBank.d700.s8.p4	Therefore, do not administer Myfortic with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of @DRUG$.	DDI-false
DDI-DrugBank.d700.s8.p5	Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of @DRUG$.	DDI-false
DDI-DrugBank.d700.s9.p0	Oral @DRUG$: Given the different metabolism of @DRUG$ and oral contraceptives, no drug interaction between these two classes of drug is expected.	DDI-false
DDI-DrugBank.d700.s9.p1	Oral @DRUG$: Given the different metabolism of Myfortic and oral @DRUG$, no drug interaction between these two classes of drug is expected.	DDI-false
DDI-DrugBank.d700.s9.p2	Oral Contraceptives: Given the different metabolism of @DRUG$ and oral @DRUG$, no drug interaction between these two classes of drug is expected.	DDI-false
DDI-DrugBank.d702.s1.p0	These include @DRUG$, @DRUG$, and oral and inhaled steroids.	DDI-false
DDI-DrugBank.d702.s1.p1	These include @DRUG$, methylxanthines, and oral and inhaled @DRUG$.	DDI-false
DDI-DrugBank.d702.s1.p2	These include sympathomimetic bronchodilators, @DRUG$, and oral and inhaled @DRUG$.	DDI-false
DDI-DrugBank.d702.s2.p0	However, the co   administration of @DRUG$ with other @DRUG$   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.	DDI-advise
DDI-DrugBank.d702.s2.p1	However, the co   administration of @DRUG$ with other anticholinergic   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended.	DDI-advise
DDI-DrugBank.d702.s2.p2	However, the co   administration of SPIRIVA with other @DRUG$   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended.	DDI-false
DDI-DrugBank.d703.s0.p0	Interaction with Other @DRUG$: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p1	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p2	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p3	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p4	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p5	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p6	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p7	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p8	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p9	Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d703.s0.p10	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-advise
DDI-DrugBank.d703.s0.p11	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-advise
DDI-DrugBank.d703.s0.p12	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-advise
DDI-DrugBank.d703.s0.p13	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-advise
DDI-DrugBank.d703.s0.p14	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-advise
DDI-DrugBank.d703.s0.p15	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-advise
DDI-DrugBank.d703.s0.p16	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-advise
DDI-DrugBank.d703.s0.p17	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-advise
DDI-DrugBank.d703.s0.p18	Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-advise
DDI-DrugBank.d703.s0.p19	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p20	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p21	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p22	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p23	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p24	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p25	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p26	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d703.s0.p27	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p28	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p29	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p30	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p31	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p32	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p33	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d703.s0.p34	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p35	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p36	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p37	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p38	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p39	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d703.s0.p40	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p41	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p42	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p43	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p44	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d703.s0.p45	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p46	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p47	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p48	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d703.s0.p49	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p50	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p51	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d703.s0.p52	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER @DRUG$ (INCLUDING ALCOHOL).	DDI-false
DDI-DrugBank.d703.s0.p53	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d703.s0.p54	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING @DRUG$).	DDI-false
DDI-DrugBank.d704.s0.p0	Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between @DRUG$ capsules and other @DRUG$ have not been determined.	DDI-false
DDI-DrugBank.d704.s1.p0	However, interactions may be expected and @DRUG$ capsules should NOT be used in combination with other @DRUG$.	DDI-advise
DDI-DrugBank.d704.s2.p0	The pharmacokinetic interaction between @DRUG$ and @DRUG$ capsules was investigated.	DDI-false
DDI-DrugBank.d704.s4.p0	Therefore, @DRUG$ capsules should be used with caution in combination with @DRUG$, particularly at doses higher than 0.4 mg.	DDI-advise
DDI-DrugBank.d704.s5.p0	Results from limited in vitro and in vivo drug-drug interaction studies between @DRUG$ and @DRUG$ are inconclusive.	DDI-false
DDI-DrugBank.d704.s6.p0	Therefore, caution should be exercised with concomitant administration of @DRUG$ and @DRUG$ capsules.	DDI-advise
DDI-DrugBank.d706.s0.p0	Catecholamine-depleting drugs (e.g., @DRUG$) may have an additive effect when given with @DRUG$.	DDI-effect
DDI-DrugBank.d709.s1.p0	Concomitant administrations not recommended:  - @DRUG$ and @DRUG$: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	DDI-false
DDI-DrugBank.d709.s1.p1	Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain @DRUG$ interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	DDI-false
DDI-DrugBank.d709.s1.p2	Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain macrolides interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter.	DDI-false
DDI-DrugBank.d709.s1.p3	Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain macrolides interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter.	DDI-false
DDI-DrugBank.d709.s1.p4	Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain @DRUG$ interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	DDI-false
DDI-DrugBank.d709.s1.p5	Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain macrolides interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter.	DDI-false
DDI-DrugBank.d709.s1.p6	Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain macrolides interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter.	DDI-false
DDI-DrugBank.d709.s1.p7	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain @DRUG$ interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter.	DDI-int
DDI-DrugBank.d709.s1.p8	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain @DRUG$ interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter.	DDI-int
DDI-DrugBank.d709.s1.p9	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with @DRUG$ and @DRUG$ leading to increased serum concentrations of the latter.	DDI-false
DDI-DrugBank.d709.s3.p0	Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of @DRUG$ with terfenadine or astemizole is not recommended.	DDI-false
DDI-DrugBank.d709.s3.p1	Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of roxithromycin with @DRUG$ or astemizole is not recommended.	DDI-false
DDI-DrugBank.d709.s3.p2	Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of roxithromycin with terfenadine or @DRUG$ is not recommended.	DDI-false
DDI-DrugBank.d709.s3.p3	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of @DRUG$ with @DRUG$ or astemizole is not recommended.	DDI-advise
DDI-DrugBank.d709.s3.p4	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of @DRUG$ with terfenadine or @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d709.s3.p5	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with @DRUG$ or @DRUG$ is not recommended.	DDI-false
DDI-DrugBank.d709.s4.p0	- @DRUG$, @DRUG$: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	DDI-false
DDI-DrugBank.d709.s4.p1	- @DRUG$, pimozide: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	DDI-false
DDI-DrugBank.d709.s4.p2	- @DRUG$, pimozide: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	DDI-false
DDI-DrugBank.d709.s4.p3	- @DRUG$, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$.	DDI-false
DDI-DrugBank.d709.s4.p4	- Cisapride, @DRUG$: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	DDI-false
DDI-DrugBank.d709.s4.p5	- Cisapride, @DRUG$: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	DDI-false
DDI-DrugBank.d709.s4.p6	- Cisapride, @DRUG$: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$.	DDI-mechanism
DDI-DrugBank.d709.s4.p7	- Cisapride, pimozide: Other drugs such as @DRUG$ or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	DDI-false
DDI-DrugBank.d709.s4.p8	- Cisapride, pimozide: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$.	DDI-mechanism
DDI-DrugBank.d709.s4.p9	- Cisapride, pimozide: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$.	DDI-false
DDI-DrugBank.d709.s5.p0	Although such a risk is not verified for @DRUG$, combination of @DRUG$ with such drugs is not recommended.	DDI-false
DDI-DrugBank.d710.s0.p0	@DRUG$: The effects of chronic @DRUG$ use on the metabolism of rimantadine are not known.	DDI-false
DDI-DrugBank.d710.s0.p1	@DRUG$: The effects of chronic cimetidine use on the metabolism of @DRUG$ are not known.	DDI-false
DDI-DrugBank.d710.s0.p2	Cimetidine: The effects of chronic @DRUG$ use on the metabolism of @DRUG$ are not known.	DDI-false
DDI-DrugBank.d710.s1.p0	When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	DDI-mechanism
DDI-DrugBank.d710.s1.p1	When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	DDI-false
DDI-DrugBank.d710.s1.p2	When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine).	DDI-false
DDI-DrugBank.d710.s1.p3	When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$).	DDI-false
DDI-DrugBank.d710.s1.p4	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	DDI-false
DDI-DrugBank.d710.s1.p5	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine).	DDI-false
DDI-DrugBank.d710.s1.p6	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$).	DDI-false
DDI-DrugBank.d710.s1.p7	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine).	DDI-false
DDI-DrugBank.d710.s1.p8	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$).	DDI-false
DDI-DrugBank.d710.s1.p9	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of @DRUG$).	DDI-false
DDI-DrugBank.d710.s2.p0	@DRUG$: @DRUG$, 100 mg, was given twice daily for 13 days to 12 healthy volunteers.	DDI-false
DDI-DrugBank.d710.s5.p0	Coadministration with @DRUG$ reduced the peak concentration and AUC values for @DRUG$ by approximately 11%.	DDI-mechanism
DDI-DrugBank.d710.s6.p0	@DRUG$: @DRUG$, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers.	DDI-false
DDI-DrugBank.d710.s9.p0	Peak plasma concentrations and AUC of @DRUG$ were reduced approximately 10% in the presence of @DRUG$.	DDI-mechanism
DDI-DrugBank.d711.s0.p0	Because @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their anticoagulant dosage.	DDI-advise
DDI-DrugBank.d711.s0.p1	Because @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their @DRUG$ dosage.	DDI-false
DDI-DrugBank.d711.s0.p2	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their @DRUG$ dosage.	DDI-false
DDI-DrugBank.d711.s1.p0	Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving @DRUG$ in conjunction with penicillin.	DDI-false
DDI-DrugBank.d711.s1.p1	Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving tetracycline class drugs in conjunction with @DRUG$.	DDI-false
DDI-DrugBank.d711.s1.p2	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving @DRUG$ in conjunction with @DRUG$.	DDI-advise
DDI-DrugBank.d711.s2.p0	Absorption of @DRUG$ is impaired by @DRUG$ containing aluminum, calcium or magnesium, and iron-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p1	Absorption of @DRUG$ is impaired by antacids containing @DRUG$, calcium or magnesium, and iron-containing preparations.	DDI-mechanism
DDI-DrugBank.d711.s2.p2	Absorption of @DRUG$ is impaired by antacids containing aluminum, @DRUG$ or magnesium, and iron-containing preparations.	DDI-mechanism
DDI-DrugBank.d711.s2.p3	Absorption of @DRUG$ is impaired by antacids containing aluminum, calcium or @DRUG$, and iron-containing preparations.	DDI-mechanism
DDI-DrugBank.d711.s2.p4	Absorption of @DRUG$ is impaired by antacids containing aluminum, calcium or magnesium, and @DRUG$-containing preparations.	DDI-mechanism
DDI-DrugBank.d711.s2.p5	Absorption of tetracyclines is impaired by @DRUG$ containing @DRUG$, calcium or magnesium, and iron-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p6	Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, @DRUG$ or magnesium, and iron-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p7	Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, calcium or @DRUG$, and iron-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p8	Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, calcium or magnesium, and @DRUG$-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p9	Absorption of tetracyclines is impaired by antacids containing @DRUG$, @DRUG$ or magnesium, and iron-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p10	Absorption of tetracyclines is impaired by antacids containing @DRUG$, calcium or @DRUG$, and iron-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p11	Absorption of tetracyclines is impaired by antacids containing @DRUG$, calcium or magnesium, and @DRUG$-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p12	Absorption of tetracyclines is impaired by antacids containing aluminum, @DRUG$ or @DRUG$, and iron-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p13	Absorption of tetracyclines is impaired by antacids containing aluminum, @DRUG$ or magnesium, and @DRUG$-containing preparations.	DDI-false
DDI-DrugBank.d711.s2.p14	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or @DRUG$, and @DRUG$-containing preparations.	DDI-false
DDI-DrugBank.d711.s3.p0	The concurrent use of @DRUG$ and @DRUG$ has been reported to result in fatal renal toxicity.	DDI-effect
DDI-DrugBank.d711.s4.p0	Concurrent use of @DRUG$ with oral @DRUG$ may render oral contraceptives less effective.	DDI-effect
DDI-DrugBank.d711.s4.p1	Concurrent use of @DRUG$ with oral contraceptives may render oral @DRUG$ less effective.	DDI-false
DDI-DrugBank.d711.s4.p2	Concurrent use of tetracyclines with oral @DRUG$ may render oral @DRUG$ less effective.	DDI-false
DDI-DrugBank.d712.s1.p0	Administration of @DRUG$ in combination with @DRUG$ resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	DDI-mechanism
DDI-DrugBank.d712.s1.p1	Administration of @DRUG$ in combination with HERCEPTIN resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	DDI-false
DDI-DrugBank.d712.s1.p2	Administration of @DRUG$ in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies.	DDI-false
DDI-DrugBank.d712.s1.p3	Administration of paclitaxel in combination with @DRUG$ resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	DDI-false
DDI-DrugBank.d712.s1.p4	Administration of paclitaxel in combination with @DRUG$ resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies.	DDI-false
DDI-DrugBank.d712.s1.p5	Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies.	DDI-false
DDI-DrugBank.d713.s0.p0	The concomitant use of @DRUG$ with other @DRUG$ that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.	DDI-effect
DDI-DrugBank.d713.s2.p0	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p1	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p2	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p3	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p4	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p5	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p6	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p7	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$).	DDI-false
DDI-DrugBank.d713.s2.p8	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	DDI-mechanism
DDI-DrugBank.d713.s2.p9	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir).	DDI-mechanism
DDI-DrugBank.d713.s2.p10	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir).	DDI-mechanism
DDI-DrugBank.d713.s2.p11	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir).	DDI-mechanism
DDI-DrugBank.d713.s2.p12	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir).	DDI-mechanism
DDI-DrugBank.d713.s2.p13	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir).	DDI-mechanism
DDI-DrugBank.d713.s2.p14	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$).	DDI-mechanism
DDI-DrugBank.d713.s2.p15	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p16	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p17	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p18	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p19	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p20	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$).	DDI-false
DDI-DrugBank.d713.s2.p21	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, @DRUG$, morphine, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p22	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, @DRUG$, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p23	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, @DRUG$, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p24	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p25	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and @DRUG$).	DDI-false
DDI-DrugBank.d713.s2.p26	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, @DRUG$, vancomycin, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p27	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, @DRUG$, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p28	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, @DRUG$ and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p29	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and @DRUG$).	DDI-false
DDI-DrugBank.d713.s2.p30	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, @DRUG$, metformin and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p31	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, @DRUG$ and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p32	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and @DRUG$).	DDI-false
DDI-DrugBank.d713.s2.p33	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, @DRUG$ and tenofovir).	DDI-false
DDI-DrugBank.d713.s2.p34	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and @DRUG$).	DDI-false
DDI-DrugBank.d713.s2.p35	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d713.s3.p0	Coadministration of @DRUG$ with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of @DRUG$ and/or the coadministered drug due to competition for this elimination pathway.	DDI-false
DDI-DrugBank.d715.s0.p0	Caution should be observed in administering @DRUG$ to patients receiving @DRUG$ or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	DDI-advise
DDI-DrugBank.d715.s0.p1	Caution should be observed in administering @DRUG$ to patients receiving phenothiazines or @DRUG$ because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	DDI-advise
DDI-DrugBank.d715.s0.p2	Caution should be observed in administering DEMSER to patients receiving @DRUG$ or @DRUG$ because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	DDI-false
DDI-DrugBank.d715.s1.p0	Concurrent use of @DRUG$ with @DRUG$ or other CNS depressants can increase their sedative effects.	DDI-effect
DDI-DrugBank.d715.s1.p1	Concurrent use of @DRUG$ with alcohol or other @DRUG$ can increase their sedative effects.	DDI-effect
DDI-DrugBank.d715.s1.p2	Concurrent use of DEMSER with @DRUG$ or other @DRUG$ can increase their sedative effects.	DDI-false
DDI-DrugBank.d716.s0.p0	You cannot take @DRUG$ if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-advise
DDI-DrugBank.d716.s0.p1	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-advise
DDI-DrugBank.d716.s0.p2	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-advise
DDI-DrugBank.d716.s0.p3	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-advise
DDI-DrugBank.d716.s0.p4	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-advise
DDI-DrugBank.d716.s0.p5	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.	DDI-advise
DDI-DrugBank.d716.s0.p6	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.	DDI-advise
DDI-DrugBank.d716.s0.p7	You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.	DDI-advise
DDI-DrugBank.d716.s0.p8	You cannot take mazindol if you have taken a @DRUG$ (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p9	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p10	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p11	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p12	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p13	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p14	You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p15	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p16	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p17	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p18	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p19	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p20	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p21	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p22	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p23	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p24	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p25	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p26	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p27	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p28	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p29	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p30	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (@DRUG$), or phenelzine (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p31	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or @DRUG$ (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p32	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (@DRUG$) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p33	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or @DRUG$ (Nardil) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p34	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (@DRUG$) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s0.p35	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (@DRUG$) in the last 14 days.	DDI-false
DDI-DrugBank.d716.s1.p0	Changes in @DRUG$ and other diabetes drug therapies may be necessary during treatment with @DRUG$.	DDI-advise
DDI-DrugBank.d716.s2.p0	@DRUG$ may reduce the effects of @DRUG$ (Ismelin).	DDI-effect
DDI-DrugBank.d716.s2.p1	@DRUG$ may reduce the effects of guanethidine (@DRUG$).	DDI-effect
DDI-DrugBank.d716.s2.p2	Mazindol may reduce the effects of @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p0	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p1	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p2	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p3	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p4	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p5	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p6	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p7	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p8	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p9	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p10	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p11	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p12	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p13	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p14	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p15	Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p16	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p17	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p18	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p19	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p20	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p21	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p22	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p23	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p24	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p25	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p26	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p27	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p28	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p29	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p30	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p31	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p32	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p33	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p34	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p35	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p36	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p37	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p38	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p39	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p40	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p41	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p42	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p43	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p44	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p45	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p46	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p47	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p48	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p49	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p50	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p51	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p52	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p53	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p54	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p55	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p56	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p57	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p58	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p59	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p60	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p61	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p62	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p63	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p64	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p65	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p66	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p67	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p68	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p69	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p70	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p71	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p72	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p73	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p74	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p75	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p76	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p77	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p78	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p79	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p80	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p81	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p82	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p83	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p84	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p85	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p86	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p87	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p88	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p89	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p90	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p91	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p92	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p93	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p94	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p95	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p96	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p97	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p98	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p99	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p100	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p101	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p102	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p103	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p104	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p105	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p106	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p107	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p108	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p109	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p110	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p111	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p112	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p113	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p114	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p115	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p116	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p117	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p118	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p119	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p120	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p121	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p122	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p123	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p124	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p125	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p126	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), @DRUG$ (Vivactil), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p127	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p128	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p129	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p130	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (@DRUG$), or desipramine (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p131	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p132	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p133	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or @DRUG$ (Norpramin).	DDI-false
DDI-DrugBank.d716.s5.p134	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (@DRUG$).	DDI-false
DDI-DrugBank.d716.s5.p135	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d717.s0.p0	@DRUG$ has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.	DDI-mechanism
DDI-DrugBank.d717.s0.p1	@DRUG$ has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$.	DDI-false
DDI-DrugBank.d717.s0.p2	Mitotane has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$.	DDI-false
DDI-DrugBank.d717.s1.p0	Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants.	DDI-false
DDI-DrugBank.d717.s1.p1	Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering Mitotane to patients on @DRUG$.	DDI-false
DDI-DrugBank.d717.s1.p2	Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering @DRUG$ to patients on @DRUG$.	DDI-advise
DDI-DrugBank.d720.s1.p0	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or @DRUG$ (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	DDI-false
DDI-DrugBank.d720.s1.p1	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like @DRUG$ or methysergide) and sumatriptan within 24 hours of each other should be avoided.	DDI-false
DDI-DrugBank.d720.s1.p2	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and sumatriptan within 24 hours of each other should be avoided.	DDI-false
DDI-DrugBank.d720.s1.p3	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
DDI-DrugBank.d720.s1.p4	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and sumatriptan within 24 hours of each other should be avoided.	DDI-false
DDI-DrugBank.d720.s1.p5	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and sumatriptan within 24 hours of each other should be avoided.	DDI-false
DDI-DrugBank.d720.s1.p6	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
DDI-DrugBank.d720.s1.p7	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or @DRUG$) and sumatriptan within 24 hours of each other should be avoided.	DDI-false
DDI-DrugBank.d720.s1.p8	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
DDI-DrugBank.d720.s1.p9	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
DDI-DrugBank.d720.s2.p0	@DRUG$ reduce @DRUG$ clearance, significantly increasing systemic exposure.	DDI-mechanism
DDI-DrugBank.d720.s3.p0	Therefore, the use of @DRUG$ tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-advise
DDI-DrugBank.d720.s3.p1	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p2	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p3	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p4	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p5	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p6	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p7	Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d720.s3.p8	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p9	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p10	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p11	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p12	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p13	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p14	Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d720.s3.p15	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p16	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p17	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p18	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p19	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p20	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d720.s3.p21	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p22	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p23	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p24	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p25	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d720.s3.p26	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p27	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p28	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p29	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d720.s3.p30	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p31	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p32	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d720.s3.p33	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	DDI-false
DDI-DrugBank.d720.s3.p34	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d720.s3.p35	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d720.s4.p0	If concomitant treatment with @DRUG$ and an @DRUG$ is clinically warranted, appropriate observation of the patient is advised.	DDI-advise
DDI-DrugBank.d721.s0.p0	The bioavailability of @DRUG$ is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-mechanism
DDI-DrugBank.d721.s0.p1	The bioavailability of @DRUG$ is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p2	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p3	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p4	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p5	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p6	The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$.	DDI-false
DDI-DrugBank.d721.s0.p7	The bioavailability of SKELID is decreased 80% by @DRUG$, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p8	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p9	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p10	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p11	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p12	The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$.	DDI-false
DDI-DrugBank.d721.s0.p13	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p14	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p15	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p16	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p17	The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$.	DDI-false
DDI-DrugBank.d721.s0.p18	The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p19	The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p20	The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p21	The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$.	DDI-false
DDI-DrugBank.d721.s0.p22	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or @DRUG$-containing antacids, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p23	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing @DRUG$, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p24	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before @DRUG$.	DDI-mechanism
DDI-DrugBank.d721.s0.p25	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing @DRUG$, when administered 1 hour before SKELID.	DDI-false
DDI-DrugBank.d721.s0.p26	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before @DRUG$.	DDI-mechanism
DDI-DrugBank.d721.s0.p27	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before @DRUG$.	DDI-false
DDI-DrugBank.d721.s1.p0	@DRUG$ may decrease bioavailability of @DRUG$ by up to 50% when taken 2 hours after SKELID.	DDI-mechanism
DDI-DrugBank.d721.s1.p1	@DRUG$ may decrease bioavailability of SKELID by up to 50% when taken 2 hours after @DRUG$.	DDI-false
DDI-DrugBank.d721.s1.p2	Aspirin may decrease bioavailability of @DRUG$ by up to 50% when taken 2 hours after @DRUG$.	DDI-false
DDI-DrugBank.d721.s2.p0	The bioavailability of @DRUG$ is increased 2-4 fold by @DRUG$ but is not significantly altered by coadministration of diclofenac.	DDI-mechanism
DDI-DrugBank.d721.s2.p1	The bioavailability of @DRUG$ is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of @DRUG$.	DDI-false
DDI-DrugBank.d721.s2.p2	The bioavailability of SKELID is increased 2-4 fold by @DRUG$ but is not significantly altered by coadministration of @DRUG$.	DDI-false
DDI-DrugBank.d721.s3.p0	The pharmacokinetic parameters of @DRUG$ are not significantly modified by @DRUG$ coadministration.	DDI-false
DDI-DrugBank.d721.s4.p0	In vitro studies show that @DRUG$ does not displace @DRUG$ from its binding site on protein.	DDI-false
DDI-DrugBank.d722.s0.p0	There is usually complete cross-resistance between @DRUG$ (@DRUG$) and TABLOID brand Thioguanine.	DDI-false
DDI-DrugBank.d722.s0.p1	There is usually complete cross-resistance between @DRUG$ (mercaptopurine) and @DRUG$ brand Thioguanine.	DDI-effect
DDI-DrugBank.d722.s0.p2	There is usually complete cross-resistance between @DRUG$ (mercaptopurine) and TABLOID brand @DRUG$.	DDI-effect
DDI-DrugBank.d722.s0.p3	There is usually complete cross-resistance between PURINETHOL (@DRUG$) and @DRUG$ brand Thioguanine.	DDI-effect
DDI-DrugBank.d722.s0.p4	There is usually complete cross-resistance between PURINETHOL (@DRUG$) and TABLOID brand @DRUG$.	DDI-effect
DDI-DrugBank.d722.s0.p5	There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and @DRUG$ brand @DRUG$.	DDI-false
DDI-DrugBank.d722.s1.p0	As there is in vitro evidence that @DRUG$ (e.g., @DRUG$, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	DDI-false
DDI-DrugBank.d722.s1.p1	As there is in vitro evidence that @DRUG$ (e.g., olsalazine, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	DDI-false
DDI-DrugBank.d722.s1.p2	As there is in vitro evidence that @DRUG$ (e.g., olsalazine, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	DDI-false
DDI-DrugBank.d722.s1.p3	As there is in vitro evidence that @DRUG$ (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy.	DDI-mechanism
DDI-DrugBank.d722.s1.p4	As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	DDI-false
DDI-DrugBank.d722.s1.p5	As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	DDI-false
DDI-DrugBank.d722.s1.p6	As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy.	DDI-mechanism
DDI-DrugBank.d722.s1.p7	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, @DRUG$, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	DDI-false
DDI-DrugBank.d722.s1.p8	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy.	DDI-mechanism
DDI-DrugBank.d722.s1.p9	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy.	DDI-mechanism
DDI-DrugBank.d723.s0.p0	Other eye drops or medications such as @DRUG$ (@DRUG$) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p1	Other eye drops or medications such as @DRUG$ (Miochol) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p2	Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p3	Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p4	Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic.	DDI-effect
DDI-DrugBank.d723.s0.p5	Other eye drops or medications such as acetylcholine chloride (@DRUG$) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p6	Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p7	Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p8	Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic.	DDI-effect
DDI-DrugBank.d723.s0.p9	Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p10	Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p11	Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic.	DDI-effect
DDI-DrugBank.d723.s0.p12	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (@DRUG$, @DRUG$) may decrease the effects of suprofen ophthalmic.	DDI-false
DDI-DrugBank.d723.s0.p13	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic.	DDI-effect
DDI-DrugBank.d723.s0.p14	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, @DRUG$) may decrease the effects of @DRUG$ ophthalmic.	DDI-effect
DDI-DrugBank.d725.s0.p0	@DRUG$, particularly @DRUG$, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	DDI-false
DDI-DrugBank.d725.s0.p1	@DRUG$, particularly metaraminol, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all.	DDI-effect
DDI-DrugBank.d725.s0.p2	Vasopressors, particularly @DRUG$, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all.	DDI-effect
DDI-DrugBank.d725.s1.p0	@DRUG$: The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).	DDI-false
DDI-DrugBank.d725.s1.p1	@DRUG$: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (MAOI).	DDI-false
DDI-DrugBank.d725.s1.p2	@DRUG$: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$).	DDI-false
DDI-DrugBank.d725.s1.p3	MAO Inhibitors: The pressor effect of @DRUG$ is markedly potentiated in patients receiving @DRUG$ (MAOI).	DDI-effect
DDI-DrugBank.d725.s1.p4	MAO Inhibitors: The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$).	DDI-effect
DDI-DrugBank.d725.s1.p5	MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d725.s3.p0	The pressor response of @DRUG$ may also be potentiated by @DRUG$.	DDI-effect
DDI-DrugBank.d726.s1.p0	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-mechanism
DDI-DrugBank.d726.s1.p1	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p2	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p3	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p4	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p5	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p6	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p7	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p8	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p9	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p10	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p11	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p12	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p13	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p14	A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p15	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p16	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p17	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p18	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p19	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p20	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p21	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p22	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p23	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p24	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p25	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p26	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p27	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p28	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p29	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p30	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p31	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p32	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p33	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p34	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p35	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p36	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p37	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p38	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p39	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p40	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p41	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p42	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p43	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p44	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p45	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p46	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p47	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p48	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p49	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p50	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p51	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p52	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p53	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p54	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p55	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p56	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p57	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p58	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p59	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p60	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p61	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p62	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p63	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-advise
DDI-DrugBank.d726.s1.p64	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-advise
DDI-DrugBank.d726.s1.p65	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p66	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p67	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p68	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p69	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p70	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p71	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p72	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p73	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p74	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p75	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p76	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p77	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p78	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p79	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p80	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p81	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p82	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p83	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p84	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p85	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p86	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p87	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p88	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p89	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p90	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p91	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p92	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p93	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p94	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p95	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p96	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p97	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p98	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p99	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p100	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p101	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p102	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p103	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p104	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p105	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p106	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p107	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p108	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p109	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p110	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, @DRUG$, saquinavir, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p111	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p112	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p113	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p114	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, @DRUG$, telithromycin or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p115	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p116	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p117	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, @DRUG$ or voriconazole.	DDI-false
DDI-DrugBank.d726.s1.p118	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d726.s1.p119	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d726.s2.p0	Dose adjustment of @DRUG$ Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as @DRUG$.	DDI-advise
DDI-DrugBank.d726.s3.p0	Drugs that impair intestinal absorption of @DRUG$, such as @DRUG$, may interfere with the absorption of Zemplar Capsules.	DDI-mechanism
DDI-DrugBank.d726.s3.p1	Drugs that impair intestinal absorption of @DRUG$, such as cholestyramine, may interfere with the absorption of @DRUG$ Capsules.	DDI-false
DDI-DrugBank.d726.s3.p2	Drugs that impair intestinal absorption of fat-soluble vitamins, such as @DRUG$, may interfere with the absorption of @DRUG$ Capsules.	DDI-mechanism
DDI-DrugBank.d727.s0.p0	@DRUG$ competitively inhibits the intracellular phosphorylation of @DRUG$.	DDI-effect
DDI-DrugBank.d727.s1.p0	Therefore, use of @DRUG$ in combination with @DRUG$ should be avoided.	DDI-advise
DDI-DrugBank.d727.s2.p0	In vitro data indicate that the phosphorylation of @DRUG$ is also inhibited at relevant concentrations by @DRUG$ and ribavirin.	DDI-effect
DDI-DrugBank.d727.s2.p1	In vitro data indicate that the phosphorylation of @DRUG$ is also inhibited at relevant concentrations by doxorubicin and @DRUG$.	DDI-effect
DDI-DrugBank.d727.s2.p2	In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d728.s1.p0	No pharmacokinetic interaction between 85 mg/m2 @DRUG$ and infusional @DRUG$ has been observed in patients treated every 2 weeks.	DDI-false
DDI-DrugBank.d728.s2.p0	Increases of @DRUG$ plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 @DRUG$ dosed every 3 weeks.	DDI-mechanism
DDI-DrugBank.d732.s0.p0	@DRUG$ is not known to interact with other drugs including @DRUG$ supplements;	DDI-false
DDI-DrugBank.d732.s2.p0	Concomitant administration of @DRUG$ with other chelation therapy, such as @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d734.s0.p0	@DRUG$ may accentuate the orthostatic hypotension that may occur with @DRUG$.	DDI-effect
DDI-DrugBank.d734.s1.p0	Antihypertensive effects of @DRUG$ and related compounds may be counteracted when @DRUG$ are used concomitantly.	DDI-effect
DDI-DrugBank.d734.s2.p0	Concomitant administration of @DRUG$ with @DRUG$ results in increased plasma levels of both drugs.	DDI-mechanism
DDI-DrugBank.d735.s0.p0	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p1	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p2	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p3	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p4	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p5	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p6	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p7	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p8	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s0.p9	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p10	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p11	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p12	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p13	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p14	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p15	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p16	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s0.p17	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p18	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p19	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p20	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p21	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p22	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p23	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s0.p24	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p25	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p26	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p27	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p28	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p29	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s0.p30	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p31	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p32	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p33	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p34	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s0.p35	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, @DRUG$, fluconazole, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p36	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, @DRUG$, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p37	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, @DRUG$, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p38	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s0.p39	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, @DRUG$, ritonavir, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p40	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, @DRUG$, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p41	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s0.p42	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, @DRUG$, and rifampin.	DDI-false
DDI-DrugBank.d735.s0.p43	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s0.p44	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d735.s2.p0	There was no effect of a single dose or multiple doses of @DRUG$ on @DRUG$, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p1	There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p2	There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p3	There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p4	There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p5	There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, @DRUG$, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p6	There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, @DRUG$, prednisolone, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p7	There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, tacrolimus, @DRUG$, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p8	There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p9	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, @DRUG$, prednisolone, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p10	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, tacrolimus, @DRUG$, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p11	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p12	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, @DRUG$, @DRUG$, and fluconazole pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p13	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, and @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s2.p14	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, and @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d735.s3.p0	@DRUG$ AUC was increased by 21% with no effect on Cmax in the presence of steady-state @DRUG$ compared with sirolimus alone.	DDI-mechanism
DDI-DrugBank.d735.s3.p1	@DRUG$ AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with @DRUG$ alone.	DDI-false
DDI-DrugBank.d735.s3.p2	Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state @DRUG$ compared with @DRUG$ alone.	DDI-false
DDI-DrugBank.d735.s4.p0	@DRUG$ AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state @DRUG$ compared with nifedipine alone.	DDI-mechanism
DDI-DrugBank.d735.s4.p1	@DRUG$ AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with @DRUG$ alone.	DDI-false
DDI-DrugBank.d735.s4.p2	Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state @DRUG$ compared with @DRUG$ alone.	DDI-false
DDI-DrugBank.d735.s5.p0	Patients receiving @DRUG$ or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p1	Patients receiving @DRUG$ or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-advise
DDI-DrugBank.d735.s5.p2	Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p3	Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p4	Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p5	Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p6	Patients receiving sirolimus or @DRUG$ in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-advise
DDI-DrugBank.d735.s5.p7	Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p8	Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p9	Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p10	Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p11	Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p12	Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p13	Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p14	Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p15	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p16	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p17	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p18	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p19	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d735.s5.p20	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or @DRUG$ dosage should be reduced if necessary.	DDI-false
DDI-DrugBank.d736.s1.p0	Hypokalemia may develop during concomitant use of @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d736.s3.p0	@DRUG$ may decrease arterial responsiveness to @DRUG$.	DDI-effect
DDI-DrugBank.d736.s5.p0	@DRUG$ may increase the responsiveness of @DRUG$.	DDI-effect
DDI-DrugBank.d736.s6.p0	@DRUG$ renal clearance is reduced by @DRUG$, increasing the risk of lithium toxicity.	DDI-mechanism
DDI-DrugBank.d736.s6.p1	@DRUG$ renal clearance is reduced by thiazides, increasing the risk of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d736.s6.p2	Lithium renal clearance is reduced by @DRUG$, increasing the risk of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d736.s7.p0	@DRUG$ may add to or potentiate the action of other @DRUG$.	DDI-effect
DDI-DrugBank.d736.s8.p0	Potentiation occurs with @DRUG-DRUG$.	DDI-false
DDI-DrugBank.d737.s0.p0	@DRUG$/@DRUG$: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p1	@DRUG$/Levodopa: @DRUG$/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p2	@DRUG$/Levodopa: Carbidopa/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p3	@DRUG$/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p4	Carbidopa/@DRUG$: @DRUG$/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p5	Carbidopa/@DRUG$: Carbidopa/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p6	Carbidopa/@DRUG$: Carbidopa/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p7	Carbidopa/Levodopa: @DRUG$/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p8	Carbidopa/Levodopa: @DRUG$/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s0.p9	Carbidopa/Levodopa: Carbidopa/@DRUG$ does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10).	DDI-false
DDI-DrugBank.d737.s10.p0	@DRUG$: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p1	@DRUG$: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p2	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p3	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p4	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p5	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p6	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p7	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p8	@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
DDI-DrugBank.d737.s10.p9	Dopamine antagonists: Since @DRUG$ is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p10	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p11	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p12	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p13	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p14	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p15	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p16	Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
DDI-DrugBank.d737.s10.p17	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p18	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p19	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p20	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p21	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p22	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p23	Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
DDI-DrugBank.d737.s10.p24	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p25	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p26	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p27	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p28	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p29	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
DDI-DrugBank.d737.s10.p30	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p31	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p32	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p33	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p34	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
DDI-DrugBank.d737.s10.p35	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p36	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p37	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p38	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
DDI-DrugBank.d737.s10.p39	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p40	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p41	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
DDI-DrugBank.d737.s10.p42	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or @DRUG$, may diminish the effectiveness of MIRAPEX.	DDI-false
DDI-DrugBank.d737.s10.p43	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
DDI-DrugBank.d737.s10.p44	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of @DRUG$.	DDI-effect
DDI-DrugBank.d737.s2.p0	@DRUG$: In healthy volunteers (N= 11), @DRUG$ did not influence the pharmacokinetics of pramipexole.	DDI-false
DDI-DrugBank.d737.s2.p1	@DRUG$: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d737.s2.p2	Selegiline: In healthy volunteers (N= 11), @DRUG$ did not influence the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d737.s3.p0	@DRUG$: Population pharmacokinetic analysis suggests that @DRUG$ is unlikely to alter the oral clearance of pramipexole (N= 54).	DDI-false
DDI-DrugBank.d737.s3.p1	@DRUG$: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of @DRUG$ (N= 54).	DDI-false
DDI-DrugBank.d737.s3.p2	Amantadine: Population pharmacokinetic analysis suggests that @DRUG$ is unlikely to alter the oral clearance of @DRUG$ (N= 54).	DDI-false
DDI-DrugBank.d737.s4.p0	@DRUG$: @DRUG$, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12).	DDI-false
DDI-DrugBank.d737.s4.p1	@DRUG$: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in @DRUG$ AUC and a 40% increase in half-life (N= 12).	DDI-false
DDI-DrugBank.d737.s4.p2	Cimetidine: @DRUG$, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in @DRUG$ AUC and a 40% increase in half-life (N= 12).	DDI-mechanism
DDI-DrugBank.d737.s5.p0	@DRUG$: @DRUG$, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12).	DDI-false
DDI-DrugBank.d737.s5.p1	@DRUG$: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence @DRUG$ pharmacokinetics (N= 12).	DDI-false
DDI-DrugBank.d737.s5.p2	Probenecid: @DRUG$, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence @DRUG$ pharmacokinetics (N= 12).	DDI-false
DDI-DrugBank.d737.s6.p0	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p1	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p2	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p3	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p4	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p5	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p6	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-mechanism
DDI-DrugBank.d737.s6.p7	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p8	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p9	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p10	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p11	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p12	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-false
DDI-DrugBank.d737.s6.p13	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p14	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p15	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p16	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p17	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p18	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-mechanism
DDI-DrugBank.d737.s6.p19	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p20	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p21	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p22	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p23	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p24	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-false
DDI-DrugBank.d737.s6.p25	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p26	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p27	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p28	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p29	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-mechanism
DDI-DrugBank.d737.s6.p30	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p31	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p32	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p33	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p34	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p35	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-false
DDI-DrugBank.d737.s6.p36	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p37	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p38	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p39	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-mechanism
DDI-DrugBank.d737.s6.p40	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p41	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p42	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p43	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p44	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p45	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-false
DDI-DrugBank.d737.s6.p46	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p47	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p48	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-mechanism
DDI-DrugBank.d737.s6.p49	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p50	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p51	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p52	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p53	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p54	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-false
DDI-DrugBank.d737.s6.p55	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p56	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-mechanism
DDI-DrugBank.d737.s6.p57	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p58	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p59	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p60	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p61	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p62	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-false
DDI-DrugBank.d737.s6.p63	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-mechanism
DDI-DrugBank.d737.s6.p64	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p65	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p66	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p67	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p68	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p69	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-false
DDI-DrugBank.d737.s6.p70	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p71	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p72	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p73	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p74	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p75	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-false
DDI-DrugBank.d737.s6.p76	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p77	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p78	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p79	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p80	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d737.s6.p81	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p82	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p83	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p84	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d737.s6.p85	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p86	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p87	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d737.s6.p88	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole.	DDI-false
DDI-DrugBank.d737.s6.p89	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d737.s6.p90	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d737.s7.p0	CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect @DRUG$ elimination because @DRUG$ is not appreciably metabolized by these enzymes in vivo or in vitro.	DDI-false
DDI-DrugBank.d738.s0.p0	Do not exceed a 5 mg daily dose of @DRUG$ when administered with therapeutic doses of @DRUG$ or other potent CYP3A4 inhibitors.	DDI-advise
DDI-DrugBank.d738.s1.p0	Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	DDI-false
DDI-DrugBank.d738.s1.p1	Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	DDI-false
DDI-DrugBank.d738.s1.p2	Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose.	DDI-false
DDI-DrugBank.d738.s1.p3	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	DDI-false
DDI-DrugBank.d738.s1.p4	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose.	DDI-false
DDI-DrugBank.d738.s1.p5	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose.	DDI-false
DDI-DrugBank.d739.s0.p0	@DRUG$ at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of @DRUG$ (predominantly a cytochrome P450 1A2 substrate).	DDI-false
DDI-DrugBank.d739.s1.p0	- did not change the pharmacokinetic profile of @DRUG$ (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of @DRUG$ on prothrombin time or the INR (International Normalized Ratio).	DDI-false
DDI-DrugBank.d739.s10.p0	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p1	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p2	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p3	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p4	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p5	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p6	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p7	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p8	In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s10.p9	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p10	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p11	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p12	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p13	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p14	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p15	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p16	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s10.p17	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p18	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p19	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p20	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p21	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p22	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p23	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s10.p24	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p25	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p26	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p27	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p28	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p29	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s10.p30	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p31	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p32	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p33	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p34	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s10.p35	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p36	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p37	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p38	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s10.p39	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), @DRUG$, digoxin, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p40	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, @DRUG$, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p41	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s10.p42	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, @DRUG$, and warfarin.	DDI-false
DDI-DrugBank.d739.s10.p43	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s10.p44	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s12.p0	These medications included @DRUG$, @DRUG$, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	DDI-false
DDI-DrugBank.d739.s12.p1	These medications included @DRUG$, sedative hypnotics, @DRUG$, benzodiazepines, and decongestants.	DDI-false
DDI-DrugBank.d739.s12.p2	These medications included @DRUG$, sedative hypnotics, non-steroidal anti-inflammatory agents, @DRUG$, and decongestants.	DDI-false
DDI-DrugBank.d739.s12.p3	These medications included @DRUG$, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s12.p4	These medications included thyroid hormones, @DRUG$, @DRUG$, benzodiazepines, and decongestants.	DDI-false
DDI-DrugBank.d739.s12.p5	These medications included thyroid hormones, @DRUG$, non-steroidal anti-inflammatory agents, @DRUG$, and decongestants.	DDI-false
DDI-DrugBank.d739.s12.p6	These medications included thyroid hormones, @DRUG$, non-steroidal anti-inflammatory agents, benzodiazepines, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s12.p7	These medications included thyroid hormones, sedative hypnotics, @DRUG$, @DRUG$, and decongestants.	DDI-false
DDI-DrugBank.d739.s12.p8	These medications included thyroid hormones, sedative hypnotics, @DRUG$, benzodiazepines, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s12.p9	These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d739.s13.p0	@DRUG$, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of montelukast.	DDI-false
DDI-DrugBank.d739.s13.p1	@DRUG$, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d739.s13.p2	Phenobarbital, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d739.s15.p0	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or @DRUG$, are co-administered with montelukast.	DDI-false
DDI-DrugBank.d739.s15.p1	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$.	DDI-advise
DDI-DrugBank.d739.s15.p2	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or @DRUG$, are co-administered with @DRUG$.	DDI-advise
DDI-DrugBank.d739.s3.p0	- did not change the plasma concentration profile of @DRUG$ (a substrate of cytochrome P450 3A4) or @DRUG$, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily.	DDI-false
DDI-DrugBank.d739.s3.p1	- did not change the plasma concentration profile of @DRUG$ (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with @DRUG$ 60 mg twice daily.	DDI-false
DDI-DrugBank.d739.s3.p2	- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or @DRUG$, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with @DRUG$ 60 mg twice daily.	DDI-false
DDI-DrugBank.d739.s4.p0	@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing norethindrone 1 mg/ethinyl estradiol 35 mcg.	DDI-false
DDI-DrugBank.d739.s4.p1	@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing @DRUG$ 1 mg/ethinyl estradiol 35 mcg.	DDI-false
DDI-DrugBank.d739.s4.p2	@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl @DRUG$ 35 mcg.	DDI-false
DDI-DrugBank.d739.s4.p3	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing @DRUG$ 1 mg/ethinyl estradiol 35 mcg.	DDI-false
DDI-DrugBank.d739.s4.p4	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing norethindrone 1 mg/ethinyl @DRUG$ 35 mcg.	DDI-false
DDI-DrugBank.d739.s4.p5	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing @DRUG$ 1 mg/ethinyl @DRUG$ 35 mcg.	DDI-false
DDI-DrugBank.d739.s5.p0	- did not cause any clinically significant change in plasma profiles of @DRUG$ or @DRUG$ following administration of either oral prednisone or intravenous prednisolone.	DDI-false
DDI-DrugBank.d739.s5.p1	- did not cause any clinically significant change in plasma profiles of @DRUG$ or prednisolone following administration of either oral @DRUG$ or intravenous prednisolone.	DDI-false
DDI-DrugBank.d739.s5.p2	- did not cause any clinically significant change in plasma profiles of @DRUG$ or prednisolone following administration of either oral prednisone or intravenous @DRUG$.	DDI-false
DDI-DrugBank.d739.s5.p3	- did not cause any clinically significant change in plasma profiles of prednisone or @DRUG$ following administration of either oral @DRUG$ or intravenous prednisolone.	DDI-false
DDI-DrugBank.d739.s5.p4	- did not cause any clinically significant change in plasma profiles of prednisone or @DRUG$ following administration of either oral prednisone or intravenous @DRUG$.	DDI-false
DDI-DrugBank.d739.s5.p5	- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral @DRUG$ or intravenous @DRUG$.	DDI-false
DDI-DrugBank.d739.s6.p0	@DRUG$, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of montelukast.	DDI-false
DDI-DrugBank.d739.s6.p1	@DRUG$, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d739.s6.p2	Phenobarbital, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d739.s8.p0	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or @DRUG$, are co-administered with montelukast.	DDI-false
DDI-DrugBank.d739.s8.p1	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$.	DDI-advise
DDI-DrugBank.d739.s8.p2	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or @DRUG$, are co-administered with @DRUG$.	DDI-advise
DDI-DrugBank.d741.s0.p0	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving @DRUG$, treatment with @DRUG$ once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;	DDI-mechanism
DDI-DrugBank.d741.s0.p1	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving @DRUG$, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in @DRUG$ AUC;	DDI-false
DDI-DrugBank.d741.s0.p2	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with @DRUG$ once weekly for 4 weeks was associated with a mean increase of 16% in @DRUG$ AUC;	DDI-false
DDI-DrugBank.d742.s10.p0	However, the impairment of motor skills produced by @DRUG$ has been shown to be additive with those caused by @DRUG$.	DDI-effect
DDI-DrugBank.d742.s11.p0	Accordingly, patients should be advised to avoid @DRUG$ and other similar drugs while taking @DRUG$.	DDI-advise
DDI-DrugBank.d742.s2.p0	Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of @DRUG$    (@DRUG$) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes.	DDI-false
DDI-DrugBank.d742.s5.p0	While in vitro studies have shown that @DRUG$ is not a potent inhibitor of any of these enzymes, an indication that @DRUG$ is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied.	DDI-false
DDI-DrugBank.d742.s5.p1	While in vitro studies have shown that @DRUG$ is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of @DRUG$ with most other drugs metabolized by these enzymes has not been formally studied.	DDI-false
DDI-DrugBank.d742.s5.p2	While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that @DRUG$ is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of @DRUG$ with most other drugs metabolized by these enzymes has not been formally studied.	DDI-false
DDI-DrugBank.d742.s7.p0	@DRUG$: Concomitant administration of @DRUG$ (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.	DDI-false
DDI-DrugBank.d742.s7.p1	@DRUG$: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 6 healthy male subjects.	DDI-false
DDI-DrugBank.d742.s7.p2	Alcohol: Concomitant administration of @DRUG$ (equivalent to 60 g) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 6 healthy male subjects.	DDI-mechanism
DDI-DrugBank.d742.s8.p0	However, the impairment of cognitive and motor skills produced by @DRUG$    were shown to be additive with those produced by @DRUG$.	DDI-effect
DDI-DrugBank.d742.s9.p0	Accordingly, patients should be advised to avoid @DRUG$ while taking @DRUG$. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	DDI-advise
DDI-DrugBank.d742.s9.p1	Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	DDI-false
DDI-DrugBank.d742.s9.p2	Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	DDI-false
DDI-DrugBank.d742.s9.p3	Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects.	DDI-false
DDI-DrugBank.d742.s9.p4	Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	DDI-false
DDI-DrugBank.d742.s9.p5	Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	DDI-false
DDI-DrugBank.d742.s9.p6	Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects.	DDI-false
DDI-DrugBank.d742.s9.p7	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. @DRUG$: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	DDI-false
DDI-DrugBank.d742.s9.p8	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects.	DDI-false
DDI-DrugBank.d742.s9.p9	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects.	DDI-mechanism
DDI-DrugBank.d743.s0.p0	@DRUG$: Spontaneous adverse reaction reports of patients taking concomitant @DRUG$ with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g.	DDI-false
DDI-DrugBank.d743.s0.p1	@DRUG$: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of @DRUG$ demonstrate QT interval prolongation and rare serious cardiac events, e.g.	DDI-false
DDI-DrugBank.d743.s0.p2	Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant @DRUG$ with recommended doses of @DRUG$ demonstrate QT interval prolongation and rare serious cardiac events, e.g.	DDI-effect
DDI-DrugBank.d743.s11.p0	A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d743.s12.p0	Concomitant administration of @DRUG$ with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-advise
DDI-DrugBank.d743.s12.p1	Concomitant administration of @DRUG$ with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-advise
DDI-DrugBank.d743.s12.p2	Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-advise
DDI-DrugBank.d743.s12.p3	Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p4	Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p5	Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p6	Concomitant administration of terfenadine with @DRUG$, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p7	Concomitant administration of terfenadine with @DRUG$, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p8	Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p9	Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p10	Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p11	Concomitant administration of terfenadine with clarithromycin, @DRUG$, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p12	Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p13	Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p14	Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p15	Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p16	Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p17	Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended.	DDI-false
DDI-DrugBank.d743.s12.p18	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other @DRUG$, including azithromycin, is not recommended.	DDI-advise
DDI-DrugBank.d743.s12.p19	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including @DRUG$, is not recommended.	DDI-advise
DDI-DrugBank.d743.s12.p20	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including @DRUG$, is not recommended.	DDI-false
DDI-DrugBank.d743.s13.p0	Studies to evaluate potential interactions of @DRUG$ with @DRUG$ are in progress.	DDI-false
DDI-DrugBank.d743.s2.p0	Pharmacokinetic data indicate that @DRUG$ markedly inhibits the metabolism of @DRUG$, resulting in elevated plasma terfenadine levels.	DDI-mechanism
DDI-DrugBank.d743.s2.p1	Pharmacokinetic data indicate that @DRUG$ markedly inhibits the metabolism of terfenadine, resulting in elevated plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d743.s2.p2	Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of @DRUG$, resulting in elevated plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d743.s4.p0	Concomitant administration of @DRUG$ and @DRUG$ is contraindicated.	DDI-advise
DDI-DrugBank.d743.s5.p0	@DRUG$: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s5.p1	@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s5.p2	@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s5.p3	@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s5.p4	Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s5.p5	Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s5.p6	Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s5.p7	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources.	DDI-mechanism
DDI-DrugBank.d743.s5.p8	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s5.p9	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of @DRUG$ and from foreign post-marketing sources.	DDI-false
DDI-DrugBank.d743.s7.p0	Concomitant administration of @DRUG$ and @DRUG$ is contraindicated.	DDI-advise
DDI-DrugBank.d743.s8.p0	Due to the chemical similarity of other @DRUG$ (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p1	Due to the chemical similarity of other @DRUG$ (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p2	Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p3	Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p4	Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p5	Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.	DDI-advise
DDI-DrugBank.d743.s8.p6	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p7	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p8	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p9	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p10	Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.	DDI-advise
DDI-DrugBank.d743.s8.p11	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p12	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p13	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p14	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.	DDI-advise
DDI-DrugBank.d743.s8.p15	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p16	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p17	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.	DDI-advise
DDI-DrugBank.d743.s8.p18	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to @DRUG$, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p19	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s8.p20	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions.	DDI-false
DDI-DrugBank.d743.s9.p0	@DRUG$: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	DDI-false
DDI-DrugBank.d743.s9.p1	@DRUG$: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	DDI-false
DDI-DrugBank.d743.s9.p2	@DRUG$: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	DDI-false
DDI-DrugBank.d743.s9.p3	@DRUG$: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent.	DDI-false
DDI-DrugBank.d743.s9.p4	Macrolides: Clinical drug interaction studies indicate that @DRUG$ and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	DDI-false
DDI-DrugBank.d743.s9.p5	Macrolides: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	DDI-mechanism
DDI-DrugBank.d743.s9.p6	Macrolides: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent.	DDI-false
DDI-DrugBank.d743.s9.p7	Macrolides: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	DDI-mechanism
DDI-DrugBank.d743.s9.p8	Macrolides: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent.	DDI-false
DDI-DrugBank.d743.s9.p9	Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent.	DDI-false
DDI-DrugBank.d744.s0.p0	Acromegalic patients with diabetes mellitus being treated with @DRUG$ and/or oral @DRUG$ agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.	DDI-false
DDI-DrugBank.d744.s0.p1	Acromegalic patients with diabetes mellitus being treated with @DRUG$ and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with @DRUG$.	DDI-advise
DDI-DrugBank.d744.s0.p2	Acromegalic patients with diabetes mellitus being treated with insulin and/or oral @DRUG$ agents may require dose reductions of these therapeutic agents after the initiation of therapy with @DRUG$.	DDI-advise
DDI-DrugBank.d744.s1.p0	In clinical studies, patients on @DRUG$ often needed higher serum @DRUG$ concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.	DDI-mechanism
DDI-DrugBank.d744.s1.p1	In clinical studies, patients on @DRUG$ often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving @DRUG$.	DDI-false
DDI-DrugBank.d744.s1.p2	In clinical studies, patients on opioids often needed higher serum @DRUG$ concentrations to achieve appropriate IGF-I suppression compared with patients not receiving @DRUG$.	DDI-false
DDI-DrugBank.d746.s0.p0	@DRUG$ should be used with caution in digitalized patients, since the combination of @DRUG$ and sympathomimetic amines may cause ectopic arrhythmias.	DDI-false
DDI-DrugBank.d746.s0.p1	@DRUG$ should be used with caution in digitalized patients, since the combination of digitalis and @DRUG$ may cause ectopic arrhythmias.	DDI-false
DDI-DrugBank.d746.s0.p2	ARAMINE should be used with caution in digitalized patients, since the combination of @DRUG$ and @DRUG$ may cause ectopic arrhythmias.	DDI-effect
DDI-DrugBank.d746.s1.p0	@DRUG$ or @DRUG$ may potentiate the action of sympathomimetic amines.	DDI-false
DDI-DrugBank.d746.s1.p1	@DRUG$ or tricyclic antidepressants may potentiate the action of @DRUG$.	DDI-effect
DDI-DrugBank.d746.s1.p2	Monoamine oxidase inhibitors or @DRUG$ may potentiate the action of @DRUG$.	DDI-effect
DDI-DrugBank.d747.s0.p0	@DRUG$, a bacteriostatic @DRUG$, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	DDI-false
DDI-DrugBank.d747.s0.p1	@DRUG$, a bacteriostatic antibiotic, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.	DDI-effect
DDI-DrugBank.d747.s0.p2	Tetracycline, a bacteriostatic @DRUG$, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.	DDI-false
DDI-DrugBank.d750.s0.p0	Concomitant use of @DRUG$ with @DRUG$ may result in an adverse drug interaction.	DDI-int
DDI-DrugBank.d751.s0.p0	@DRUG$ has been studied on a background of @DRUG$ and heparin.	DDI-false
DDI-DrugBank.d751.s0.p1	@DRUG$ has been studied on a background of aspirin and @DRUG$.	DDI-false
DDI-DrugBank.d751.s0.p2	AGGRASTAT has been studied on a background of @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d751.s1.p0	The use of @DRUG$, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	DDI-effect
DDI-DrugBank.d751.s1.p1	The use of @DRUG$, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	DDI-effect
DDI-DrugBank.d751.s1.p2	The use of @DRUG$, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see	DDI-false
DDI-DrugBank.d751.s1.p3	The use of @DRUG$, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see	DDI-false
DDI-DrugBank.d751.s1.p4	The use of AGGRASTAT, in combination with @DRUG$ and @DRUG$, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	DDI-false
DDI-DrugBank.d751.s1.p5	The use of AGGRASTAT, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see	DDI-false
DDI-DrugBank.d751.s1.p6	The use of AGGRASTAT, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see	DDI-false
DDI-DrugBank.d751.s1.p7	The use of AGGRASTAT, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see	DDI-false
DDI-DrugBank.d751.s1.p8	The use of AGGRASTAT, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see	DDI-false
DDI-DrugBank.d751.s1.p9	The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and @DRUG$ alone (see	DDI-false
DDI-DrugBank.d752.s0.p0	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	DDI-advise
DDI-DrugBank.d752.s0.p1	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, calcium channel antagonists, and macrolide antibiotics).	DDI-advise
DDI-DrugBank.d752.s0.p2	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, @DRUG$, and macrolide antibiotics).	DDI-advise
DDI-DrugBank.d752.s0.p3	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and @DRUG$).	DDI-advise
DDI-DrugBank.d752.s0.p4	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, @DRUG$, calcium channel antagonists, and macrolide antibiotics).	DDI-false
DDI-DrugBank.d752.s0.p5	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, @DRUG$, and macrolide antibiotics).	DDI-false
DDI-DrugBank.d752.s0.p6	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, calcium channel antagonists, and @DRUG$).	DDI-false
DDI-DrugBank.d752.s0.p7	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, @DRUG$, and macrolide antibiotics).	DDI-false
DDI-DrugBank.d752.s0.p8	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, calcium channel antagonists, and @DRUG$).	DDI-false
DDI-DrugBank.d752.s0.p9	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, @DRUG$, and @DRUG$).	DDI-false
DDI-DrugBank.d752.s1.p0	Drugs such as @DRUG$, @DRUG$, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p1	Drugs such as @DRUG$, diltiazem, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p2	Drugs such as @DRUG$, diltiazem, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p3	Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p4	Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p5	Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.	DDI-mechanism
DDI-DrugBank.d752.s1.p6	Drugs such as erythromycin, @DRUG$, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p7	Drugs such as erythromycin, @DRUG$, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p8	Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p9	Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p10	Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.	DDI-mechanism
DDI-DrugBank.d752.s1.p11	Drugs such as erythromycin, diltiazem, @DRUG$, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p12	Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p13	Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p14	Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.	DDI-mechanism
DDI-DrugBank.d752.s1.p15	Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p16	Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p17	Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.	DDI-mechanism
DDI-DrugBank.d752.s1.p18	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, @DRUG$ and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam.	DDI-false
DDI-DrugBank.d752.s1.p19	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$.	DDI-mechanism
DDI-DrugBank.d752.s1.p20	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered @DRUG$.	DDI-mechanism
DDI-DrugBank.d752.s10.p0	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-effect
DDI-DrugBank.d752.s10.p1	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-effect
DDI-DrugBank.d752.s10.p2	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-effect
DDI-DrugBank.d752.s10.p3	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-effect
DDI-DrugBank.d752.s10.p4	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-effect
DDI-DrugBank.d752.s10.p5	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.	DDI-effect
DDI-DrugBank.d752.s10.p6	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol.	DDI-effect
DDI-DrugBank.d752.s10.p7	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.	DDI-effect
DDI-DrugBank.d752.s10.p8	The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.	DDI-effect
DDI-DrugBank.d752.s10.p9	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p10	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p11	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p12	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p13	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p14	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p15	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p16	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.	DDI-false
DDI-DrugBank.d752.s10.p17	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p18	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p19	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p20	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p21	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p22	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p23	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.	DDI-false
DDI-DrugBank.d752.s10.p24	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p25	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p26	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p27	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p28	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p29	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.	DDI-false
DDI-DrugBank.d752.s10.p30	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p31	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p32	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, @DRUG$, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p33	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p34	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$.	DDI-false
DDI-DrugBank.d752.s10.p35	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, @DRUG$, nitrous oxide, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p36	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, @DRUG$, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p37	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, @DRUG$ and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p38	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and @DRUG$.	DDI-false
DDI-DrugBank.d752.s10.p39	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, @DRUG$, secobarbital and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p40	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, @DRUG$ and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p41	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and @DRUG$.	DDI-false
DDI-DrugBank.d752.s10.p42	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, @DRUG$ and droperidol.	DDI-false
DDI-DrugBank.d752.s10.p43	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and @DRUG$.	DDI-false
DDI-DrugBank.d752.s10.p44	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d752.s12.p0	No significant adverse interactions with common premedications (such as @DRUG$, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p1	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p2	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p3	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p4	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p5	No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d752.s12.p6	No significant adverse interactions with common premedications (such as atropine, @DRUG$, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p7	No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p8	No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p9	No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p10	No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d752.s12.p11	No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p12	No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p13	No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p14	No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d752.s12.p15	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, @DRUG$, and other muscle relaxants) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p16	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other @DRUG$) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p17	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d752.s12.p18	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other @DRUG$) or local anesthetics have been observed.	DDI-false
DDI-DrugBank.d752.s12.p19	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d752.s12.p20	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d752.s3.p0	Although not studied, the potent cytochrome P450 3A4 inhibitors @DRUG$ and @DRUG$ may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.	DDI-false
DDI-DrugBank.d752.s3.p1	Although not studied, the potent cytochrome P450 3A4 inhibitors @DRUG$ and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d752.s3.p2	Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and @DRUG$ may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d752.s6.p0	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, @DRUG$, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.	DDI-false
DDI-DrugBank.d752.s6.p1	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, carbamazepine, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.	DDI-false
DDI-DrugBank.d752.s6.p2	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies.	DDI-mechanism
DDI-DrugBank.d752.s6.p3	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, @DRUG$, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.	DDI-false
DDI-DrugBank.d752.s6.p4	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, @DRUG$, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies.	DDI-mechanism
DDI-DrugBank.d752.s6.p5	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies.	DDI-mechanism
DDI-DrugBank.d752.s9.p0	The difficulty in achieving adequate sedation may have been the result of decreased absorption of the @DRUG$ due to both the gastrointestinal effects and stimulant effects of @DRUG$.	DDI-false
DDI-DrugBank.d753.s0.p0	The concomitant use of other @DRUG$ including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p1	The concomitant use of other @DRUG$ including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p2	The concomitant use of other @DRUG$ including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p3	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p4	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p5	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p6	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p7	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p8	The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p9	The concomitant use of other CNS depressants including @DRUG$, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p10	The concomitant use of other CNS depressants including @DRUG$, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p11	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p12	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p13	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p14	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p15	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p16	The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p17	The concomitant use of other CNS depressants including sedatives, @DRUG$, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p18	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p19	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p20	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p21	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p22	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p23	The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p24	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p25	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p26	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p27	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p28	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p29	The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p30	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p31	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p32	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p33	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p34	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p35	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p36	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p37	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p38	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p39	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p40	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p41	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p42	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, @DRUG$, and alcohol may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p43	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s0.p44	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and @DRUG$ may produce additive CNS depressant effects.	DDI-false
DDI-DrugBank.d753.s2.p0	@DRUG$ or other medications with anticholinergic activity when used concurrently with @DRUG$ may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.	DDI-effect
DDI-DrugBank.d753.s3.p0	It has been reported that the incidence of bradycardia was increased when @DRUG$ was combined with @DRUG$ for induction of anesthesia.	DDI-effect
DDI-DrugBank.d753.s4.p0	In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of @DRUG$ with @DRUG$;	DDI-effect
DDI-DrugBank.d756.s0.p0	Dosages of concomitantly administered @DRUG$ should be reduced by approximately half, because @DRUG$ amplifies the therapeutic actions and side-effects of opioids.	DDI-effect
DDI-DrugBank.d756.s0.p1	Dosages of concomitantly administered @DRUG$ should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of @DRUG$.	DDI-false
DDI-DrugBank.d756.s0.p2	Dosages of concomitantly administered opioids should be reduced by approximately half, because @DRUG$ amplifies the therapeutic actions and side-effects of @DRUG$.	DDI-effect
DDI-DrugBank.d756.s1.p0	Combination with @DRUG$ (@DRUG$) is associated with increased risk of seizures.	DDI-false
DDI-DrugBank.d756.s2.p0	Additive sedative effects and confusional states may emerge if @DRUG$ is given with @DRUG$ or barbiturates.	DDI-effect
DDI-DrugBank.d756.s2.p1	Additive sedative effects and confusional states may emerge if @DRUG$ is given with benzodiazepines or @DRUG$.	DDI-effect
DDI-DrugBank.d756.s2.p2	Additive sedative effects and confusional states may emerge if levomepromazine is given with @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d756.s4.p0	Exert particular caution in combining @DRUG$ with other @DRUG$ (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	DDI-advise
DDI-DrugBank.d756.s4.p1	Exert particular caution in combining @DRUG$ with other anticholinergic drugs (@DRUG$ and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	DDI-advise
DDI-DrugBank.d756.s4.p2	Exert particular caution in combining @DRUG$ with other anticholinergic drugs (tricyclic antidepressants and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	DDI-advise
DDI-DrugBank.d756.s4.p3	Exert particular caution in combining levomepromazine with other @DRUG$ (@DRUG$ and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	DDI-false
DDI-DrugBank.d756.s4.p4	Exert particular caution in combining levomepromazine with other @DRUG$ (tricyclic antidepressants and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	DDI-false
DDI-DrugBank.d756.s4.p5	Exert particular caution in combining levomepromazine with other anticholinergic drugs (@DRUG$ and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	DDI-false
DDI-DrugBank.d756.s7.p0	@DRUG$ and/or stimulantes of the @DRUG$/amphetamine type may counteract the specific actions of levomepromazine.	DDI-false
DDI-DrugBank.d756.s7.p1	@DRUG$ and/or stimulantes of the ephedrine/@DRUG$ type may counteract the specific actions of levomepromazine.	DDI-false
DDI-DrugBank.d756.s7.p2	@DRUG$ and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of @DRUG$.	DDI-effect
DDI-DrugBank.d756.s7.p3	Caffeine and/or stimulantes of the @DRUG$/@DRUG$ type may counteract the specific actions of levomepromazine.	DDI-false
DDI-DrugBank.d756.s7.p4	Caffeine and/or stimulantes of the @DRUG$/amphetamine type may counteract the specific actions of @DRUG$.	DDI-effect
DDI-DrugBank.d756.s7.p5	Caffeine and/or stimulantes of the ephedrine/@DRUG$ type may counteract the specific actions of @DRUG$.	DDI-effect
DDI-DrugBank.d757.s0.p0	Usage with @DRUG$: Due to the potential for increased CNS depressants effects, @DRUG$ should be used with caution in patients who are currently receiving pentazocine.	DDI-false
DDI-DrugBank.d757.s0.p1	Usage with @DRUG$: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving @DRUG$.	DDI-false
DDI-DrugBank.d757.s0.p2	Usage with Alcohol: Due to the potential for increased CNS depressants effects, @DRUG$ should be used with caution in patients who are currently receiving @DRUG$.	DDI-advise
DDI-DrugBank.d758.s0.p0	The CNS depressant effects of @DRUG$ may be additive with that of other @DRUG$..	DDI-effect
DDI-DrugBank.d759.s0.p0	Limited evidence suggests that @DRUG$ may influence the intensity and duration of action of @DRUG$.	DDI-mechanism
DDI-DrugBank.d761.s0.p0	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p1	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p2	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p3	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p4	@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.	DDI-false
DDI-DrugBank.d761.s0.p5	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p6	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p7	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p8	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.	DDI-false
DDI-DrugBank.d761.s0.p9	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p10	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p11	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.	DDI-false
DDI-DrugBank.d761.s0.p12	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	DDI-false
DDI-DrugBank.d761.s0.p13	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.	DDI-false
DDI-DrugBank.d761.s0.p14	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$.	DDI-false
DDI-DrugBank.d761.s1.p0	@DRUG$: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p1	@DRUG$: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p2	@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p3	@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p4	@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d761.s1.p5	Cyclosporine: Preliminary data from a @DRUG$ and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p6	Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p7	Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p8	Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d761.s1.p9	Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p10	Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p11	Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d761.s1.p12	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when @DRUG$ was coadministered with cyclosporine.	DDI-false
DDI-DrugBank.d761.s1.p13	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d761.s1.p14	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with @DRUG$.	DDI-mechanism
DDI-DrugBank.d761.s10.p0	@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin.	DDI-false
DDI-DrugBank.d761.s10.p1	@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of pravastatin.	DDI-false
DDI-DrugBank.d761.s10.p2	@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d761.s10.p3	Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of pravastatin.	DDI-false
DDI-DrugBank.d761.s10.p4	Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d761.s10.p5	Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d761.s11.p0	@DRUG$: In 12 normal-weight subjects, administration of @DRUG$ 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).	DDI-false
DDI-DrugBank.d761.s11.p1	@DRUG$: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either @DRUG$ pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).	DDI-false
DDI-DrugBank.d761.s11.p2	Warfarin: In 12 normal-weight subjects, administration of @DRUG$ 120 mg three times a day for 16 days did not result in any change in either @DRUG$ pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).	DDI-false
DDI-DrugBank.d761.s12.p0	Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with @DRUG$ administration, vitamin K levels tended to decline in subjects taking @DRUG$.	DDI-false
DDI-DrugBank.d761.s13.p0	Therefore, as @DRUG$ absorption may be decreased with @DRUG$, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	DDI-mechanism
DDI-DrugBank.d761.s13.p1	Therefore, as @DRUG$ absorption may be decreased with XENICAL, patients on chronic stable doses of @DRUG$ who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	DDI-false
DDI-DrugBank.d761.s13.p2	Therefore, as @DRUG$ absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters.	DDI-false
DDI-DrugBank.d761.s13.p3	Therefore, as vitamin K absorption may be decreased with @DRUG$, patients on chronic stable doses of @DRUG$ who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	DDI-false
DDI-DrugBank.d761.s13.p4	Therefore, as vitamin K absorption may be decreased with @DRUG$, patients on chronic stable doses of warfarin who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters.	DDI-false
DDI-DrugBank.d761.s13.p5	Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of @DRUG$ who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters.	DDI-advise
DDI-DrugBank.d761.s2.p0	@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin.	DDI-false
DDI-DrugBank.d761.s2.p1	@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of digoxin.	DDI-false
DDI-DrugBank.d761.s2.p2	@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of @DRUG$.	DDI-false
DDI-DrugBank.d761.s2.p3	Digoxin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of digoxin.	DDI-false
DDI-DrugBank.d761.s2.p4	Digoxin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of @DRUG$.	DDI-false
DDI-DrugBank.d761.s2.p5	Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of @DRUG$.	DDI-false
DDI-DrugBank.d761.s3.p0	@DRUG$ and Analogues: A pharmacokinetic interaction study showed a 30% reduction in @DRUG$ supplement absorption when concomitantly administered with XENICAL.	DDI-false
DDI-DrugBank.d761.s3.p1	@DRUG$ and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with @DRUG$.	DDI-false
DDI-DrugBank.d761.s3.p2	Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in @DRUG$ supplement absorption when concomitantly administered with @DRUG$.	DDI-mechanism
DDI-DrugBank.d761.s4.p0	@DRUG$ inhibited absorption of a @DRUG$ supplement by approximately 60%.	DDI-mechanism
DDI-DrugBank.d761.s5.p0	The effect of @DRUG$ on the absorption of supplemental @DRUG$, vitamin A, and nutritionally-derived vitamin K is not known at this time.	DDI-false
DDI-DrugBank.d761.s5.p1	The effect of @DRUG$ on the absorption of supplemental vitamin D, @DRUG$, and nutritionally-derived vitamin K is not known at this time.	DDI-false
DDI-DrugBank.d761.s5.p2	The effect of @DRUG$ on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived @DRUG$ is not known at this time.	DDI-false
DDI-DrugBank.d761.s5.p3	The effect of orlistat on the absorption of supplemental @DRUG$, @DRUG$, and nutritionally-derived vitamin K is not known at this time.	DDI-false
DDI-DrugBank.d761.s5.p4	The effect of orlistat on the absorption of supplemental @DRUG$, vitamin A, and nutritionally-derived @DRUG$ is not known at this time.	DDI-false
DDI-DrugBank.d761.s5.p5	The effect of orlistat on the absorption of supplemental vitamin D, @DRUG$, and nutritionally-derived @DRUG$ is not known at this time.	DDI-false
DDI-DrugBank.d761.s6.p0	@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	DDI-false
DDI-DrugBank.d761.s6.p1	@DRUG$: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	DDI-false
DDI-DrugBank.d761.s6.p2	@DRUG$: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$.	DDI-false
DDI-DrugBank.d761.s6.p3	Glyburide: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	DDI-false
DDI-DrugBank.d761.s6.p4	Glyburide: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$.	DDI-false
DDI-DrugBank.d761.s6.p5	Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$.	DDI-false
DDI-DrugBank.d761.s7.p0	@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets).	DDI-false
DDI-DrugBank.d761.s7.p1	@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of nifedipine (extended-release tablets).	DDI-false
DDI-DrugBank.d761.s7.p2	@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of @DRUG$ (extended-release tablets).	DDI-false
DDI-DrugBank.d761.s7.p3	Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of nifedipine (extended-release tablets).	DDI-false
DDI-DrugBank.d761.s7.p4	Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of @DRUG$ (extended-release tablets).	DDI-false
DDI-DrugBank.d761.s7.p5	Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of @DRUG$ (extended-release tablets).	DDI-false
DDI-DrugBank.d761.s8.p0	Oral @DRUG$: In 20 normal-weight female subjects, the treatment of @DRUG$ 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.	DDI-false
DDI-DrugBank.d761.s8.p1	Oral @DRUG$: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral @DRUG$.	DDI-false
DDI-DrugBank.d761.s8.p2	Oral Contraceptives: In 20 normal-weight female subjects, the treatment of @DRUG$ 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral @DRUG$.	DDI-false
DDI-DrugBank.d761.s9.p0	@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	DDI-false
DDI-DrugBank.d761.s9.p1	@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	DDI-false
DDI-DrugBank.d761.s9.p2	@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d761.s9.p3	Phenytoin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	DDI-false
DDI-DrugBank.d761.s9.p4	Phenytoin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d761.s9.p5	Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d762.s0.p0	@DRUG$ competes with @DRUG$ for active tubular secretion and thus inhibits the renal excretion of meropenem.	DDI-mechanism
DDI-DrugBank.d762.s0.p1	@DRUG$ competes with meropenem for active tubular secretion and thus inhibits the renal excretion of @DRUG$.	DDI-false
DDI-DrugBank.d762.s0.p2	Probenecid competes with @DRUG$ for active tubular secretion and thus inhibits the renal excretion of @DRUG$.	DDI-false
DDI-DrugBank.d762.s2.p0	Therefore, the coadministration of @DRUG$ with @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d762.s3.p0	There is evidence that @DRUG$ may reduce serum levels of @DRUG$ to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).	DDI-mechanism
DDI-DrugBank.d762.s3.p1	There is evidence that @DRUG$ may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total @DRUG$).	DDI-false
DDI-DrugBank.d762.s3.p2	There is evidence that meropenem may reduce serum levels of @DRUG$ to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total @DRUG$).	DDI-false
DDI-DrugBank.d763.s1.p0	Because @DRUG$ is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of @DRUG$.	DDI-false
DDI-DrugBank.d763.s3.p0	@DRUG$, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p1	@DRUG$, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p2	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p3	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p4	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p5	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p6	@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p7	Phenytoin, @DRUG$, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p8	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p9	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p10	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p11	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p12	Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p13	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p14	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p15	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p16	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p17	Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p18	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p19	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p20	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.	DDI-mechanism
DDI-DrugBank.d763.s3.p21	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.	DDI-mechanism
DDI-DrugBank.d763.s3.p22	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s3.p23	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.	DDI-mechanism
DDI-DrugBank.d763.s3.p24	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.	DDI-mechanism
DDI-DrugBank.d763.s3.p25	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased.	DDI-mechanism
DDI-DrugBank.d763.s3.p26	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased.	DDI-mechanism
DDI-DrugBank.d763.s3.p27	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and @DRUG$ blood concentrations were decreased.	DDI-false
DDI-DrugBank.d763.s4.p0	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p1	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p2	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p3	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p4	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p5	However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.	DDI-false
DDI-DrugBank.d763.s4.p6	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p7	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p8	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p9	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p10	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.	DDI-false
DDI-DrugBank.d763.s4.p11	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p12	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p13	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p14	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.	DDI-false
DDI-DrugBank.d763.s4.p15	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p16	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-false
DDI-DrugBank.d763.s4.p17	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.	DDI-false
DDI-DrugBank.d763.s4.p18	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	DDI-effect
DDI-DrugBank.d763.s4.p19	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.	DDI-false
DDI-DrugBank.d763.s4.p20	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$.	DDI-false
DDI-DrugBank.d763.s5.p0	In humans, @DRUG$, @DRUG$, and cisplatin do not affect the pharmacokinetics of ondansetron.	DDI-false
DDI-DrugBank.d763.s5.p1	In humans, @DRUG$, etoposide, and @DRUG$ do not affect the pharmacokinetics of ondansetron.	DDI-false
DDI-DrugBank.d763.s5.p2	In humans, @DRUG$, etoposide, and cisplatin do not affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d763.s5.p3	In humans, carmustine, @DRUG$, and @DRUG$ do not affect the pharmacokinetics of ondansetron.	DDI-false
DDI-DrugBank.d763.s5.p4	In humans, carmustine, @DRUG$, and cisplatin do not affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d763.s5.p5	In humans, carmustine, etoposide, and @DRUG$ do not affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d763.s7.p0	@DRUG$ did not increase blood levels of high-dose @DRUG$.	DDI-false
DDI-DrugBank.d765.s0.p0	CYP3A4 Inhibitors: @DRUG$, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of @DRUG$ when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).	DDI-mechanism
DDI-DrugBank.d765.s1.p0	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p1	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p2	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p3	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p4	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p5	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p6	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p7	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p8	For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d765.s1.p9	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p10	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p11	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p12	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p13	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p14	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p15	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p16	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d765.s1.p17	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p18	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p19	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p20	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p21	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p22	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p23	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d765.s1.p24	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p25	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p26	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p27	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p28	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p29	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d765.s1.p30	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p31	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p32	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p33	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p34	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d765.s1.p35	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p36	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p37	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p38	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d765.s1.p39	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p40	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p41	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d765.s1.p42	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.	DDI-false
DDI-DrugBank.d765.s1.p43	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d765.s1.p44	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of @DRUG$ is 2 mg daily.	DDI-advise
DDI-DrugBank.d766.s0.p0	Since @DRUG$ is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d766.s1.p0	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, ketoconazole, and fluconazole.	DDI-effect
DDI-DrugBank.d766.s1.p1	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, ketoconazole, and fluconazole.	DDI-effect
DDI-DrugBank.d766.s1.p2	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, ketoconazole, and fluconazole.	DDI-effect
DDI-DrugBank.d766.s1.p3	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, @DRUG$, and fluconazole.	DDI-effect
DDI-DrugBank.d766.s1.p4	Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and @DRUG$.	DDI-effect
DDI-DrugBank.d766.s1.p5	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, @DRUG$, rifabutin, ketoconazole, and fluconazole.	DDI-false
DDI-DrugBank.d766.s1.p6	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, @DRUG$, ketoconazole, and fluconazole.	DDI-false
DDI-DrugBank.d766.s1.p7	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, @DRUG$, and fluconazole.	DDI-false
DDI-DrugBank.d766.s1.p8	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, ketoconazole, and @DRUG$.	DDI-false
DDI-DrugBank.d766.s1.p9	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, @DRUG$, ketoconazole, and fluconazole.	DDI-false
DDI-DrugBank.d766.s1.p10	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, @DRUG$, and fluconazole.	DDI-false
DDI-DrugBank.d766.s1.p11	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, ketoconazole, and @DRUG$.	DDI-false
DDI-DrugBank.d766.s1.p12	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, @DRUG$, and fluconazole.	DDI-false
DDI-DrugBank.d766.s1.p13	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, ketoconazole, and @DRUG$.	DDI-false
DDI-DrugBank.d766.s1.p14	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d766.s2.p0	In vitro perfusion of isolated rat liver has shown that @DRUG$ caused a significant reduction in @DRUG$ metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	DDI-mechanism
DDI-DrugBank.d766.s2.p1	In vitro perfusion of isolated rat liver has shown that @DRUG$ caused a significant reduction in trimetrexate metabolism and that @DRUG$ altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	DDI-false
DDI-DrugBank.d766.s2.p2	In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in @DRUG$ metabolism and that @DRUG$ altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	DDI-false
DDI-DrugBank.d766.s3.p0	Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (@DRUG$, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	DDI-false
DDI-DrugBank.d766.s3.p1	Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, @DRUG$, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	DDI-false
DDI-DrugBank.d766.s3.p2	Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism.	DDI-false
DDI-DrugBank.d766.s3.p3	Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism.	DDI-mechanism
DDI-DrugBank.d766.s3.p4	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, @DRUG$, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	DDI-false
DDI-DrugBank.d766.s3.p5	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism.	DDI-false
DDI-DrugBank.d766.s3.p6	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, ketoconazole, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism.	DDI-mechanism
DDI-DrugBank.d766.s3.p7	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, @DRUG$, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism.	DDI-false
DDI-DrugBank.d766.s3.p8	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, @DRUG$, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism.	DDI-mechanism
DDI-DrugBank.d766.s3.p9	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of @DRUG$ metabolism.	DDI-mechanism
DDI-DrugBank.d769.s0.p0	@DRUG$: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving @DRUG$ concomitantly with coumarin-derivative anticoagulants.	DDI-false
DDI-DrugBank.d769.s0.p1	@DRUG$: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with @DRUG$.	DDI-false
DDI-DrugBank.d769.s0.p2	Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving @DRUG$ concomitantly with @DRUG$.	DDI-effect
DDI-DrugBank.d769.s1.p0	Physicians should carefully monitor PT and INR in patients concurrently administered @DRUG$ and @DRUG$.	DDI-advise
DDI-DrugBank.d769.s2.p0	Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other HDAC inhibitors (e.g., valproic acid).	DDI-false
DDI-DrugBank.d769.s2.p1	Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other @DRUG$ (e.g., valproic acid).	DDI-false
DDI-DrugBank.d769.s2.p2	Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., @DRUG$).	DDI-false
DDI-DrugBank.d769.s2.p3	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other @DRUG$ (e.g., valproic acid).	DDI-effect
DDI-DrugBank.d769.s2.p4	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other HDAC inhibitors (e.g., @DRUG$).	DDI-effect
DDI-DrugBank.d769.s2.p5	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other @DRUG$ (e.g., @DRUG$).	DDI-false
DDI-DrugBank.d770.s4.p0	however, in patients with Paget's Disease prior @DRUG$ use appears to reduce the anti-resorptive response to @DRUG$ nasal spray.	DDI-effect
DDI-DrugBank.d771.s1.p0	@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, tranquilizers, or alcohol.	DDI-advise
DDI-DrugBank.d771.s1.p1	@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, @DRUG$, or alcohol.	DDI-advise
DDI-DrugBank.d771.s1.p2	@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or @DRUG$.	DDI-advise
DDI-DrugBank.d771.s1.p3	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, @DRUG$, or alcohol.	DDI-false
DDI-DrugBank.d771.s1.p4	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, tranquilizers, or @DRUG$.	DDI-false
DDI-DrugBank.d771.s1.p5	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d771.s3.p0	e.g., other @DRUG$, @DRUG$ (including meclizine), tricyclic antidepressants, and muscle relaxants.	DDI-false
DDI-DrugBank.d771.s3.p1	e.g., other @DRUG$, antihistamines (including @DRUG$), tricyclic antidepressants, and muscle relaxants.	DDI-false
DDI-DrugBank.d771.s3.p2	e.g., other @DRUG$, antihistamines (including meclizine), @DRUG$, and muscle relaxants.	DDI-false
DDI-DrugBank.d771.s3.p3	e.g., other @DRUG$, antihistamines (including meclizine), tricyclic antidepressants, and @DRUG$.	DDI-false
DDI-DrugBank.d771.s3.p4	e.g., other belladonna alkaloids, @DRUG$ (including @DRUG$), tricyclic antidepressants, and muscle relaxants.	DDI-false
DDI-DrugBank.d771.s3.p5	e.g., other belladonna alkaloids, @DRUG$ (including meclizine), @DRUG$, and muscle relaxants.	DDI-false
DDI-DrugBank.d771.s3.p6	e.g., other belladonna alkaloids, @DRUG$ (including meclizine), tricyclic antidepressants, and @DRUG$.	DDI-false
DDI-DrugBank.d771.s3.p7	e.g., other belladonna alkaloids, antihistamines (including @DRUG$), @DRUG$, and muscle relaxants.	DDI-false
DDI-DrugBank.d771.s3.p8	e.g., other belladonna alkaloids, antihistamines (including @DRUG$), tricyclic antidepressants, and @DRUG$.	DDI-false
DDI-DrugBank.d771.s3.p9	e.g., other belladonna alkaloids, antihistamines (including meclizine), @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d773.s1.p0	Patients studied in clinical trials of @DRUG$ were routinely treated with @DRUG$ and aspirin.	DDI-false
DDI-DrugBank.d773.s1.p1	Patients studied in clinical trials of @DRUG$ were routinely treated with heparin and @DRUG$.	DDI-false
DDI-DrugBank.d773.s1.p2	Patients studied in clinical trials of TNKase were routinely treated with @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d773.s2.p0	@DRUG$ (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p1	@DRUG$ (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p2	@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p3	@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p4	@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d773.s2.p5	Anticoagulants (such as @DRUG$ and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p6	Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p7	Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p8	Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d773.s2.p9	Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p10	Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p11	Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d773.s2.p12	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	DDI-false
DDI-DrugBank.d773.s2.p13	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d773.s2.p14	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d774.s0.p0	@DRUG$ may interact with @DRUG$ or mitotane (causing too great a decrease in adrenal function).	DDI-int
DDI-DrugBank.d774.s0.p1	@DRUG$ may interact with aminoglutethimide or @DRUG$ (causing too great a decrease in adrenal function).	DDI-int
DDI-DrugBank.d774.s0.p2	Trilostane may interact with @DRUG$ or @DRUG$ (causing too great a decrease in adrenal function).	DDI-false
DDI-DrugBank.d775.s0.p0	Although @DRUG$ (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between @DRUG$ and succinylcholine has not been systematically studied.	DDI-false
DDI-DrugBank.d775.s0.p1	Although @DRUG$ (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and @DRUG$ has not been systematically studied.	DDI-false
DDI-DrugBank.d775.s0.p2	Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between @DRUG$ and @DRUG$ has not been systematically studied.	DDI-false
DDI-DrugBank.d775.s1.p0	Prior administration of @DRUG$ can potentiate the neuromuscular blocking effects of @DRUG$.	DDI-effect
DDI-DrugBank.d775.s10.p0	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p1	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p2	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p3	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p4	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p5	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p6	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p7	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p8	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p9	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p10	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p11	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p12	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p13	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p14	Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-int
DDI-DrugBank.d775.s10.p15	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p16	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p17	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p18	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p19	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p20	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p21	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p22	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p23	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p24	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p25	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p26	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p27	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-int
DDI-DrugBank.d775.s10.p28	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-int
DDI-DrugBank.d775.s10.p29	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p30	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p31	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p32	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p33	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p34	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p35	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p36	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p37	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p38	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p39	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p40	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p41	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p42	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p43	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p44	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p45	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p46	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p47	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p48	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p49	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p50	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p51	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p52	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p53	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p54	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p55	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p56	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p57	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p58	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p59	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p60	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p61	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p62	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p63	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p64	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p65	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p66	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p67	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p68	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p69	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p70	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p71	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p72	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p73	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p74	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p75	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p76	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p77	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p78	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p79	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p80	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p81	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p82	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p83	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p84	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p85	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p86	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p87	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p88	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p89	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p90	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p91	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p92	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p93	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p94	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p95	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p96	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p97	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p98	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p99	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p100	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p101	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p102	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p103	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p104	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p105	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p106	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p107	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p108	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p109	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p110	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p111	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p112	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p113	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p114	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p115	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p116	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p117	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d775.s10.p118	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s10.p119	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d775.s11.p0	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-effect
DDI-DrugBank.d775.s11.p1	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-effect
DDI-DrugBank.d775.s11.p2	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-effect
DDI-DrugBank.d775.s11.p3	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p4	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p5	The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d775.s11.p6	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p7	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p8	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p9	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p10	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d775.s11.p11	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p12	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p13	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p14	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d775.s11.p15	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p16	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.	DDI-false
DDI-DrugBank.d775.s11.p17	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d775.s11.p18	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered @DRUG$ or carbamazepine.	DDI-effect
DDI-DrugBank.d775.s11.p19	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or @DRUG$.	DDI-effect
DDI-DrugBank.d775.s11.p20	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d775.s12.p0	While the effects of chronic @DRUG$ or @DRUG$ therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	DDI-false
DDI-DrugBank.d775.s12.p1	While the effects of chronic @DRUG$ or carbamazepine therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	DDI-effect
DDI-DrugBank.d775.s12.p2	While the effects of chronic phenytoin or @DRUG$ therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	DDI-effect
DDI-DrugBank.d775.s13.p0	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p1	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p2	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p3	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p4	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p5	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p6	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p7	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p8	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p9	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p10	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p11	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p12	Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p13	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p14	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p15	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p16	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p17	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p18	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p19	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p20	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p21	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p22	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p23	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p24	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p25	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p26	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p27	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p28	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p29	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p30	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p31	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p32	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p33	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p34	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p35	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p36	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p37	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p38	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p39	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p40	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p41	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p42	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p43	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p44	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p45	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p46	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p47	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p48	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p49	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p50	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p51	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p52	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p53	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p54	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p55	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p56	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p57	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p58	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p59	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p60	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p61	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p62	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p63	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p64	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p65	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p66	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p67	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p68	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p69	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p70	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p71	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p72	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p73	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p74	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p75	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p76	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p77	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p78	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p79	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p80	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p81	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p82	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p83	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p84	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p85	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general @DRUG$ - succinylcholine or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p86	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p87	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p88	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - @DRUG$ or other muscle relaxants	DDI-false
DDI-DrugBank.d775.s13.p89	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other @DRUG$	DDI-false
DDI-DrugBank.d775.s13.p90	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other @DRUG$	DDI-false
DDI-DrugBank.d775.s2.p0	Evidence of spontaneous recovery from @DRUG$ should be observed before the administration of @DRUG$.	DDI-advise
DDI-DrugBank.d775.s3.p0	The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied.	DDI-false
DDI-DrugBank.d775.s3.p1	The use of @DRUG$ before succinylcholine to attenuate some of the side effects of @DRUG$ has not been studied.	DDI-false
DDI-DrugBank.d775.s3.p2	The use of MIVACRON before @DRUG$ to attenuate some of the side effects of @DRUG$ has not been studied.	DDI-false
DDI-DrugBank.d775.s4.p0	There are no clinical data on the use of @DRUG$ with other @DRUG$.	DDI-false
DDI-DrugBank.d775.s5.p0	@DRUG$ and @DRUG$ (administered with nitrous oxide/oxygen to achieve 1.25 M.C.	DDI-false
DDI-DrugBank.d775.s5.p1	@DRUG$ and enflurane (administered with @DRUG$/oxygen to achieve 1.25 M.C.	DDI-false
DDI-DrugBank.d775.s5.p2	@DRUG$ and enflurane (administered with nitrous oxide/@DRUG$ to achieve 1.25 M.C.	DDI-false
DDI-DrugBank.d775.s5.p3	Isoflurane and @DRUG$ (administered with @DRUG$/oxygen to achieve 1.25 M.C.	DDI-false
DDI-DrugBank.d775.s5.p4	Isoflurane and @DRUG$ (administered with nitrous oxide/@DRUG$ to achieve 1.25 M.C.	DDI-false
DDI-DrugBank.d775.s5.p5	Isoflurane and enflurane (administered with @DRUG$/@DRUG$ to achieve 1.25 M.C.	DDI-false
DDI-DrugBank.d775.s8.p0	A greater potentiation of the neuromuscular blocking effects of @DRUG$ may be expected with higher concentrations of @DRUG$ or isoflurane.	DDI-false
DDI-DrugBank.d775.s8.p1	A greater potentiation of the neuromuscular blocking effects of @DRUG$ may be expected with higher concentrations of enflurane or @DRUG$.	DDI-false
DDI-DrugBank.d775.s8.p2	A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d776.s10.p0	@DRUG$: @DRUG$ increases the plasma concentrations of phenytoin.	DDI-false
DDI-DrugBank.d776.s10.p1	@DRUG$: DIFLUCAN increases the plasma concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d776.s10.p2	Phenytoin: @DRUG$ increases the plasma concentrations of @DRUG$.	DDI-mechanism
DDI-DrugBank.d776.s11.p0	Careful monitoring of @DRUG$ concentrations in patients receiving @DRUG$ and phenytoin is recommended.	DDI-false
DDI-DrugBank.d776.s11.p1	Careful monitoring of @DRUG$ concentrations in patients receiving DIFLUCAN and @DRUG$ is recommended.	DDI-false
DDI-DrugBank.d776.s11.p2	Careful monitoring of phenytoin concentrations in patients receiving @DRUG$ and @DRUG$ is recommended.	DDI-advise
DDI-DrugBank.d776.s13.p0	@DRUG$: @DRUG$ may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.	DDI-false
DDI-DrugBank.d776.s13.p1	@DRUG$: DIFLUCAN may significantly increase @DRUG$ levels in renal transplant patients with or without renal impairment.	DDI-false
DDI-DrugBank.d776.s13.p2	Cyclosporine: @DRUG$ may significantly increase @DRUG$ levels in renal transplant patients with or without renal impairment.	DDI-mechanism
DDI-DrugBank.d776.s14.p0	Careful monitoring of @DRUG$ concentrations and serum creatinine is recommended in patients receiving @DRUG$ and cyclosporine.	DDI-false
DDI-DrugBank.d776.s14.p1	Careful monitoring of @DRUG$ concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and @DRUG$.	DDI-false
DDI-DrugBank.d776.s14.p2	Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving @DRUG$ and @DRUG$.	DDI-advise
DDI-DrugBank.d776.s16.p0	@DRUG$: @DRUG$ enhances the metabolism of concurrently administered DIFLUCAN.	DDI-false
DDI-DrugBank.d776.s16.p1	@DRUG$: Rifampin enhances the metabolism of concurrently administered @DRUG$.	DDI-false
DDI-DrugBank.d776.s16.p2	Rifampin: @DRUG$ enhances the metabolism of concurrently administered @DRUG$.	DDI-mechanism
DDI-DrugBank.d776.s17.p0	Depending on clinical circumstances, consideration should be given to increasing the dose of @DRUG$ when it is administered with @DRUG$.	DDI-advise
DDI-DrugBank.d776.s18.p0	@DRUG$: @DRUG$ increases the serum concentrations of theophylline.	DDI-false
DDI-DrugBank.d776.s18.p1	@DRUG$: DIFLUCAN increases the serum concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d776.s18.p2	Theophylline: @DRUG$ increases the serum concentrations of @DRUG$.	DDI-mechanism
DDI-DrugBank.d776.s19.p0	Careful monitoring of serum @DRUG$ concentrations in patients receiving @DRUG$ and theophylline is recommended.	DDI-false
DDI-DrugBank.d776.s19.p1	Careful monitoring of serum @DRUG$ concentrations in patients receiving DIFLUCAN and @DRUG$ is recommended.	DDI-false
DDI-DrugBank.d776.s19.p2	Careful monitoring of serum theophylline concentrations in patients receiving @DRUG$ and @DRUG$ is recommended.	DDI-advise
DDI-DrugBank.d776.s2.p0	These are described in greater detail below:  Oral @DRUG$, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p1	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p2	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p3	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p4	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p5	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p6	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p7	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p8	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p9	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p10	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p11	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p12	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p13	These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p14	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p15	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p16	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p17	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p18	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p19	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p20	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p21	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p22	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p23	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p24	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p25	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p26	These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p27	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p28	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p29	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p30	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p31	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p32	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p33	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p34	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p35	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p36	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p37	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p38	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p39	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p40	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p41	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p42	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p43	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p44	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p45	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p46	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p47	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p48	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p49	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p50	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p51	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p52	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p53	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p54	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p55	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p56	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p57	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p58	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p59	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p60	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p61	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p62	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p63	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p64	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p65	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p66	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p67	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p68	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p69	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p70	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p71	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p72	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p73	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p74	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p75	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p76	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p77	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p78	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p79	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p80	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p81	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p82	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p83	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p84	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p85	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p86	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p87	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p88	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p89	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p90	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p91	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p92	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p93	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p94	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p95	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p96	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p97	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p98	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p99	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p100	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p101	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p102	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents;	DDI-false
DDI-DrugBank.d776.s2.p103	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$;	DDI-false
DDI-DrugBank.d776.s2.p104	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral @DRUG$;	DDI-effect
DDI-DrugBank.d776.s20.p0	@DRUG$: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving @DRUG$ in conjunction with terfenadine, interaction studies have been performed.	DDI-false
DDI-DrugBank.d776.s20.p1	@DRUG$: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with @DRUG$, interaction studies have been performed.	DDI-false
DDI-DrugBank.d776.s20.p2	Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving @DRUG$ in conjunction with @DRUG$, interaction studies have been performed.	DDI-effect
DDI-DrugBank.d776.s22.p0	Another study at a 400-mg and 800-mg daily dose of @DRUG$ demonstrated that @DRUG$ taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.	DDI-false
DDI-DrugBank.d776.s22.p1	Another study at a 400-mg and 800-mg daily dose of @DRUG$ demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of @DRUG$ when taken concomitantly.	DDI-false
DDI-DrugBank.d776.s22.p2	Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that @DRUG$ taken in doses of 400 mg per day or greater significantly increases plasma levels of @DRUG$ when taken concomitantly.	DDI-mechanism
DDI-DrugBank.d776.s23.p0	The combined use of @DRUG$ at doses of 400 mg or greater with @DRUG$ is contraindicated.	DDI-advise
DDI-DrugBank.d776.s24.p0	The coadministration of @DRUG$ at doses lower than 400 mg/day with @DRUG$ should be carefully monitored.	DDI-advise
DDI-DrugBank.d776.s25.p0	@DRUG$: There have been reports of cardiac events, including torsade de pointes in patients to whom @DRUG$ and cisapride were coadministered.	DDI-false
DDI-DrugBank.d776.s25.p1	@DRUG$: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and @DRUG$ were coadministered.	DDI-false
DDI-DrugBank.d776.s25.p2	Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom @DRUG$ and @DRUG$ were coadministered.	DDI-effect
DDI-DrugBank.d776.s26.p0	A controlled study found that concomitant @DRUG$ 200 mg once daily and @DRUG$ 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.	DDI-mechanism
DDI-DrugBank.d776.s26.p1	A controlled study found that concomitant @DRUG$ 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in @DRUG$ plasma levels and prolongation of QTc interval.	DDI-false
DDI-DrugBank.d776.s26.p2	A controlled study found that concomitant fluconazole 200 mg once daily and @DRUG$ 20 mg four times a day yielded a significant increase in @DRUG$ plasma levels and prolongation of QTc interval.	DDI-false
DDI-DrugBank.d776.s27.p0	The combined use of @DRUG$ with @DRUG$ is contraindicated.	DDI-advise
DDI-DrugBank.d776.s28.p0	@DRUG$: The use of @DRUG$ in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.	DDI-false
DDI-DrugBank.d776.s28.p1	@DRUG$: The use of fluconazole in patients concurrently taking @DRUG$ or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.	DDI-false
DDI-DrugBank.d776.s28.p2	Astemizole: The use of @DRUG$ in patients concurrently taking @DRUG$ or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.	DDI-mechanism
DDI-DrugBank.d776.s3.p0	one fatality has been reported from hypoglycemia in association with combined @DRUG$ and @DRUG$ use.	DDI-effect
DDI-DrugBank.d776.s31.p0	@DRUG$: There have been reports of uveitis in patients to whom @DRUG$ and rifabutin were coadministered.	DDI-false
DDI-DrugBank.d776.s31.p1	@DRUG$: There have been reports of uveitis in patients to whom fluconazole and @DRUG$ were coadministered.	DDI-false
DDI-DrugBank.d776.s31.p2	Rifabutin: There have been reports of uveitis in patients to whom @DRUG$ and @DRUG$ were coadministered.	DDI-effect
DDI-DrugBank.d776.s32.p0	Patients receiving @DRUG$ and @DRUG$ concomitantly should be carefully monitored.	DDI-advise
DDI-DrugBank.d776.s33.p0	@DRUG$: There have been reports of nephrotoxicity in patients to whom @DRUG$ and tacrolimus were coadministered.	DDI-false
DDI-DrugBank.d776.s33.p1	@DRUG$: There have been reports of nephrotoxicity in patients to whom fluconazole and @DRUG$ were coadministered.	DDI-false
DDI-DrugBank.d776.s33.p2	Tacrolimus: There have been reports of nephrotoxicity in patients to whom @DRUG$ and @DRUG$ were coadministered.	DDI-effect
DDI-DrugBank.d776.s34.p0	Patients receiving @DRUG$ and @DRUG$ concomitantly should be carefully monitored.	DDI-advise
DDI-DrugBank.d776.s35.p0	@DRUG$: Following oral administration of @DRUG$, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.	DDI-false
DDI-DrugBank.d776.s35.p1	@DRUG$: Following oral administration of midazolam, @DRUG$ resulted in substantial increases in midazolam concentrations and psychomotor effects.	DDI-false
DDI-DrugBank.d776.s35.p2	@DRUG$: Following oral administration of midazolam, fluconazole resulted in substantial increases in @DRUG$ concentrations and psychomotor effects.	DDI-false
DDI-DrugBank.d776.s35.p3	Short-acting Benzodiazepines: Following oral administration of @DRUG$, @DRUG$ resulted in substantial increases in midazolam concentrations and psychomotor effects.	DDI-mechanism
DDI-DrugBank.d776.s35.p4	Short-acting Benzodiazepines: Following oral administration of @DRUG$, fluconazole resulted in substantial increases in @DRUG$ concentrations and psychomotor effects.	DDI-false
DDI-DrugBank.d776.s35.p5	Short-acting Benzodiazepines: Following oral administration of midazolam, @DRUG$ resulted in substantial increases in @DRUG$ concentrations and psychomotor effects.	DDI-false
DDI-DrugBank.d776.s36.p0	This effect on @DRUG$ appears to be more pronounced following oral administration of @DRUG$ than with fluconazole administered intravenously.	DDI-effect
DDI-DrugBank.d776.s36.p1	This effect on @DRUG$ appears to be more pronounced following oral administration of fluconazole than with @DRUG$ administered intravenously.	DDI-false
DDI-DrugBank.d776.s36.p2	This effect on midazolam appears to be more pronounced following oral administration of @DRUG$ than with @DRUG$ administered intravenously.	DDI-false
DDI-DrugBank.d776.s37.p0	If @DRUG$, which are metabolized by the cytochrome P450 system, are concomitantly administered with @DRUG$, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.	DDI-advise
DDI-DrugBank.d776.s37.p1	If @DRUG$, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the @DRUG$ dosage, and the patients should be appropriately monitored.	DDI-false
DDI-DrugBank.d776.s37.p2	If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with @DRUG$, consideration should be given to decreasing the @DRUG$ dosage, and the patients should be appropriately monitored.	DDI-false
DDI-DrugBank.d776.s38.p0	@DRUG$ tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	DDI-mechanism
DDI-DrugBank.d776.s38.p1	@DRUG$ tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	DDI-mechanism
DDI-DrugBank.d776.s38.p2	@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	DDI-false
DDI-DrugBank.d776.s38.p3	@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels;	DDI-false
DDI-DrugBank.d776.s38.p4	@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels;	DDI-false
DDI-DrugBank.d776.s38.p5	Fluconazole tablets coadministered with @DRUG$- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	DDI-false
DDI-DrugBank.d776.s38.p6	Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	DDI-false
DDI-DrugBank.d776.s38.p7	Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels;	DDI-false
DDI-DrugBank.d776.s38.p8	Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels;	DDI-false
DDI-DrugBank.d776.s38.p9	Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	DDI-false
DDI-DrugBank.d776.s38.p10	Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels;	DDI-false
DDI-DrugBank.d776.s38.p11	Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels;	DDI-false
DDI-DrugBank.d776.s38.p12	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in @DRUG$ and levonorgestrel levels;	DDI-false
DDI-DrugBank.d776.s38.p13	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and @DRUG$ levels;	DDI-false
DDI-DrugBank.d776.s38.p14	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and @DRUG$ levels;	DDI-false
DDI-DrugBank.d776.s39.p0	however, in some patients there were decreases up to 47% and 33% of @DRUG$ and @DRUG$ levels.	DDI-false
DDI-DrugBank.d776.s4.p0	@DRUG$ reduces the metabolism of @DRUG$, glyburide, and glipizide and increases the plasma concentration of these agents.	DDI-mechanism
DDI-DrugBank.d776.s4.p1	@DRUG$ reduces the metabolism of tolbutamide, @DRUG$, and glipizide and increases the plasma concentration of these agents.	DDI-mechanism
DDI-DrugBank.d776.s4.p2	@DRUG$ reduces the metabolism of tolbutamide, glyburide, and @DRUG$ and increases the plasma concentration of these agents.	DDI-mechanism
DDI-DrugBank.d776.s4.p3	DIFLUCAN reduces the metabolism of @DRUG$, @DRUG$, and glipizide and increases the plasma concentration of these agents.	DDI-false
DDI-DrugBank.d776.s4.p4	DIFLUCAN reduces the metabolism of @DRUG$, glyburide, and @DRUG$ and increases the plasma concentration of these agents.	DDI-false
DDI-DrugBank.d776.s4.p5	DIFLUCAN reduces the metabolism of tolbutamide, @DRUG$, and @DRUG$ and increases the plasma concentration of these agents.	DDI-false
DDI-DrugBank.d776.s40.p0	The data presently available indicate that the decreases in some individual @DRUG$ and @DRUG$ AUC values with fluconazole treatment are likely the result of random variation.	DDI-false
DDI-DrugBank.d776.s40.p1	The data presently available indicate that the decreases in some individual @DRUG$ and levonorgestrel AUC values with @DRUG$ treatment are likely the result of random variation.	DDI-false
DDI-DrugBank.d776.s40.p2	The data presently available indicate that the decreases in some individual ethinyl estradiol and @DRUG$ AUC values with @DRUG$ treatment are likely the result of random variation.	DDI-false
DDI-DrugBank.d776.s41.p0	While there is evidence that @DRUG$ can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	DDI-mechanism
DDI-DrugBank.d776.s41.p1	While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	DDI-mechanism
DDI-DrugBank.d776.s41.p2	While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	DDI-false
DDI-DrugBank.d776.s41.p3	While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism.	DDI-false
DDI-DrugBank.d776.s41.p4	While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d776.s41.p5	While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	DDI-false
DDI-DrugBank.d776.s41.p6	While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	DDI-false
DDI-DrugBank.d776.s41.p7	While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism.	DDI-false
DDI-DrugBank.d776.s41.p8	While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d776.s41.p9	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	DDI-false
DDI-DrugBank.d776.s41.p10	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism.	DDI-false
DDI-DrugBank.d776.s41.p11	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d776.s41.p12	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of @DRUG$ or levonorgestrel metabolism.	DDI-false
DDI-DrugBank.d776.s41.p13	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d776.s41.p14	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d776.s5.p0	When @DRUG$ is used concomitantly with these or other @DRUG$, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.	DDI-advise
DDI-DrugBank.d776.s5.p1	When @DRUG$ is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the @DRUG$ should be adjusted as necessary.	DDI-false
DDI-DrugBank.d776.s5.p2	When DIFLUCAN is used concomitantly with these or other @DRUG$, blood glucose concentrations should be carefully monitored and the dose of the @DRUG$ should be adjusted as necessary.	DDI-false
DDI-DrugBank.d776.s6.p0	@DRUG$: Prothrombin time may be increased in patients receiving concomitant @DRUG$ and coumarin-type anticoagulants.	DDI-false
DDI-DrugBank.d776.s6.p1	@DRUG$: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and @DRUG$.	DDI-false
DDI-DrugBank.d776.s6.p2	Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d776.s7.p0	In post-marketing experience, as with other @DRUG$, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with warfarin.	DDI-false
DDI-DrugBank.d776.s7.p1	In post-marketing experience, as with other @DRUG$, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with @DRUG$.	DDI-false
DDI-DrugBank.d776.s7.p2	In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with @DRUG$.	DDI-effect
DDI-DrugBank.d776.s8.p0	Careful monitoring of prothrombin time in patients receiving @DRUG$ and @DRUG$ is recommended.	DDI-advise
DDI-DrugBank.d777.s0.p0	The interaction of @DRUG$, @DRUG$, with other drugs has not been well studied.	DDI-false
DDI-DrugBank.d777.s1.p0	Use of @DRUG$ and @DRUG$ -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p1	Use of @DRUG$ and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p2	Use of @DRUG$ and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p3	Use of @DRUG$ and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p4	Use of @DRUG$ and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p5	Use of Anticoagulants and @DRUG$ -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p6	Use of Anticoagulants and @DRUG$ -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p7	Use of Anticoagulants and @DRUG$ -- Streptase, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p8	Use of Anticoagulants and @DRUG$ -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p9	Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s1.p10	Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications.	DDI-effect
DDI-DrugBank.d777.s1.p11	Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications.	DDI-effect
DDI-DrugBank.d777.s1.p12	Use of Anticoagulants and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications.	DDI-effect
DDI-DrugBank.d777.s1.p13	Use of Anticoagulants and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications.	DDI-effect
DDI-DrugBank.d777.s1.p14	Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with @DRUG$ and @DRUG$, may cause bleeding complications.	DDI-false
DDI-DrugBank.d777.s3.p0	In the treatment of acute MI, @DRUG$, when not otherwise contraindicated, should be administered with @DRUG$ ( see below ).	DDI-false
DDI-DrugBank.d777.s4.p0	Anticoagulation and @DRUG$ After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of @DRUG$ has been shown to reduce the incidence of reinfarction and stroke.	DDI-false
DDI-DrugBank.d777.s5.p0	The addition of @DRUG$ to @DRUG$ causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see	DDI-effect
DDI-DrugBank.d779.s0.p0	When @DRUG$ is used with other @DRUG$, potentiation of antihypertensive effect may occur.	DDI-effect
DDI-DrugBank.d779.s16.p0	@DRUG$ does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin.	DDI-false
DDI-DrugBank.d779.s16.p1	@DRUG$ does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to vanillin.	DDI-false
DDI-DrugBank.d779.s16.p2	@DRUG$ does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin.	DDI-false
DDI-DrugBank.d779.s16.p3	@DRUG$ does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$.	DDI-false
DDI-DrugBank.d779.s16.p4	Methyldopa does not interfere with measurement of @DRUG$ (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to vanillin.	DDI-false
DDI-DrugBank.d779.s16.p5	Methyldopa does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin.	DDI-false
DDI-DrugBank.d779.s16.p6	Methyldopa does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$.	DDI-false
DDI-DrugBank.d779.s16.p7	Methyldopa does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin.	DDI-false
DDI-DrugBank.d779.s16.p8	Methyldopa does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$.	DDI-false
DDI-DrugBank.d779.s16.p9	Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to @DRUG$.	DDI-false
DDI-DrugBank.d779.s2.p0	Patients may require reduced doses of @DRUG$ when on @DRUG$.	DDI-advise
DDI-DrugBank.d779.s5.p0	When @DRUG$ and @DRUG$ are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.	DDI-advise
DDI-DrugBank.d779.s5.p1	When @DRUG$ and lithium are given concomitantly the patient should be carefully monitored for symptoms of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d779.s5.p2	When methyldopa and @DRUG$ are given concomitantly the patient should be carefully monitored for symptoms of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d779.s7.p0	Several studies demonstrate a decrease in the bioavailability of @DRUG$ when it is ingested with @DRUG$ or ferrous gluconate.	DDI-mechanism
DDI-DrugBank.d779.s7.p1	Several studies demonstrate a decrease in the bioavailability of @DRUG$ when it is ingested with ferrous sulfate or @DRUG$.	DDI-mechanism
DDI-DrugBank.d779.s7.p2	Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d779.s9.p0	Coadministration of @DRUG$ with @DRUG$ or ferrous gluconate is not recommended.	DDI-advise
DDI-DrugBank.d779.s9.p1	Coadministration of @DRUG$ with ferrous sulfate or @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d779.s9.p2	Coadministration of methyldopa with @DRUG$ or @DRUG$ is not recommended.	DDI-false
DDI-DrugBank.d780.s0.p0	@DRUG$: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	DDI-false
DDI-DrugBank.d780.s0.p1	@DRUG$: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	DDI-false
DDI-DrugBank.d780.s0.p2	@DRUG$: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride.	DDI-false
DDI-DrugBank.d780.s0.p3	@DRUG$: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$.	DDI-false
DDI-DrugBank.d780.s0.p4	Anticholinesterases: Concurrent use of @DRUG$ and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	DDI-effect
DDI-DrugBank.d780.s0.p5	Anticholinesterases: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride.	DDI-false
DDI-DrugBank.d780.s0.p6	Anticholinesterases: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$.	DDI-false
DDI-DrugBank.d780.s0.p7	Anticholinesterases: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride.	DDI-false
DDI-DrugBank.d780.s0.p8	Anticholinesterases: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$.	DDI-false
DDI-DrugBank.d780.s0.p9	Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of @DRUG$.	DDI-mechanism
DDI-DrugBank.d780.s4.p0	@DRUG$ medications: Concurrent use of @DRUG$ and CNS depressant medications may result in additive depressant effects.	DDI-false
DDI-DrugBank.d780.s4.p1	@DRUG$ medications: Concurrent use of procaine hydrochloride and @DRUG$ may result in additive depressant effects.	DDI-false
DDI-DrugBank.d780.s4.p2	CNS depressant medications: Concurrent use of @DRUG$ and @DRUG$ may result in additive depressant effects.	DDI-effect
DDI-DrugBank.d780.s5.p0	@DRUG$: @DRUG$ may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.	DDI-false
DDI-DrugBank.d780.s5.p1	@DRUG$: Hyaluronidase may increase the diffusion rate of @DRUG$, resulting in a decreased time of onset, but an increase in systemic toxicity.	DDI-false
DDI-DrugBank.d780.s5.p2	Hyaluronidase: @DRUG$ may increase the diffusion rate of @DRUG$, resulting in a decreased time of onset, but an increase in systemic toxicity.	DDI-mechanism
DDI-DrugBank.d780.s6.p0	@DRUG$ (such as @DRUG$): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	DDI-false
DDI-DrugBank.d780.s6.p1	@DRUG$ (such as suxamethonium chloride): Concurrent use of @DRUG$ and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	DDI-false
DDI-DrugBank.d780.s6.p2	@DRUG$ (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade.	DDI-false
DDI-DrugBank.d780.s6.p3	Neuromuscular blocking agents (such as @DRUG$): Concurrent use of @DRUG$ and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	DDI-false
DDI-DrugBank.d780.s6.p4	Neuromuscular blocking agents (such as @DRUG$): Concurrent use of procaine hydrochloride and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade.	DDI-false
DDI-DrugBank.d780.s6.p5	Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of @DRUG$ and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade.	DDI-effect
DDI-DrugBank.d780.s7.p0	@DRUG$: Concurrent use of @DRUG$ and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.	DDI-false
DDI-DrugBank.d780.s7.p1	@DRUG$: Concurrent use of procaine hydrochloride and @DRUG$ may result in a reduction of the antibacterial action of the sulfonamide.	DDI-false
DDI-DrugBank.d780.s7.p2	@DRUG$: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the @DRUG$.	DDI-false
DDI-DrugBank.d780.s7.p3	Sulfonamides: Concurrent use of @DRUG$ and @DRUG$ may result in a reduction of the antibacterial action of the sulfonamide.	DDI-effect
DDI-DrugBank.d780.s7.p4	Sulfonamides: Concurrent use of @DRUG$ and sulfonamides may result in a reduction of the antibacterial action of the @DRUG$.	DDI-false
DDI-DrugBank.d780.s7.p5	Sulfonamides: Concurrent use of procaine hydrochloride and @DRUG$ may result in a reduction of the antibacterial action of the @DRUG$.	DDI-false
DDI-DrugBank.d780.s8.p0	@DRUG$: Concurrent use of @DRUG$ and procaine hydrochloride may extend the plasma half-life of procaine.	DDI-false
DDI-DrugBank.d780.s8.p1	@DRUG$: Concurrent use of acetazolamide and @DRUG$ may extend the plasma half-life of procaine.	DDI-false
DDI-DrugBank.d780.s8.p2	@DRUG$: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of @DRUG$.	DDI-false
DDI-DrugBank.d780.s8.p3	Acetazolamide: Concurrent use of @DRUG$ and @DRUG$ may extend the plasma half-life of procaine.	DDI-mechanism
DDI-DrugBank.d780.s8.p4	Acetazolamide: Concurrent use of @DRUG$ and procaine hydrochloride may extend the plasma half-life of @DRUG$.	DDI-false
DDI-DrugBank.d780.s8.p5	Acetazolamide: Concurrent use of acetazolamide and @DRUG$ may extend the plasma half-life of @DRUG$.	DDI-false
DDI-DrugBank.d781.s0.p0	@DRUG$: Patients on @DRUG$, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy.	DDI-false
DDI-DrugBank.d781.s0.p1	@DRUG$: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of @DRUG$    Tablets therapy.	DDI-false
DDI-DrugBank.d781.s0.p2	Diuretics: Patients on @DRUG$, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of @DRUG$    Tablets therapy.	DDI-effect
DDI-DrugBank.d781.s1.p0	The possibility of hypotensive effects can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$.	DDI-effect
DDI-DrugBank.d781.s10.p0	Use of a @DRUG$ may further increase the risk of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d781.s11.p0	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p1	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p2	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p3	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p4	@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p5	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p6	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p7	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p8	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p9	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p10	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p11	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded.	DDI-false
DDI-DrugBank.d781.s11.p12	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of @DRUG$/perindoprilat has not been excluded.	DDI-mechanism
DDI-DrugBank.d781.s11.p13	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/@DRUG$ has not been excluded.	DDI-mechanism
DDI-DrugBank.d781.s11.p14	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/@DRUG$ has not been excluded.	DDI-false
DDI-DrugBank.d781.s12.p0	@DRUG$: Animal data have suggested the possibility of interaction between @DRUG$ and gentamicin.	DDI-false
DDI-DrugBank.d781.s12.p1	@DRUG$: Animal data have suggested the possibility of interaction between perindopril and @DRUG$.	DDI-false
DDI-DrugBank.d781.s12.p2	Gentamicin: Animal data have suggested the possibility of interaction between @DRUG$ and @DRUG$.	DDI-int
DDI-DrugBank.d781.s15.p0	Food Interaction: Oral administration of @DRUG$    Tablets with food does not significantly lower the rate or extent of @DRUG$ absorption relative to the fasted state.	DDI-false
DDI-DrugBank.d781.s16.p0	However, the extent of biotransformation of @DRUG$ to the active metabolite, @DRUG$, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant.	DDI-false
DDI-DrugBank.d781.s2.p0	If @DRUG$ cannot be interrupted, close medical supervision should be provided with the first dose of @DRUG$    Tablets, for at least two hours and until blood pressure has stabilized for another hour.	DDI-advise
DDI-DrugBank.d781.s3.p0	The rate and extent of @DRUG$ absorption and elimination are not affected by concomitant @DRUG$.	DDI-false
DDI-DrugBank.d781.s4.p0	The bioavailability of @DRUG$ was reduced by @DRUG$, however, and this was associated with a decrease in plasma ACE inhibition.	DDI-false
DDI-DrugBank.d781.s5.p0	@DRUG$ Supplements and @DRUG$: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production.	DDI-false
DDI-DrugBank.d781.s5.p1	@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$    Tablets may increase serum potassium because of its potential to decrease aldosterone production.	DDI-false
DDI-DrugBank.d781.s5.p2	Potassium Supplements and @DRUG$: @DRUG$    Tablets may increase serum potassium because of its potential to decrease aldosterone production.	DDI-false
DDI-DrugBank.d781.s6.p0	Use of @DRUG$ (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p1	Use of @DRUG$ (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p2	Use of @DRUG$ (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p3	Use of @DRUG$ (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p4	Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p5	Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p6	Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p7	Use of potassium-sparing diuretics (@DRUG$, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p8	Use of potassium-sparing diuretics (@DRUG$, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p9	Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p10	Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p11	Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p12	Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p13	Use of potassium-sparing diuretics (spironolactone, @DRUG$, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p14	Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p15	Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p16	Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p17	Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p18	Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p19	Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p20	Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p21	Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p22	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p23	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p24	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p25	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p26	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, @DRUG$ and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s6.p27	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, @DRUG$ and others) can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d781.s8.p0	@DRUG$: Increased serum @DRUG$ and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
DDI-DrugBank.d781.s8.p1	@DRUG$: Increased serum lithium and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
DDI-DrugBank.d781.s8.p2	@DRUG$: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
DDI-DrugBank.d781.s8.p3	Lithium: Increased serum @DRUG$ and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
DDI-DrugBank.d781.s8.p4	Lithium: Increased serum @DRUG$ and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
DDI-DrugBank.d781.s8.p5	Lithium: Increased serum lithium and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
DDI-DrugBank.d782.s0.p0	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-int
DDI-DrugBank.d782.s0.p1	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-int
DDI-DrugBank.d782.s0.p2	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p3	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-int
DDI-DrugBank.d782.s0.p4	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine	DDI-int
DDI-DrugBank.d782.s0.p5	@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$	DDI-false
DDI-DrugBank.d782.s0.p6	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p7	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p8	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p9	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p10	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$	DDI-false
DDI-DrugBank.d782.s0.p11	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p12	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p13	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p14	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$	DDI-false
DDI-DrugBank.d782.s0.p15	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p16	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p17	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$	DDI-false
DDI-DrugBank.d782.s0.p18	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine	DDI-false
DDI-DrugBank.d782.s0.p19	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$	DDI-false
DDI-DrugBank.d782.s0.p20	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the @DRUG$	DDI-false
DDI-DrugBank.d783.s0.p0	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	DDI-mechanism
DDI-DrugBank.d783.s0.p1	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, cyclosporine, and tricyclic antidepressants.	DDI-mechanism
DDI-DrugBank.d783.s0.p2	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, cyclosporine, and tricyclic antidepressants.	DDI-mechanism
DDI-DrugBank.d783.s0.p3	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, @DRUG$, and tricyclic antidepressants.	DDI-mechanism
DDI-DrugBank.d783.s0.p4	@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and @DRUG$.	DDI-mechanism
DDI-DrugBank.d783.s0.p5	Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, @DRUG$, cisapride, cyclosporine, and tricyclic antidepressants.	DDI-false
DDI-DrugBank.d783.s0.p6	Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, @DRUG$, cyclosporine, and tricyclic antidepressants.	DDI-false
DDI-DrugBank.d783.s0.p7	Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, @DRUG$, and tricyclic antidepressants.	DDI-false
DDI-DrugBank.d783.s0.p8	Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, cyclosporine, and @DRUG$.	DDI-false
DDI-DrugBank.d783.s0.p9	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, @DRUG$, cyclosporine, and tricyclic antidepressants.	DDI-false
DDI-DrugBank.d783.s0.p10	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, @DRUG$, and tricyclic antidepressants.	DDI-false
DDI-DrugBank.d783.s0.p11	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, cyclosporine, and @DRUG$.	DDI-false
DDI-DrugBank.d783.s0.p12	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, @DRUG$, and tricyclic antidepressants.	DDI-false
DDI-DrugBank.d783.s0.p13	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, cyclosporine, and @DRUG$.	DDI-false
DDI-DrugBank.d783.s0.p14	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d784.s0.p0	The concomitant use of @DRUG$ with other @DRUG$ or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.	DDI-effect
DDI-DrugBank.d784.s3.p0	Mean @DRUG$ plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with ketoconazole, a potent CYP3A4 inhibitor.	DDI-false
DDI-DrugBank.d784.s3.p1	Mean @DRUG$ plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with @DRUG$, a potent CYP3A4 inhibitor.	DDI-false
DDI-DrugBank.d784.s3.p2	Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with @DRUG$, a potent CYP3A4 inhibitor.	DDI-mechanism
DDI-DrugBank.d784.s4.p0	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p1	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p2	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p3	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p4	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p5	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-mechanism
DDI-DrugBank.d784.s4.p6	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p7	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p8	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p9	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p10	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-mechanism
DDI-DrugBank.d784.s4.p11	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p12	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p13	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p14	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-mechanism
DDI-DrugBank.d784.s4.p15	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p16	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p17	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-mechanism
DDI-DrugBank.d784.s4.p18	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-false
DDI-DrugBank.d784.s4.p19	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-mechanism
DDI-DrugBank.d784.s4.p20	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).	DDI-mechanism
DDI-DrugBank.d784.s7.p0	Concurrent ingestion of @DRUG$ (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p1	Concurrent ingestion of @DRUG$ (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p2	Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p3	Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p4	Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p5	Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.	DDI-false
DDI-DrugBank.d784.s7.p6	Concurrent ingestion of antacid (20 mL of @DRUG$ containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p7	Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p8	Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p9	Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p10	Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.	DDI-false
DDI-DrugBank.d784.s7.p11	Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p12	Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p13	Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p14	Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.	DDI-false
DDI-DrugBank.d784.s7.p15	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p16	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p17	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.	DDI-false
DDI-DrugBank.d784.s7.p18	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.	DDI-false
DDI-DrugBank.d784.s7.p19	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or @DRUG$.	DDI-false
DDI-DrugBank.d784.s7.p20	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or @DRUG$.	DDI-false
DDI-MedLine.d143.s0.p0	[Interaction between @DRUG$ and @DRUG$].	DDI-false
DDI-MedLine.d143.s1.p0	The drug interaction between @DRUG$ and @DRUG$ has been the subject of much study in recent years.	DDI-false
DDI-MedLine.d143.s2.p0	Contradictory results regarding the effect of @DRUG$ on platelet reactivity and on clinical outcome in @DRUG$-treated patients have been reported in literature.	DDI-false
DDI-MedLine.d143.s3.p0	Concomitant use of @DRUG$ and @DRUG$ was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.	DDI-mechanism
DDI-MedLine.d143.s3.p1	Concomitant use of @DRUG$ and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by @DRUG$ of CYP2C19, a cytochrome P450 (CYP) enzyme.	DDI-false
DDI-MedLine.d143.s3.p2	Concomitant use of omeprazole and @DRUG$ was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by @DRUG$ of CYP2C19, a cytochrome P450 (CYP) enzyme.	DDI-false
DDI-MedLine.d143.s4.p0	@DRUG$ has a much weaker effect on @DRUG$'s pharmacokinetics and on platelet reactivity during concomitant use.	DDI-mechanism
DDI-MedLine.d143.s5.p0	The influence of the other @DRUG$ when used simultaneously with @DRUG$ has not yet been investigated in adequately randomized studies.	DDI-false
DDI-MedLine.d143.s6.p0	Regulatory agencies state that the combination of @DRUG$ and the CYP2C19 inhibitors @DRUG$ and esomeprazole should be avoided.	DDI-advise
DDI-MedLine.d143.s6.p1	Regulatory agencies state that the combination of @DRUG$ and the CYP2C19 inhibitors omeprazole and @DRUG$ should be avoided.	DDI-advise
DDI-MedLine.d143.s6.p2	Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors @DRUG$ and @DRUG$ should be avoided.	DDI-false
DDI-MedLine.d143.s7.p0	To date, there is no conclusive evidence of a clinically-relevant interaction between any of the @DRUG$ and @DRUG$.	DDI-false
DDI-MedLine.d147.s0.p0	Interaction of @DRUG$ and @DRUG$, in vitro and in vivo, in human A375 melanoma cells.	DDI-false
DDI-MedLine.d147.s1.p0	We evaluated mechanisms of interaction between the alkyating agent @DRUG$ (@DRUG$) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	DDI-false
DDI-MedLine.d147.s1.p1	We evaluated mechanisms of interaction between the alkyating agent @DRUG$ (DTIC) and the pro-oxidant, @DRUG$, in the human A375 melanoma cell line.	DDI-false
DDI-MedLine.d147.s1.p2	We evaluated mechanisms of interaction between the alkyating agent dacarbazine (@DRUG$) and the pro-oxidant, @DRUG$, in the human A375 melanoma cell line.	DDI-false
DDI-MedLine.d147.s2.p0	The effect of @DRUG$ and @DRUG$, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay).	DDI-false
DDI-MedLine.d147.s6.p0	There was a >75% reduction in cellular glutathione and cysteine with @DRUG$ but not @DRUG$.	DDI-false
DDI-MedLine.d147.s8.p0	@DRUG$ and @DRUG$ show additive effects in vitro but not in vivo in human A375 melanoma cells.	DDI-effect
DDI-MedLine.d154.s0.p0	Enhancement of humoral immune responses to inactivated Newcastle disease and @DRUG$ by oral administration of @DRUG$ in chickens.	DDI-false
DDI-MedLine.d154.s2.p0	The objective of this study was to evaluate the effect of oral administration of @DRUG$ (@DRUG$) on the humoral immune responses of chickens to inactivated ND and AI vaccines.	DDI-false
DDI-MedLine.d154.s2.p1	The objective of this study was to evaluate the effect of oral administration of @DRUG$ (GSLS) on the humoral immune responses of chickens to @DRUG$.	DDI-false
DDI-MedLine.d154.s2.p2	The objective of this study was to evaluate the effect of oral administration of @DRUG$ (GSLS) on the humoral immune responses of chickens to @DRUG$.	DDI-false
DDI-MedLine.d154.s2.p3	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (@DRUG$) on the humoral immune responses of chickens to @DRUG$.	DDI-false
DDI-MedLine.d154.s2.p4	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (@DRUG$) on the humoral immune responses of chickens to @DRUG$.	DDI-false
DDI-MedLine.d154.s2.p5	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to @DRUG-DRUG$.	DDI-false
DDI-MedLine.d154.s3.p0	In experiment 1, oral administration of @DRUG$ at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with @DRUG$ was evaluated.	DDI-false
DDI-MedLine.d154.s5.p0	In experiment 2, the same regimen of @DRUG$ was administered to chickens inoculated with @DRUG$, and an enhanced serum antibody response to AI vaccination was also observed.	DDI-effect
DDI-MedLine.d154.s6.p0	Considering the safety of @DRUG$, because no adverse effect was found throughout the experiments, @DRUG$ may be a promising oral adjuvant to improve immunization in poultry.	DDI-false
DDI-MedLine.d159.s0.p0	Protective effect of @DRUG$ and  @DRUG$ against the acute toxicity of diepoxybutane to human lymphocytes.	DDI-false
DDI-MedLine.d159.s6.p0	(ii) @DRUG$ elicits a significant protective effect on DEB induced toxicity, which was potentiated by  @DRUG$.	DDI-effect
DDI-MedLine.d161.s3.p0	In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, @DRUG$, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of @DRUG$.	DDI-false
DDI-MedLine.d161.s4.p0	Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	DDI-false
DDI-MedLine.d161.s4.p1	Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	DDI-false
DDI-MedLine.d161.s4.p2	Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	DDI-false
DDI-MedLine.d161.s4.p3	Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle).	DDI-false
DDI-MedLine.d161.s4.p4	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	DDI-false
DDI-MedLine.d161.s4.p5	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	DDI-false
DDI-MedLine.d161.s4.p6	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle).	DDI-false
DDI-MedLine.d161.s4.p7	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	DDI-false
DDI-MedLine.d161.s4.p8	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle).	DDI-false
DDI-MedLine.d161.s4.p9	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus @DRUG$/vehicle).	DDI-false
DDI-MedLine.d161.s5.p0	After 21 weeks of @DRUG$ treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	DDI-false
DDI-MedLine.d161.s5.p1	After 21 weeks of @DRUG$ treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	DDI-false
DDI-MedLine.d161.s5.p2	After 21 weeks of @DRUG$ treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys were significantly affected.	DDI-false
DDI-MedLine.d161.s5.p3	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	DDI-false
DDI-MedLine.d161.s5.p4	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys were significantly affected.	DDI-false
DDI-MedLine.d161.s5.p5	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/@DRUG$-treated monkeys were significantly affected.	DDI-effect
DDI-MedLine.d161.s6.p0	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in @DRUG$/@DRUG$-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.	DDI-effect
DDI-MedLine.d161.s6.p1	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in @DRUG$/vehicle-treated monkeys.	DDI-false
DDI-MedLine.d161.s6.p2	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated animals than in @DRUG$/vehicle-treated monkeys.	DDI-false
DDI-MedLine.d161.s7.p0	The @DRUG$ treatment also had a significant effect on the @DRUG$-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.	DDI-effect
DDI-MedLine.d161.s8.p0	In @DRUG$/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.	DDI-false
DDI-MedLine.d161.s8.p1	In @DRUG$/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys.	DDI-false
DDI-MedLine.d161.s8.p2	In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in @DRUG$/@DRUG$-treated monkeys.	DDI-effect
DDI-MedLine.d161.s9.p0	Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, @DRUG$, significantly reduces @DRUG$ toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.	DDI-effect
DDI-MedLine.d163.s0.p0	In vitro activity of @DRUG$ combined with @DRUG$ against clinical isolates of methicillin-resistant Staphylococcus aureus.	DDI-false
DDI-MedLine.d163.s0.p1	In vitro activity of @DRUG$ combined with fosfomycin against clinical isolates of @DRUG$-resistant Staphylococcus aureus.	DDI-false
DDI-MedLine.d163.s0.p2	In vitro activity of minocycline combined with @DRUG$ against clinical isolates of @DRUG$-resistant Staphylococcus aureus.	DDI-false
DDI-MedLine.d163.s1.p0	This study aimed to evaluate the in vitro activity of @DRUG$ combined with @DRUG$ against isolates of methicillin-resistant Staphylococcus aureus (MRSA).	DDI-false
DDI-MedLine.d163.s1.p1	This study aimed to evaluate the in vitro activity of @DRUG$ combined with fosfomycin against isolates of @DRUG$-resistant Staphylococcus aureus (MRSA).	DDI-false
DDI-MedLine.d163.s1.p2	This study aimed to evaluate the in vitro activity of minocycline combined with @DRUG$ against isolates of @DRUG$-resistant Staphylococcus aureus (MRSA).	DDI-false
DDI-MedLine.d163.s4.p0	The susceptibility results for @DRUG$ and @DRUG$ were interpreted according to the most relevant criteria.	DDI-false
DDI-MedLine.d163.s7.p0	The combination of @DRUG$ and @DRUG$ can be synergistic against MRSA.	DDI-effect
DDI-MedLine.d164.s0.p0	@DRUG$ enhances @DRUG$-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.	DDI-effect
DDI-MedLine.d164.s1.p0	Although it was previously reported that @DRUG$ combined with @DRUG$ improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	DDI-effect
DDI-MedLine.d164.s1.p1	Although it was previously reported that @DRUG$ combined with Herceptin improved the progression-free survival rate compared with @DRUG$ alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	DDI-false
DDI-MedLine.d164.s1.p2	Although it was previously reported that @DRUG$ combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	DDI-false
DDI-MedLine.d164.s1.p3	Although it was previously reported that lapatinib combined with @DRUG$ improved the progression-free survival rate compared with @DRUG$ alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	DDI-false
DDI-MedLine.d164.s1.p4	Although it was previously reported that lapatinib combined with @DRUG$ improved the progression-free survival rate compared with lapatinib alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	DDI-false
DDI-MedLine.d164.s1.p5	Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with @DRUG$ alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	DDI-false
DDI-MedLine.d164.s2.p0	We evaluated how @DRUG$ interacts with @DRUG$ in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC).	DDI-false
DDI-MedLine.d164.s2.p1	We evaluated how @DRUG$ interacts with Herceptin in HER2-positive breast cancer, with a particular focus on @DRUG$-mediated antibody-dependent cellular cytotoxicity (ADCC).	DDI-false
DDI-MedLine.d164.s2.p2	We evaluated how lapatinib interacts with @DRUG$ in HER2-positive breast cancer, with a particular focus on @DRUG$-mediated antibody-dependent cellular cytotoxicity (ADCC).	DDI-false
DDI-MedLine.d164.s3.p0	In an in vitro assay, @DRUG$ induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of @DRUG$-mediated ADCC.	DDI-effect
DDI-MedLine.d164.s4.p0	Furthermore, we present a case report in which a second @DRUG$ treatment following @DRUG$ resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.	DDI-effect
DDI-MedLine.d164.s5.p0	@DRUG$ may have the potential to convert @DRUG$-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	DDI-false
DDI-MedLine.d164.s5.p1	@DRUG$ may have the potential to convert Herceptin-refractory to @DRUG$-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	DDI-false
DDI-MedLine.d164.s5.p2	Lapatinib may have the potential to convert @DRUG$-refractory to @DRUG$-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	DDI-false
DDI-MedLine.d166.s0.p0	Improved parathyroid hormone control by @DRUG$ is associated with reduction in @DRUG$ requirement in patients with end-stage renal disease.	DDI-false
DDI-MedLine.d166.s1.p0	Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to @DRUG$ (@DRUG$) resistance.	DDI-false
DDI-MedLine.d166.s17.p0	Reduction of PTH by @DRUG$ is associated with a decrease in @DRUG$ requirement.	DDI-effect
DDI-MedLine.d166.s2.p0	Medical treatment with @DRUG$ is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on @DRUG$ dosing is unknown.	DDI-false
DDI-MedLine.d166.s6.p0	The primary objective of the study was to ascertain the difference in @DRUG$ responsiveness before and after 12 months of @DRUG$ therapy.	DDI-false
DDI-MedLine.d169.s0.p0	@DRUG$ does not inhibit the absorption of 5 milligrams of @DRUG$ at doses less than 800 milligrams in nonpregnant women.	DDI-false
DDI-MedLine.d169.s0.p1	@DRUG$ does not inhibit the absorption of 5 milligrams of nonheme or @DRUG$ at doses less than 800 milligrams in nonpregnant women.	DDI-false
DDI-MedLine.d169.s0.p2	Calcium does not inhibit the absorption of 5 milligrams of @DRUG-DRUG$ at doses less than 800 milligrams in nonpregnant women.	DDI-false
DDI-MedLine.d169.s1.p0	@DRUG$ is the only known component in the diet that may affect absorption of both @DRUG$.	DDI-mechanism
DDI-MedLine.d169.s1.p1	@DRUG$ is the only known component in the diet that may affect absorption of both nonheme and @DRUG$.	DDI-mechanism
DDI-MedLine.d169.s1.p2	Calcium is the only known component in the diet that may affect absorption of both @DRUG-DRUG$.	DDI-false
DDI-MedLine.d169.s10.p0	In conclusion, we demonstrated an isolated effect of @DRUG$ (as chloride) on absorption of 5 mg of iron provided as @DRUG$.	DDI-mechanism
DDI-MedLine.d169.s10.p1	In conclusion, we demonstrated an isolated effect of @DRUG$ (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and @DRUG$.	DDI-mechanism
DDI-MedLine.d169.s10.p2	In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as @DRUG-DRUG$.	DDI-false
DDI-MedLine.d169.s2.p0	However, the evidence for a @DRUG$ effect on @DRUG$ absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.	DDI-mechanism
DDI-MedLine.d169.s2.p1	However, the evidence for a @DRUG$ effect on iron absorption mainly comes from studies that did not isolate the effect of @DRUG$ from that of other dietary components, because it was detected in single-meal studies.	DDI-false
DDI-MedLine.d169.s2.p2	However, the evidence for a calcium effect on @DRUG$ absorption mainly comes from studies that did not isolate the effect of @DRUG$ from that of other dietary components, because it was detected in single-meal studies.	DDI-false
DDI-MedLine.d169.s3.p0	Our objective was to establish potential effects of @DRUG$ on absorption of @DRUG$ and the dose response for this effect in the absence of a meal.	DDI-false
DDI-MedLine.d169.s3.p1	Our objective was to establish potential effects of @DRUG$ on absorption of nonheme and @DRUG$ and the dose response for this effect in the absence of a meal.	DDI-false
DDI-MedLine.d169.s3.p2	Our objective was to establish potential effects of calcium on absorption of @DRUG-DRUG$ and the dose response for this effect in the absence of a meal.	DDI-false
DDI-MedLine.d169.s5.p0	We evaluated the effects of @DRUG$ doses between 200 and 1500 mg on absorption of 5 mg @DRUG$ (as ferrous sulfate).	DDI-false
DDI-MedLine.d169.s5.p1	We evaluated the effects of @DRUG$ doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as @DRUG$).	DDI-false
DDI-MedLine.d169.s5.p2	We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg @DRUG$ (as @DRUG$).	DDI-false
DDI-MedLine.d169.s6.p0	We also evaluated the effects of @DRUG$ doses between 200 and 800 mg on absorption of 5 mg @DRUG$ [as concentrated RBC (CRBC)].	DDI-false
DDI-MedLine.d169.s7.p0	@DRUG$ was administered as @DRUG$ in all studies and minerals were ingested on an empty stomach.	DDI-false
DDI-MedLine.d169.s7.p1	@DRUG$ was administered as calcium chloride in all studies and @DRUG$ were ingested on an empty stomach.	DDI-false
DDI-MedLine.d169.s7.p2	Calcium was administered as @DRUG$ in all studies and @DRUG$ were ingested on an empty stomach.	DDI-false
DDI-MedLine.d169.s8.p0	@DRUG$ doses   1000 mg diminished @DRUG$ absorption by an average of 49.6%.	DDI-mechanism
DDI-MedLine.d169.s9.p0	A @DRUG$ dose of 800 mg diminished absorption of 5 mg @DRUG$ by 37.7%.	DDI-mechanism
DDI-MedLine.d179.s0.p0	Synergistic interaction between @DRUG$ and @DRUG$ is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.	DDI-int
DDI-MedLine.d179.s10.p0	@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	DDI-false
DDI-MedLine.d179.s10.p1	@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to sunitinib followed by docetaxel and concurrent administration.	DDI-false
DDI-MedLine.d179.s10.p2	@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to @DRUG$ followed by docetaxel and concurrent administration.	DDI-false
DDI-MedLine.d179.s10.p3	@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by @DRUG$ and concurrent administration.	DDI-false
DDI-MedLine.d179.s10.p4	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by @DRUG$ is superior to sunitinib followed by docetaxel and concurrent administration.	DDI-effect
DDI-MedLine.d179.s10.p5	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to @DRUG$ followed by docetaxel and concurrent administration.	DDI-false
DDI-MedLine.d179.s10.p6	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to sunitinib followed by @DRUG$ and concurrent administration.	DDI-false
DDI-MedLine.d179.s10.p7	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to @DRUG$ followed by docetaxel and concurrent administration.	DDI-false
DDI-MedLine.d179.s10.p8	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to sunitinib followed by @DRUG$ and concurrent administration.	DDI-false
DDI-MedLine.d179.s10.p9	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to @DRUG$ followed by @DRUG$ and concurrent administration.	DDI-false
DDI-MedLine.d179.s2.p0	This study was aimed to investigate the efficacy of single use of @DRUG$ and that of concurrent or sequential administration of @DRUG$ and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	DDI-false
DDI-MedLine.d179.s2.p1	This study was aimed to investigate the efficacy of single use of @DRUG$ and that of concurrent or sequential administration of sunitinib and @DRUG$ in NSCLC cell lines that are resistant to EGFR TKIs.	DDI-false
DDI-MedLine.d179.s2.p2	This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of @DRUG$ and @DRUG$ in NSCLC cell lines that are resistant to EGFR TKIs.	DDI-false
DDI-MedLine.d179.s3.p0	NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either @DRUG$ or @DRUG$ or both based on various sequential administrations.	DDI-false
DDI-MedLine.d179.s5.p0	@DRUG$ exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas @DRUG$ arrested at S phase.	DDI-false
DDI-MedLine.d179.s6.p0	Although single or concurrent use of @DRUG$ and @DRUG$ has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.	DDI-effect
DDI-MedLine.d179.s7.p0	When cells were exposed to @DRUG$ followed by @DRUG$, synergism was observed.	DDI-effect
DDI-MedLine.d179.s8.p0	The molecular basis of this synergism is that the signaling pathways that were initially activated by @DRUG$ exposure were efficiently suppressed by the subsequent exposure to @DRUG$.	DDI-effect
DDI-MedLine.d180.s1.p0	The @DRUG$ (@DRUG$), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia.	DDI-false
DDI-MedLine.d180.s10.p0	We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with @DRUG$ and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.	DDI-false
DDI-MedLine.d180.s10.p1	We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with DZNep and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.	DDI-false
DDI-MedLine.d180.s10.p2	We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells.	DDI-false
DDI-MedLine.d180.s10.p3	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with @DRUG$ and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.	DDI-effect
DDI-MedLine.d180.s10.p4	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with @DRUG$ and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells.	DDI-false
DDI-MedLine.d180.s10.p5	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells.	DDI-false
DDI-MedLine.d180.s12.p0	In addition, @DRUG$ insensitivity might be associated with overexpression of Bcl-2, and the combination of @DRUG$ and DZNep could synergistically induced apoptosis.	DDI-false
DDI-MedLine.d180.s12.p1	In addition, @DRUG$ insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and @DRUG$ could synergistically induced apoptosis.	DDI-false
DDI-MedLine.d180.s12.p2	In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of @DRUG$ and @DRUG$ could synergistically induced apoptosis.	DDI-effect
DDI-MedLine.d181.s4.p0	The authors report the case of an infant with confirmed congenital hypothyroidism on @DRUG$ who experienced a possible drug interaction with @DRUG$.	DDI-int
DDI-MedLine.d181.s6.p0	Questioning revealed the child was taking @DRUG$ drops before feeds while on @DRUG$.	DDI-false
DDI-MedLine.d181.s8.p0	Drug interaction of @DRUG$ with @DRUG$ has not been reported previously and is not listed in the British National Formulary for Children.	DDI-false
DDI-MedLine.d184.s0.p0	@DRUG$ locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with @DRUG$.	DDI-false
DDI-MedLine.d184.s2.p0	The objective was to analyze the effects of neonatal @DRUG$ treatment on effects of @DRUG$ in adolescent rats using locomotor sensitization and conditioned place preference procedures.	DDI-false
DDI-MedLine.d184.s5.p0	In female rats, neonatal @DRUG$ treatment enhanced @DRUG$ locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.	DDI-effect
DDI-MedLine.d184.s5.p1	In female rats, neonatal @DRUG$ treatment enhanced amphetamine locomotor sensitization compared with @DRUG$-free controls sensitized to amphetamine.	DDI-false
DDI-MedLine.d184.s5.p2	In female rats, neonatal @DRUG$ treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to @DRUG$.	DDI-false
DDI-MedLine.d184.s5.p3	In female rats, neonatal quinpirole treatment enhanced @DRUG$ locomotor sensitization compared with @DRUG$-free controls sensitized to amphetamine.	DDI-false
DDI-MedLine.d184.s5.p4	In female rats, neonatal quinpirole treatment enhanced @DRUG$ locomotor sensitization compared with quinpirole-free controls sensitized to @DRUG$.	DDI-false
DDI-MedLine.d184.s5.p5	In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with @DRUG$-free controls sensitized to @DRUG$.	DDI-false
DDI-MedLine.d184.s6.p0	Male rats demonstrated sensitization to @DRUG$, although this was muted compared with female rats, and were unaffected by neonatal @DRUG$.	DDI-false
DDI-MedLine.d184.s8.p0	Rats treated with neonatal @DRUG$ enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p1	Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p2	Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p3	Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p4	Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p5	Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p6	Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p7	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p8	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d184.s8.p9	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls.	DDI-false
DDI-MedLine.d185.s0.p0	Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (LBH589), an orally active histone deacetylase inhibitor.	DDI-false
DDI-MedLine.d185.s0.p1	Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (@DRUG$), an orally active histone deacetylase inhibitor.	DDI-false
DDI-MedLine.d185.s0.p2	Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active @DRUG$.	DDI-false
DDI-MedLine.d185.s0.p3	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (@DRUG$), an orally active histone deacetylase inhibitor.	DDI-false
DDI-MedLine.d185.s0.p4	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (LBH589), an orally active @DRUG$.	DDI-false
DDI-MedLine.d185.s0.p5	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (@DRUG$), an orally active @DRUG$.	DDI-false
DDI-MedLine.d185.s12.p0	Co-administration of @DRUG$ with CYP3A inhibitors is feasible as the observed increase in @DRUG$ PK parameters was not considered clinically relevant.	DDI-false
DDI-MedLine.d185.s13.p0	Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of @DRUG$ was not studied with CYP3A inhibitors, close monitoring of @DRUG$-related adverse events is necessary.	DDI-false
DDI-MedLine.d185.s2.p0	This study evaluated the effect of a potent CYP3A inhibitor, @DRUG$, on the pharmacokinetics and safety of @DRUG$.	DDI-false
DDI-MedLine.d185.s5.p0	On day 8, a single @DRUG$ dose was co-administered with @DRUG$.	DDI-false
DDI-MedLine.d185.s7.p0	In the presence of @DRUG$, there was 1.6- and 1.8-fold increase in C (max) and AUC of @DRUG$, respectively.	DDI-mechanism
DDI-MedLine.d189.s10.p0	@DRUG$ and @DRUG$ had no effect, while quinidine appeared to augment precocene I toxicity.	DDI-false
DDI-MedLine.d189.s10.p1	@DRUG$ and sulfaphenazole had no effect, while @DRUG$ appeared to augment precocene I toxicity.	DDI-false
DDI-MedLine.d189.s10.p2	@DRUG$ and sulfaphenazole had no effect, while quinidine appeared to augment @DRUG$ toxicity.	DDI-false
DDI-MedLine.d189.s10.p3	Furafylline and @DRUG$ had no effect, while @DRUG$ appeared to augment precocene I toxicity.	DDI-false
DDI-MedLine.d189.s10.p4	Furafylline and @DRUG$ had no effect, while quinidine appeared to augment @DRUG$ toxicity.	DDI-false
DDI-MedLine.d189.s10.p5	Furafylline and sulfaphenazole had no effect, while @DRUG$ appeared to augment @DRUG$ toxicity.	DDI-effect
DDI-MedLine.d189.s11.p0	These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of @DRUG$ and therefore may not be an appropriate model for @DRUG$ metabolism.	DDI-false
DDI-MedLine.d189.s3.p0	The incubations were performed in the absence and presence of the non-specific CYP inhibitor, @DRUG$ (@DRUG$) and isoform-specific inhibitors.	DDI-false
DDI-MedLine.d189.s7.p0	@DRUG$ decreased the toxicity of @DRUG$, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.	DDI-effect
DDI-MedLine.d189.s8.p0	Of the isoform-specific CYP inhibitors tested for an effect on the @DRUG$ metabolite profile, only @DRUG$ was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1.	DDI-false
DDI-MedLine.d189.s9.p0	With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>@DRUG$~tranylcypromine>ketoconazole.	DDI-false
DDI-MedLine.d189.s9.p1	With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>diethyldithiocarbamate~@DRUG$>ketoconazole.	DDI-false
DDI-MedLine.d189.s9.p2	With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>diethyldithiocarbamate~tranylcypromine>@DRUG$.	DDI-false
DDI-MedLine.d189.s9.p3	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>@DRUG$~@DRUG$>ketoconazole.	DDI-false
DDI-MedLine.d189.s9.p4	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>@DRUG$~tranylcypromine>@DRUG$.	DDI-false
DDI-MedLine.d189.s9.p5	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~@DRUG$>@DRUG$.	DDI-false
DDI-MedLine.d190.s1.p0	To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of @DRUG$ (@DRUG$).	DDI-false
DDI-MedLine.d190.s2.p0	@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, heparinase III, or chondroitin ABC lyase.	DDI-false
DDI-MedLine.d190.s2.p1	@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, heparinase III, or chondroitin ABC lyase.	DDI-false
DDI-MedLine.d190.s2.p2	@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, @DRUG$, or chondroitin ABC lyase.	DDI-false
DDI-MedLine.d190.s2.p3	@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or @DRUG$.	DDI-false
DDI-MedLine.d190.s2.p4	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, @DRUG$, heparinase III, or chondroitin ABC lyase.	DDI-false
DDI-MedLine.d190.s2.p5	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, @DRUG$, or chondroitin ABC lyase.	DDI-false
DDI-MedLine.d190.s2.p6	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, heparinase III, or @DRUG$.	DDI-false
DDI-MedLine.d190.s2.p7	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, @DRUG$, or chondroitin ABC lyase.	DDI-false
DDI-MedLine.d190.s2.p8	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, heparinase III, or @DRUG$.	DDI-false
DDI-MedLine.d190.s2.p9	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, @DRUG$, or @DRUG$.	DDI-false
DDI-MedLine.d190.s5.p0	The addition of @DRUG$ or @DRUG$ greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.	DDI-false
DDI-MedLine.d190.s6.p0	@DRUG$ had a limited effect and @DRUG$ was ineffective.	DDI-false
DDI-MedLine.d190.s7.p0	Electroretinograms survived with higher concentrations of @DRUG$ and @DRUG$ than were required for optimal retinal transduction.	DDI-false
DDI-MedLine.d190.s8.p0	@DRUG$-mediated retinal transduction is improved by co-injection of @DRUG$ or chondroitin ABC lyase.	DDI-effect
DDI-MedLine.d190.s8.p1	@DRUG$-mediated retinal transduction is improved by co-injection of heparinase III or @DRUG$.	DDI-effect
DDI-MedLine.d190.s8.p2	AAV2-mediated retinal transduction is improved by co-injection of @DRUG$ or @DRUG$.	DDI-false
DDI-MedLine.d193.s0.p0	@DRUG$ (@DRUG$)--better than clopidogrel (Plavix)	DDI-false
DDI-MedLine.d193.s0.p1	@DRUG$ (Brilinta)--better than @DRUG$ (Plavix)	DDI-false
DDI-MedLine.d193.s0.p2	@DRUG$ (Brilinta)--better than clopidogrel (@DRUG$)	DDI-false
DDI-MedLine.d193.s0.p3	Ticagrelor (@DRUG$)--better than @DRUG$ (Plavix)	DDI-false
DDI-MedLine.d193.s0.p4	Ticagrelor (@DRUG$)--better than clopidogrel (@DRUG$)	DDI-false
DDI-MedLine.d193.s0.p5	Ticagrelor (Brilinta)--better than @DRUG$ (@DRUG$)	DDI-false
DDI-MedLine.d193.s1.p0	The FDA has approved @DRUG$ (@DRUG$-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	DDI-false
DDI-MedLine.d193.s1.p1	The FDA has approved @DRUG$ (Brilinta-AstraZeneca), an oral @DRUG$, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	DDI-false
DDI-MedLine.d193.s1.p2	The FDA has approved @DRUG$ (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	DDI-effect
DDI-MedLine.d193.s1.p3	The FDA has approved ticagrelor (@DRUG$-AstraZeneca), an oral @DRUG$, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	DDI-false
DDI-MedLine.d193.s1.p4	The FDA has approved ticagrelor (@DRUG$-AstraZeneca), an oral antiplatelet drug, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	DDI-effect
DDI-MedLine.d193.s1.p5	The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral @DRUG$, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	DDI-false
DDI-MedLine.d193.s2.p0	It will compete with @DRUG$ (@DRUG$) and prasugrel (Effient) for such use.	DDI-false
DDI-MedLine.d193.s2.p1	It will compete with @DRUG$ (Plavix) and @DRUG$ (Effient) for such use.	DDI-false
DDI-MedLine.d193.s2.p2	It will compete with @DRUG$ (Plavix) and prasugrel (@DRUG$) for such use.	DDI-false
DDI-MedLine.d193.s2.p3	It will compete with clopidogrel (@DRUG$) and @DRUG$ (Effient) for such use.	DDI-false
DDI-MedLine.d193.s2.p4	It will compete with clopidogrel (@DRUG$) and prasugrel (@DRUG$) for such use.	DDI-false
DDI-MedLine.d193.s2.p5	It will compete with clopidogrel (Plavix) and @DRUG$ (@DRUG$) for such use.	DDI-false
DDI-MedLine.d194.s0.p0	The role of p27(Kip1) in @DRUG$-enhanced @DRUG$ cytotoxicity in human ovarian cancer cells.	DDI-effect
DDI-MedLine.d194.s10.p0	Treatment of HEY xenograft-bearing mice with @DRUG$ plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-effect
DDI-MedLine.d194.s10.p1	Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s10.p2	Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s10.p3	Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s10.p4	Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s10.p5	Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s10.p6	Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s10.p7	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s10.p8	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s10.p9	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	DDI-false
DDI-MedLine.d194.s11.p0	@DRUG$ + @DRUG$ vs.	DDI-false
DDI-MedLine.d194.s15.p0	The siRNA knockdown of p27(Kip1) decreased @DRUG$- and @DRUG$-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).	DDI-false
DDI-MedLine.d194.s16.p0	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that @DRUG$-mediated induction of p27(Kip1) enhanced @DRUG$-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.	DDI-effect
DDI-MedLine.d194.s17.p0	Inhibition of Src family and Abl kinases with either siRNAs or @DRUG$ enhances @DRUG$ sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.	DDI-effect
DDI-MedLine.d194.s4.p0	The effect of @DRUG$, an inhibitor of Src and Abl kinases, on @DRUG$ sensitivity was measured in ovarian cancer cells and HEY xenografts.	DDI-false
DDI-MedLine.d194.s5.p0	The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by @DRUG$ and @DRUG$ were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry.	DDI-false
DDI-MedLine.d194.s9.p0	HEY cells treated with @DRUG$ plus @DRUG$ formed fewer colonies than did cells treated with either agent alone.	DDI-effect
DDI-MedLine.d195.s0.p0	Influence of @DRUG$ on @DRUG$ induced antinociception and its pharmacokinetics.	DDI-false
DDI-MedLine.d195.s4.p0	In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.	DDI-effect
DDI-MedLine.d195.s4.p1	In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both @DRUG$ writhing and formalin test, when it was administered with ibuprofen.	DDI-false
DDI-MedLine.d195.s4.p2	In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with @DRUG$.	DDI-false
DDI-MedLine.d195.s4.p3	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both @DRUG$ writhing and formalin test, when it was administered with ibuprofen.	DDI-false
DDI-MedLine.d195.s4.p4	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both acetic acid writhing and formalin test, when it was administered with @DRUG$.	DDI-false
DDI-MedLine.d195.s4.p5	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both @DRUG$ writhing and formalin test, when it was administered with @DRUG$.	DDI-false
DDI-MedLine.d195.s5.p0	@DRUG$ plasma concentration was also increased when it was administered with @DRUG$.	DDI-mechanism
DDI-MedLine.d195.s6.p0	The synergistic antinociception activity of @DRUG$ when administered with @DRUG$ can be attributed to increased plasma concentration of ibuprofen.	DDI-mechanism
DDI-MedLine.d195.s6.p1	The synergistic antinociception activity of @DRUG$ when administered with piperine can be attributed to increased plasma concentration of @DRUG$.	DDI-false
DDI-MedLine.d195.s6.p2	The synergistic antinociception activity of ibuprofen when administered with @DRUG$ can be attributed to increased plasma concentration of @DRUG$.	DDI-false
DDI-MedLine.d195.s7.p0	From this study it can be concluded that @DRUG$ can be used as a bioenhancer along with @DRUG$.	DDI-effect
DDI-MedLine.d199.s0.p0	Prevention of emergence agitation in seven children receiving low-dose @DRUG$ and @DRUG$ total intravenous anesthesia.	DDI-false
DDI-MedLine.d199.s2.p0	We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose @DRUG$ in conjunction with @DRUG$ for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.	DDI-false
DDI-MedLine.d199.s3.p0	EA signs were observed in all 7 patients in association with @DRUG$ TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose @DRUG$ was added to propofol.	DDI-false
DDI-MedLine.d199.s3.p1	EA signs were observed in all 7 patients in association with @DRUG$ TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to @DRUG$.	DDI-false
DDI-MedLine.d199.s3.p2	EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose @DRUG$ was added to @DRUG$.	DDI-false
DDI-MedLine.d199.s4.p0	Based on this experience, we suggest that low-dose @DRUG$ added to @DRUG$ may be associated with prevention of EA in children with a history of EA with propofol TIVA.	DDI-effect
DDI-MedLine.d199.s4.p1	Based on this experience, we suggest that low-dose @DRUG$ added to propofol may be associated with prevention of EA in children with a history of EA with @DRUG$ TIVA.	DDI-false
DDI-MedLine.d199.s4.p2	Based on this experience, we suggest that low-dose ketamine added to @DRUG$ may be associated with prevention of EA in children with a history of EA with @DRUG$ TIVA.	DDI-false
DDI-MedLine.d200.s0.p0	[Efficacy of fixed combination @DRUG$/@DRUG$ in hospitalized patients with hypertensive disease]	DDI-false
DDI-MedLine.d200.s1.p0	Efficacy and tolerability of fixed @DRUG$/@DRUG$ combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology.	DDI-false
DDI-MedLine.d200.s10.p0	We have demonstrated appropriateness of inhospital administration of fixed @DRUG$/@DRUG$ combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	DDI-effect
DDI-MedLine.d200.s10.p1	We have demonstrated appropriateness of inhospital administration of fixed @DRUG$/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer @DRUG$, and diminishing concealed inefficacy of treatment.	DDI-false
DDI-MedLine.d200.s10.p2	We have demonstrated appropriateness of inhospital administration of fixed amlodipine/@DRUG$ combination as an approach allowing to achieve target BP in shorter time, with the use of fewer @DRUG$, and diminishing concealed inefficacy of treatment.	DDI-false
DDI-MedLine.d200.s2.p0	All patients had indications for antihypertensive therapy and were randomized either to fixed combination @DRUG$/@DRUG$ (n=43) or to therapy which corresponded to the hospital formulary (n=43).	DDI-false
DDI-MedLine.d200.s7.p0	Rate of achievement of target BP with fixed combination @DRUG$/@DRUG$ (93%) was comparable with that on traditional therapy (90%).	DDI-false
DDI-MedLine.d200.s8.p0	But the use of fixed combination @DRUG$/@DRUG$ compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	DDI-effect
DDI-MedLine.d200.s8.p1	But the use of fixed combination @DRUG$/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of @DRUG$ (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	DDI-false
DDI-MedLine.d200.s8.p2	But the use of fixed combination amlodipine/@DRUG$ compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of @DRUG$ (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	DDI-false
DDI-MedLine.d201.s4.p0	The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, @DRUG$ (@DRUG$).	DDI-false
DDI-MedLine.d201.s5.p0	We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of @DRUG$ on these cells alone or in combination with @DRUG$.	DDI-false
DDI-MedLine.d201.s9.p0	@DRUG$ induced apoptosis, and furthermore, the combination of @DRUG$ plus doxorubicin enhanced cytotoxicity in a T-ALL cell line.	DDI-false
DDI-MedLine.d201.s9.p1	@DRUG$ induced apoptosis, and furthermore, the combination of CRM197 plus @DRUG$ enhanced cytotoxicity in a T-ALL cell line.	DDI-false
DDI-MedLine.d201.s9.p2	CRM197 induced apoptosis, and furthermore, the combination of @DRUG$ plus @DRUG$ enhanced cytotoxicity in a T-ALL cell line.	DDI-effect
DDI-MedLine.d204.s0.p0	Distinct synergistic action of @DRUG$ and @DRUG$ against Pseudomonas aeruginosa.	DDI-false
DDI-MedLine.d204.s11.p0	Synergism was also noted when @DRUG$ was combined with @DRUG$ and amikacin.	DDI-effect
DDI-MedLine.d204.s11.p1	Synergism was also noted when @DRUG$ was combined with carbenicillin and @DRUG$.	DDI-effect
DDI-MedLine.d204.s11.p2	Synergism was also noted when methylglyoxal was combined with @DRUG$ and @DRUG$.	DDI-false
DDI-MedLine.d204.s7.p0	Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, @DRUG$, amikacin and ciprofloxacin showed resistances at comparatively lower levels.	DDI-false
DDI-MedLine.d204.s7.p1	Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, carbenicillin, @DRUG$ and ciprofloxacin showed resistances at comparatively lower levels.	DDI-false
DDI-MedLine.d204.s7.p2	Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, carbenicillin, amikacin and @DRUG$ showed resistances at comparatively lower levels.	DDI-false
DDI-MedLine.d204.s7.p3	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, @DRUG$, @DRUG$ and ciprofloxacin showed resistances at comparatively lower levels.	DDI-false
DDI-MedLine.d204.s7.p4	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, @DRUG$, amikacin and @DRUG$ showed resistances at comparatively lower levels.	DDI-false
DDI-MedLine.d204.s7.p5	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, @DRUG$ and @DRUG$ showed resistances at comparatively lower levels.	DDI-false
DDI-MedLine.d204.s9.p0	Distinct and statistically significant synergism was observed between @DRUG$ and @DRUG$ by disc diffusion tests when compared with their individual effects.	DDI-effect
DDI-MedLine.d208.s0.p0	@DRUG$   failure in an HIV-positive woman on @DRUG$ therapy resulting in two ectopic pregnancies.	DDI-effect
DDI-MedLine.d208.s3.p0	We present an interesting case of an HIV-positive woman on @DRUG$ therapy having tubal pregnancies on two separate occasions with @DRUG$ in place.	DDI-effect
DDI-MedLine.d209.s1.p0	@DRUG$, an @DRUG$, is the standard hormone treatment for breast cancer.	DDI-false
DDI-MedLine.d209.s10.p0	Depression does not always require @DRUG$ therapy, and @DRUG$ have no proven preventive impact on hot flushes linked to the menopause.	DDI-false
DDI-MedLine.d209.s11.p0	If in certain cases, an @DRUG$ is considered necessary, it may be advisable to replace @DRUG$ with anastrozole.	DDI-advise
DDI-MedLine.d209.s11.p1	If in certain cases, an @DRUG$ is considered necessary, it may be advisable to replace tamoxifen with @DRUG$.	DDI-false
DDI-MedLine.d209.s11.p2	If in certain cases, an antidepressant is considered necessary, it may be advisable to replace @DRUG$ with @DRUG$.	DDI-false
DDI-MedLine.d209.s5.p0	@DRUG$ and @DRUG$ reduce the plasma concentration of endoxifen by about 50%.	DDI-false
DDI-MedLine.d209.s5.p1	@DRUG$ and fluoxetine reduce the plasma concentration of @DRUG$ by about 50%.	DDI-mechanism
DDI-MedLine.d209.s5.p2	Paroxetine and @DRUG$ reduce the plasma concentration of @DRUG$ by about 50%.	DDI-mechanism
DDI-MedLine.d209.s9.p0	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially @DRUG$ such as paroxetine and fluoxetine.	DDI-advise
DDI-MedLine.d209.s9.p1	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially SSRI antidepressants such as @DRUG$ and fluoxetine.	DDI-advise
DDI-MedLine.d209.s9.p2	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially SSRI antidepressants such as paroxetine and @DRUG$.	DDI-advise
DDI-MedLine.d209.s9.p3	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially @DRUG$ such as @DRUG$ and fluoxetine.	DDI-false
DDI-MedLine.d209.s9.p4	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially @DRUG$ such as paroxetine and @DRUG$.	DDI-false
DDI-MedLine.d209.s9.p5	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as @DRUG$ and @DRUG$.	DDI-false
DDI-MedLine.d211.s0.p0	Phase I trial of @DRUG$ and @DRUG$ in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.	DDI-false
DDI-MedLine.d211.s0.p1	Phase I trial of @DRUG$ and CCI-779 in patients with relapsed multiple myeloma: evidence for @DRUG$-CCI-779 interaction via P-glycoprotein.	DDI-false
DDI-MedLine.d211.s0.p2	Phase I trial of @DRUG$ and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-@DRUG$ interaction via P-glycoprotein.	DDI-false
DDI-MedLine.d211.s0.p3	Phase I trial of lenalidomide and @DRUG$ in patients with relapsed multiple myeloma: evidence for @DRUG$-CCI-779 interaction via P-glycoprotein.	DDI-false
DDI-MedLine.d211.s0.p4	Phase I trial of lenalidomide and @DRUG$ in patients with relapsed multiple myeloma: evidence for lenalidomide-@DRUG$ interaction via P-glycoprotein.	DDI-false
DDI-MedLine.d211.s0.p5	Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for @DRUG$-@DRUG$ interaction via P-glycoprotein.	DDI-false
DDI-MedLine.d211.s2.p0	The preclinical combination of @DRUG$ with the mTOR inhibitor @DRUG$ has displayed synergy in vitro and represents a novel combination in MM.	DDI-effect
DDI-MedLine.d213.s0.p0	In vivo CYP3A activity is significantly lower in @DRUG$-treated as compared with @DRUG$-treated renal allograft recipients.	DDI-false
DDI-MedLine.d213.s1.p0	In vitro studies have identified @DRUG$ and @DRUG$ as CYP3A inhibitors.	DDI-false
DDI-MedLine.d213.s3.p0	Systemic and apparent oral @DRUG$ clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in @DRUG$-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).	DDI-mechanism
DDI-MedLine.d213.s3.p1	Systemic and apparent oral @DRUG$ clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched @DRUG$-treated patients (n = 20).	DDI-false
DDI-MedLine.d213.s3.p2	Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in @DRUG$-treated patients (n = 20) than in matched @DRUG$-treated patients (n = 20).	DDI-false
DDI-MedLine.d213.s4.p0	The latter displayed @DRUG$ clearances similar to those in two larger cohorts of nonmatched @DRUG$-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).	DDI-false
DDI-MedLine.d213.s4.p1	The latter displayed @DRUG$ clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a @DRUG$-free regimen (n = 6).	DDI-false
DDI-MedLine.d213.s4.p2	The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched @DRUG$-treated patients (n = 58 and n = 80) and to those receiving a @DRUG$-free regimen (n = 6).	DDI-false
DDI-MedLine.d213.s5.p0	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving @DRUG$ than in those receiving @DRUG$, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.	DDI-false
DDI-MedLine.d213.s5.p1	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving @DRUG$ than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, @DRUG$ is the stronger of the two with respect to CYP3A inhibition.	DDI-false
DDI-MedLine.d213.s5.p2	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving @DRUG$, indicating that, at the doses generally used in clinical practice, @DRUG$ is the stronger of the two with respect to CYP3A inhibition.	DDI-false
DDI-MedLine.d214.s0.p0	[Influence of @DRUG$ and @DRUG$ on MPTP-evoked behavior violations in C57BL/6 mice].	DDI-false
DDI-MedLine.d214.s1.p0	The effects of @DRUG$ @DRUG$ [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)	DDI-false
DDI-MedLine.d214.s1.p1	The effects of @DRUG$ hemantane [@DRUG$] (10 mg/kg, p. o.)	DDI-false
DDI-MedLine.d214.s1.p2	The effects of anti-parkinsonian drug @DRUG$ [@DRUG$] (10 mg/kg, p. o.)	DDI-false
DDI-MedLine.d214.s2.p0	and/or @DRUG$ @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.)	DDI-false
DDI-MedLine.d214.s2.p1	and/or @DRUG$ doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (MPTP) (4 x 20 mg/kg, i. p.)	DDI-false
DDI-MedLine.d214.s2.p2	and/or @DRUG$ doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (@DRUG$) (4 x 20 mg/kg, i. p.)	DDI-false
DDI-MedLine.d214.s2.p3	and/or antibiotic drug @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (MPTP) (4 x 20 mg/kg, i. p.)	DDI-false
DDI-MedLine.d214.s2.p4	and/or antibiotic drug @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (@DRUG$) (4 x 20 mg/kg, i. p.)	DDI-false
DDI-MedLine.d214.s2.p5	and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (@DRUG$) (4 x 20 mg/kg, i. p.)	DDI-false
DDI-MedLine.d214.s5.p0	Acute administration of @DRUG$ or @DRUG$ failed to influence locomotion in mice, while their combination normalized motor activity.	DDI-effect
DDI-MedLine.d216.s0.p0	Exposure to oral @DRUG$ is unaffected by @DRUG$ but greatly increased by ticlopidine.	DDI-false
DDI-MedLine.d216.s0.p1	Exposure to oral @DRUG$ is unaffected by itraconazole but greatly increased by @DRUG$.	DDI-effect
DDI-MedLine.d216.s0.p2	Exposure to oral S-ketamine is unaffected by @DRUG$ but greatly increased by @DRUG$.	DDI-false
DDI-MedLine.d216.s1.p0	This study examined drug-drug interactions of oral @DRUG$ with the cytochrome P450 (CYP) 2B6 inhibitor @DRUG$ and the CYP3A inhibitor itraconazole.	DDI-false
DDI-MedLine.d216.s1.p1	This study examined drug-drug interactions of oral @DRUG$ with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor @DRUG$.	DDI-false
DDI-MedLine.d216.s1.p2	This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor @DRUG$ and the CYP3A inhibitor @DRUG$.	DDI-false
DDI-MedLine.d216.s2.p0	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg @DRUG$ after pretreatments with oral @DRUG$ (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	DDI-false
DDI-MedLine.d216.s2.p1	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg @DRUG$ after pretreatments with oral ticlopidine (250 mg twice daily), @DRUG$ (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	DDI-false
DDI-MedLine.d216.s2.p2	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral @DRUG$ (250 mg twice daily), @DRUG$ (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	DDI-false
DDI-MedLine.d216.s3.p0	@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine.	DDI-mechanism
DDI-MedLine.d216.s3.p1	@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to S-ketamine.	DDI-false
DDI-MedLine.d216.s3.p2	@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to @DRUG$.	DDI-false
DDI-MedLine.d216.s3.p3	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to S-ketamine.	DDI-false
DDI-MedLine.d216.s3.p4	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas itraconazole treatment did not increase the exposure to @DRUG$.	DDI-false
DDI-MedLine.d216.s3.p5	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to @DRUG$.	DDI-false
DDI-MedLine.d216.s4.p0	The ratio of @DRUG$ AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.	DDI-false
DDI-MedLine.d216.s4.p1	The ratio of @DRUG$ AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.	DDI-false
DDI-MedLine.d216.s4.p2	The ratio of @DRUG$ AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo.	DDI-false
DDI-MedLine.d216.s4.p3	The ratio of norketamine AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.	DDI-false
DDI-MedLine.d216.s4.p4	The ratio of norketamine AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo.	DDI-false
DDI-MedLine.d216.s4.p5	The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo.	DDI-false
DDI-MedLine.d216.s5.p0	In the @DRUG$ and @DRUG$ phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05).	DDI-false
DDI-MedLine.d216.s6.p0	The findings suggest that the dosage of @DRUG$ should be reduced in patients receiving @DRUG$.	DDI-advise
DDI-MedLine.d217.s0.p0	Interaction of @DRUG$ with different @DRUG$ is antagonistic in breast but not in other cancer cells.	DDI-effect
DDI-MedLine.d217.s11.p0	These results, if confirmed in-vivo, indicate that @DRUG$ is not a suitable chemosensitizer for breast cancer or with @DRUG$ for other cancers.	DDI-false
DDI-MedLine.d217.s2.p0	This study investigates the ability of @DRUG$ to sensitize cells from different origins to several @DRUG$.	DDI-false
DDI-MedLine.d217.s4.p0	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, @DRUG$, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p1	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, @DRUG$ and etoposide   celecoxib following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p2	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, doxorubicin and @DRUG$   celecoxib following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p3	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, doxorubicin and etoposide   @DRUG$ following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p4	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, @DRUG$ and etoposide   celecoxib following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p5	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, doxorubicin and @DRUG$   celecoxib following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p6	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, doxorubicin and etoposide   @DRUG$ following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p7	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, @DRUG$ and @DRUG$   celecoxib following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p8	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, @DRUG$ and etoposide   @DRUG$ following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s4.p9	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and @DRUG$   @DRUG$ following different incubation schedules were analyzed.	DDI-false
DDI-MedLine.d217.s5.p0	We found antagonism between @DRUG$ and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between @DRUG$ and doxorubicin in all cell lines except for two combinations in HCT116 cells.	DDI-false
DDI-MedLine.d217.s5.p1	We found antagonism between @DRUG$ and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and @DRUG$ in all cell lines except for two combinations in HCT116 cells.	DDI-false
DDI-MedLine.d217.s5.p2	We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between @DRUG$ and @DRUG$ in all cell lines except for two combinations in HCT116 cells.	DDI-effect
DDI-MedLine.d218.s0.p0	@DRUG$-@DRUG$ interaction and associated gastrointestinal bleeding risk in a case-control study.	DDI-false
DDI-MedLine.d218.s10.p0	@DRUG$ users who initiated @DRUG$, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-effect
DDI-MedLine.d218.s10.p1	@DRUG$ users who initiated citalopram, @DRUG$, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-effect
DDI-MedLine.d218.s10.p2	@DRUG$ users who initiated citalopram, fluoxetine, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-effect
DDI-MedLine.d218.s10.p3	@DRUG$ users who initiated citalopram, fluoxetine, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-effect
DDI-MedLine.d218.s10.p4	@DRUG$ users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-effect
DDI-MedLine.d218.s10.p5	Warfarin users who initiated @DRUG$, @DRUG$, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p6	Warfarin users who initiated @DRUG$, fluoxetine, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p7	Warfarin users who initiated @DRUG$, fluoxetine, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p8	Warfarin users who initiated @DRUG$, fluoxetine, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p9	Warfarin users who initiated citalopram, @DRUG$, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p10	Warfarin users who initiated citalopram, @DRUG$, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p11	Warfarin users who initiated citalopram, @DRUG$, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p12	Warfarin users who initiated citalopram, fluoxetine, @DRUG$, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p13	Warfarin users who initiated citalopram, fluoxetine, @DRUG$, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s10.p14	Warfarin users who initiated citalopram, fluoxetine, paroxetine, @DRUG$, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding.	DDI-false
DDI-MedLine.d218.s3.p0	We sought to evaluate whether initiation of an @DRUG$ increases the risk of hospitalization for gastrointestinal bleeding in @DRUG$ users.	DDI-false
DDI-MedLine.d218.s5.p0	In total, 430,455 @DRUG$ users contributed 407,370 person-years of @DRUG$ use.	DDI-false
DDI-MedLine.d218.s8.p0	@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-effect
DDI-MedLine.d218.s8.p1	@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-effect
DDI-MedLine.d218.s8.p2	@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-effect
DDI-MedLine.d218.s8.p3	@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-effect
DDI-MedLine.d218.s8.p4	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-false
DDI-MedLine.d218.s8.p5	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-false
DDI-MedLine.d218.s8.p6	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-false
DDI-MedLine.d218.s8.p7	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-false
DDI-MedLine.d218.s8.p8	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-false
DDI-MedLine.d218.s8.p9	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]).	DDI-false
DDI-MedLine.d218.s9.p0	Also @DRUG$, which is not believed to interact with @DRUG$, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]).	DDI-effect
DDI-MedLine.d227.s0.p0	@DRUG$ enhances the antinociceptive effect of @DRUG$ in mice.	DDI-effect
DDI-MedLine.d227.s2.p0	The purpose of this study was to evaluate whether the psychostimulant drug @DRUG$ has any effect on @DRUG$-induced antinociception and locomotor inhibitor activity in mice in acute application.	DDI-false
DDI-MedLine.d227.s6.p0	saline + saline, @DRUG$ (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	DDI-false
DDI-MedLine.d227.s6.p1	saline + saline, @DRUG$ (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and @DRUG$ (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	DDI-false
DDI-MedLine.d227.s6.p2	saline + saline, @DRUG$ (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	DDI-false
DDI-MedLine.d227.s6.p3	saline + saline, ephedrine (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and @DRUG$ (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	DDI-false
DDI-MedLine.d227.s6.p4	saline + saline, ephedrine (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and ephedrine (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	DDI-false
DDI-MedLine.d227.s6.p5	saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and @DRUG$ (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	DDI-false
DDI-MedLine.d227.s7.p0	In the hot plate test in mice, co-administration of 15     g/kg @DRUG$ with 10   mg/kg @DRUG$ intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.	DDI-effect
DDI-MedLine.d227.s7.p1	In the hot plate test in mice, co-administration of 15     g/kg @DRUG$ with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by @DRUG$.	DDI-false
DDI-MedLine.d227.s7.p2	In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg @DRUG$ intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by @DRUG$.	DDI-false
DDI-MedLine.d227.s8.p0	At the same time, the locomotor inhibitory effect of @DRUG$ was counteracted by @DRUG$.	DDI-effect
DDI-MedLine.d227.s9.p0	We concluded that the combined administration of @DRUG$ with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	DDI-effect
DDI-MedLine.d227.s9.p1	We concluded that the combined administration of @DRUG$ with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an analgesic in humans.	DDI-false
DDI-MedLine.d227.s9.p2	We concluded that the combined administration of @DRUG$ with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an @DRUG$ in humans.	DDI-false
DDI-MedLine.d227.s9.p3	We concluded that the combined administration of dexmedetomidine with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an analgesic in humans.	DDI-false
DDI-MedLine.d227.s9.p4	We concluded that the combined administration of dexmedetomidine with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an @DRUG$ in humans.	DDI-false
DDI-MedLine.d227.s9.p5	We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an @DRUG$ in humans.	DDI-false
DDI-MedLine.d231.s0.p0	Interaction study of @DRUG$ and @DRUG$ with co-administered drugs.	DDI-false
DDI-MedLine.d231.s1.p0	@DRUG$ and @DRUG$ are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.	DDI-false
DDI-MedLine.d231.s1.p1	@DRUG$ and lomefloxacin are @DRUG$ used in treating urinary and respiratory tract infections.	DDI-false
DDI-MedLine.d231.s1.p2	Moxifloxacin and @DRUG$ are @DRUG$ used in treating urinary and respiratory tract infections.	DDI-false
DDI-MedLine.d231.s3.p0	Being @DRUG$ and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p1	Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, erythromycin and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p2	Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p3	Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p4	Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and @DRUG$.	DDI-false
DDI-MedLine.d231.s3.p5	Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with @DRUG$, gelusil, erythromycin and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p6	Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p7	Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p8	Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, erythromycin and @DRUG$.	DDI-false
DDI-MedLine.d231.s3.p9	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, @DRUG$, erythromycin and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p10	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, @DRUG$ and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p11	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, erythromycin and @DRUG$.	DDI-false
DDI-MedLine.d231.s3.p12	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, @DRUG$ and multi minerals.	DDI-false
DDI-MedLine.d231.s3.p13	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and @DRUG$.	DDI-false
DDI-MedLine.d231.s3.p14	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and @DRUG$.	DDI-false
DDI-MedLine.d231.s6.p0	The response of @DRUG$ and @DRUG$ after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector.	DDI-false
DDI-MedLine.d231.s8.p0	@DRUG$ and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	DDI-false
DDI-MedLine.d231.s8.p1	@DRUG$ and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	DDI-mechanism
DDI-MedLine.d231.s8.p2	@DRUG$ and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	DDI-mechanism
DDI-MedLine.d231.s8.p3	@DRUG$ and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media.	DDI-mechanism
DDI-MedLine.d231.s8.p4	@DRUG$ and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media.	DDI-mechanism
DDI-MedLine.d231.s8.p5	Moxifloxacin and @DRUG$ reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	DDI-mechanism
DDI-MedLine.d231.s8.p6	Moxifloxacin and @DRUG$ reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	DDI-mechanism
DDI-MedLine.d231.s8.p7	Moxifloxacin and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media.	DDI-mechanism
DDI-MedLine.d231.s8.p8	Moxifloxacin and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media.	DDI-mechanism
DDI-MedLine.d231.s8.p9	Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	DDI-false
DDI-MedLine.d231.s8.p10	Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media.	DDI-false
DDI-MedLine.d231.s8.p11	Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media.	DDI-false
DDI-MedLine.d231.s8.p12	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media.	DDI-false
DDI-MedLine.d231.s8.p13	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media.	DDI-false
DDI-MedLine.d231.s8.p14	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and @DRUG$ in neutral media.	DDI-false
DrugDDI.d21928724.s0.p0	Evaluation of antidepressant like activity of @DRUG$ and its combination with @DRUG$ and imipramine: an acute and chronic study.	DDI-false
DrugDDI.d21928724.s0.p1	Evaluation of antidepressant like activity of @DRUG$ and its combination with fluoxetine and @DRUG$: an acute and chronic study.	DDI-false
DrugDDI.d21928724.s0.p2	Evaluation of antidepressant like activity of curcumin and its combination with @DRUG$ and @DRUG$: an acute and chronic study.	DDI-false
DrugDDI.d21928724.s2.p0	In the present study, the antidepressant like activity of @DRUG$ and its combination with @DRUG$ and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats.	DDI-false
DrugDDI.d21928724.s2.p1	In the present study, the antidepressant like activity of @DRUG$ and its combination with fluoxetine and @DRUG$ was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats.	DDI-false
DrugDDI.d21928724.s2.p2	In the present study, the antidepressant like activity of curcumin and its combination with @DRUG$ and @DRUG$ was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats.	DDI-false
DrugDDI.d21928724.s3.p0	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p1	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p2	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p3	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p4	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p5	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p6	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p7	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p8	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p9	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p10	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p11	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p12	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p13	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p14	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p15	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p16	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p17	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p18	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p19	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p20	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p21	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p22	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p23	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p24	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p25	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p26	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg).	DDI-false
DrugDDI.d21928724.s3.p27	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus @DRUG$ 15 mg/kg).	DDI-false
DrugDDI.d21928724.s6.p0	The effect of @DRUG$ (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p1	The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p2	The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p3	The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p4	The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and @DRUG$ (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p5	The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p6	The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p7	The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p8	The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s6.p9	The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to @DRUG$ and @DRUG$ did not improve their antidepressant activity (p > 0.05).	DDI-false
DrugDDI.d21928724.s8.p0	@DRUG$ can be a useful @DRUG$ especially in cases which respond to drugs having mixed effects on serotonin and catecholamines levels in the brain.	DDI-false
